# ESC Guidelines: Pregnancy CVD (2025)

**Source**: `2025_Pregnancy_CVD.pdf`
**Converted**: 2025-11-27 10:02
**Pages**: 107

---

## Table of Contents

- [2025 ESC Guidelines for the management of cardiovascular disease and pregnancy](#2025-esc-guidelines-for-the-management-of-cardiova) *(p. 1)*
  - [1. Preamble](#1-preamble) *(p. 7)*
  - [2. Introduction](#2-introduction) *(p. 8)*
    - [2.1. Why we need new Guidelines on cardiovascular disease and pregnancy](#21-why-we-need-new-guidelines-on-cardiovascular-di) *(p. 8)*
    - [2.2. Why these Guidelines are important](#22-why-these-guidelines-are-important) *(p. 8)*
    - [2.3. What is new](#23-what-is-new) *(p. 8)*
    - [2.4. What has changed](#24-what-has-changed) *(p. 11)*
  - [3. General considerations](#3-general-considerations) *(p. 12)*
    - [3.1. Epidemiology](#31-epidemiology) *(p. 12)*
    - [3.2. Physiology of pregnancy](#32-physiology-of-pregnancy) *(p. 12)*
  - [4. The Pregnancy Heart Team](#4-the-pregnancy-heart-team) *(p. 14)*
    - [4.1. Concept and requirements](#41-concept-and-requirements) *(p. 14)*
    - [4.2. Pre-pregnancy counselling and family planning](#42-pre-pregnancy-counselling-and-family-planning) *(p. 14)*
      - [4.2.1. Risk assessment](#421-risk-assessment) *(p. 14)*
        - [4.2.1.1. Maternal risk assessment](#4211-maternal-risk-assessment) *(p. 14)*
      - [4.2.2. Genetic counselling](#422-genetic-counselling) *(p. 14)*
        - [4.2.2.1. Pre-natal and pre-implantation diagnosis](#4221-pre-natal-and-pre-implantation-diagnosis) *(p. 14)*
      - [4.2.3. Reproductive technology](#423-reproductive-technology) *(p. 14)*
      - [4.2.4. Contraception](#424-contraception) *(p. 21)*
      - [4.2.5. Termination of pregnancy including psychological support](#425-termination-of-pregnancy-including-psychologic) *(p. 21)*
    - [4.3. Diagnostic methods in pregnancy](#43-diagnostic-methods-in-pregnancy) *(p. 23)*
      - [4.3.1. Electrocardiogram, including mobile rhythm devices](#431-electrocardiogram,-including-mobile-rhythm-dev) *(p. 23)*
      - [4.3.2. Echocardiography](#432-echocardiography) *(p. 23)*
      - [4.3.3. Cardiopulmonary exercise testing](#433-cardiopulmonary-exercise-testing) *(p. 23)*
      - [4.3.4. Biomarkers](#434-biomarkers) *(p. 23)*
      - [4.3.5. Ionizing radiation exposure](#435-ionizing-radiation-exposure) *(p. 23)*
        - [4.3.5.1. Chest radiography](#4351-chest-radiography) *(p. 23)*
        - [4.3.5.2. Computed tomography and nuclear medicine imaging](#4352-computed-tomography-and-nuclear-medicine-ima) *(p. 23)*
        - [4.3.5.3. Cardiac catheterization](#4353-cardiac-catheterization) *(p. 24)*
      - [4.3.6. Cardiovascular magnetic resonance](#436-cardiovascular-magnetic-resonance) *(p. 24)*
    - [4.4. Foetal assessment](#44-foetal-assessment) *(p. 24)*
      - [4.4.1. Risk of foetal/obstetric complications](#441-risk-of-foetal/obstetric-complications) *(p. 24)*
      - [4.4.2. Screening for congenital heart disease in the foetus](#442-screening-for-congenital-heart-disease-in-the-) *(p. 24)*
      - [4.4.3. Assessing foetal well-being](#443-assessing-foetal-well-being) *(p. 24)*
      - [4.4.4. Foetal assessment of heritable primary arrhythmias](#444-foetal-assessment-of-heritable-primary-arrhyth) *(p. 25)*
    - [4.5. Timing and mode of delivery](#45-timing-and-mode-of-delivery) *(p. 25)*
      - [4.5.1. Timing of delivery](#451-timing-of-delivery) *(p. 25)*
      - [4.5.2. Induction of labour](#452-induction-of-labour) *(p. 25)*
      - [4.5.3. Vaginal or caesarean delivery](#453-vaginal-or-caesarean-delivery) *(p. 25)*
      - [4.5.4. Haemodynamic monitoring during delivery](#454-haemodynamic-monitoring-during-delivery) *(p. 25)*
      - [4.5.5. Anaesthesia/analgesia](#455-anaesthesia/analgesia) *(p. 25)*
      - [4.5.6. Delivery in women on anticoagulants](#456-delivery-in-women-on-anticoagulants) *(p. 26)*
        - [4.5.6.1. Planned delivery](#4561-planned-delivery) *(p. 26)*
        - [4.5.6.2. Urgent delivery on therapeutic anticoagulation](#4562-urgent-delivery-on-therapeutic-anticoagulatio) *(p. 26)*
          - [4.5.6.2.1. Delivery on vitamin K antagonists](#45621-delivery-on-vitamin-k-antagonists) *(p. 26)*
          - [4.5.6.2.2. Delivery on heparin](#45622-delivery-on-heparin) *(p. 26)*
        - [4.5.6.3. Restarting anticoagulation after delivery](#4563-restarting-anticoagulation-after-delivery) *(p. 26)*
      - [4.5.7. Endocarditis prophylaxis for delivery](#457-endocarditis-prophylaxis-for-delivery) *(p. 26)*
    - [4.6. Post-partum monitoring and complications](#46-post-partum-monitoring-and-complications) *(p. 28)*
      - [4.6.1. Monitoring](#461-monitoring) *(p. 28)*
      - [4.6.2. Breastfeeding and lactation](#462-breastfeeding-and-lactation) *(p. 28)*
      - [4.6.3. Complications](#463-complications) *(p. 28)*
        - [4.6.3.1. Haemorrhage](#4631-haemorrhage) *(p. 28)*
        - [4.6.3.2. Psychological reactions, post-partum depression](#4632-psychological-reactions,-post-partum-depressi) *(p. 28)*
  - [5. Drugs during pregnancy and lactation](#5-drugs-during-pregnancy-and-lactation) *(p. 28)*
    - [5.1. General principles](#51-general-principles) *(p. 28)*
      - [5.1.1. Pharmacokinetics and pharmacodynamics in pregnancy](#511-pharmacokinetics-and-pharmacodynamics-in-pregn) *(p. 28)*
      - [5.1.2. Pharmacogenetics](#512-pharmacogenetics) *(p. 28)*
      - [5.1.3. Newborn drug exposure in breast milk](#513-newborn-drug-exposure-in-breast-milk) *(p. 28)*
    - [5.2. Drug classes in pregnancy](#52-drug-classes-in-pregnancy) *(p. 28)*
      - [5.2.1. Anticoagulants](#521-anticoagulants) *(p. 28)*
        - [Low-molecular-weight heparin treatment regimen glossary](#low-molecular-weight-heparin-treatment-regimen-glo) *(p. 29)*
        - [5.2.1.1. Vitamin K antagonists](#5211-vitamin-k-antagonists) *(p. 29)*
        - [5.2.1.2. Low-molecular-weight heparins](#5212-low-molecular-weight-heparins) *(p. 30)*
          - [5.2.1.2.1. Low-molecular-weight heparin dosing](#52121-low-molecular-weight-heparin-dosing) *(p. 30)*
          - [5.2.1.2.2. Once-daily vs twice-daily administration](#52122-once-daily-vs-twice-daily-administration) *(p. 30)*
        - [5.2.1.3. Unfractionated heparin](#5213-unfractionated-heparin) *(p. 30)*
        - [5.2.1.4. Fondaparinux](#5214-fondaparinux) *(p. 30)*
        - [5.2.1.5. Direct oral anticoagulants](#5215-direct-oral-anticoagulants) *(p. 30)*
      - [5.2.2. Antiplatelet treatment](#522-antiplatelet-treatment) *(p. 31)*
      - [5.2.3. Diuretics and SGLT2 inhibitors](#523-diuretics-and-sglt2-inhibitors) *(p. 31)*
      - [5.2.4. Pulmonary hypertension](#524-pulmonary-hypertension) *(p. 31)*
      - [5.2.5. Anti-arrhythmic agents](#525-anti-arrhythmic-agents) *(p. 31)*
      - [5.2.6. Calcium channel blockers](#526-calcium-channel-blockers) *(p. 31)*
      - [5.2.7. Renin–angiotensin–aldosterone system inhibitors](#527-renin–angiotensin–aldosterone-system-inhibitor) *(p. 32)*
      - [5.2.8. Lipid-lowering agents](#528-lipid-lowering-agents) *(p. 32)*
      - [5.2.9. Beta-adrenergic blocking agents](#529-beta-adrenergic-blocking-agents) *(p. 32)*
      - [5.2.10. Immunosuppressants](#5210-immunosuppressants) *(p. 32)*
      - [5.2.11. Neuroactive drugs](#5211-neuroactive-drugs) *(p. 32)*
      - [5.2.12. Obstetric drugs in patients with cardiovascular disease](#5212-obstetric-drugs-in-patients-with-cardiovascul) *(p. 32)*
    - [5.3. Internet databases](#53-internet-databases) *(p. 32)*
    - [5.4. List of drugs](#54-list-of-drugs) *(p. 32)*
  - [6. Pregnancy in women with cardiomyopathies and primary arrhythmia syndromes](#6-pregnancy-in-women-with-cardiomyopathies-and-pri) *(p. 34)*
    - [6.1. Cardiomyopathies](#61-cardiomyopathies) *(p. 34)*
      - [6.1.1. Dilated cardiomyopathy and non-dilated left ventricular cardiomyopathy](#611-dilated-cardiomyopathy-and-non-dilated-left-ve) *(p. 34)*
      - [6.1.2. Arrhythmogenic right ventricular cardiomyopathy](#612-arrhythmogenic-right-ventricular-cardiomyopath) *(p. 34)*
      - [6.1.3. Hypertrophic cardiomyopathy](#613-hypertrophic-cardiomyopathy) *(p. 34)*
        - [6.1.3.1. Treatment of hypertrophic cardiomyopathy in pregnancy](#6131-treatment-of-hypertrophic-cardiomyopathy-in-p) *(p. 34)*
        - [6.1.3.2. Left ventricular outflow tract obstruction](#6132-left-ventricular-outflow-tract-obstruction) *(p. 34)*
      - [6.1.4. Hypertrabeculation of the left ventricle](#614-hypertrabeculation-of-the-left-ventricle) *(p. 35)*
      - [6.1.5. Labour and delivery in cardiomyopathies](#615-labour-and-delivery-in-cardiomyopathies) *(p. 35)*
    - [6.2. Primary arrhythmia syndromes](#62-primary-arrhythmia-syndromes) *(p. 35)*
      - [6.2.1. Long QT syndrome](#621-long-qt-syndrome) *(p. 35)*
      - [6.2.2. Brugada syndrome](#622-brugada-syndrome) *(p. 36)*
      - [6.2.3. Catecholaminergic polymorphic ventricular tachycardia](#623-catecholaminergic-polymorphic-ventricular-tac) *(p. 36)*
      - [6.2.4. Short QT syndrome](#624-short-qt-syndrome) *(p. 36)*
      - [6.2.5. Labour and delivery in primary arrhythmia syndromes](#625-labour-and-delivery-in-primary-arrhythmia-synd) *(p. 36)*
  - [7. Peripartum cardiomyopathy](#7-peripartum-cardiomyopathy) *(p. 37)*
    - [7.1. Epidemiology](#71-epidemiology) *(p. 37)*
    - [7.2. Mechanisms](#72-mechanisms) *(p. 37)*
    - [7.3. Diagnosis and clinical interventions](#73-diagnosis-and-clinical-interventions) *(p. 37)*
    - [7.4. Outcomes](#74-outcomes) *(p. 39)*
  - [8. Pregnancy in women with aortopathies](#8-pregnancy-in-women-with-aortopathies) *(p. 39)*
    - [8.1. Women with heritable thoracic aortic disease](#81-women-with-heritable-thoracic-aortic-disease) *(p. 39)*
      - [8.1.1. Marfan syndrome](#811-marfan-syndrome) *(p. 40)*
      - [8.1.2. Loeys–Dietz syndrome](#812-loeys–dietz-syndrome) *(p. 40)*
      - [8.1.3. Vascular Ehlers–Danlos syndrome](#813-vascular-ehlers–danlos-syndrome) *(p. 40)*
      - [8.1.4. Non-syndromic heritable thoracic aortic diseases](#814-non-syndromic-heritable-thoracic-aortic-diseas) *(p. 40)*
      - [8.1.5. Aortic disease with no identifiable (likely) pathogenic variant](#815-aortic-disease-with-no-identifiable-(likely)-p) *(p. 40)*
    - [8.2. Turner syndrome](#82-turner-syndrome) *(p. 40)*
    - [8.3. Bicuspid aortic valve disease](#83-bicuspid-aortic-valve-disease) *(p. 40)*
    - [8.4. Aortic aneurysms other than root or ascending aorta](#84-aortic-aneurysms-other-than-root-or-ascending-a) *(p. 41)*
    - [8.5. Aortic dissection](#85-aortic-dissection) *(p. 41)*
    - [8.6. Management](#86-management) *(p. 41)*
    - [8.7. Cardiac surgery during pregnancy](#87-cardiac-surgery-during-pregnancy) *(p. 42)*
  - [9. Pregnancy in women with known congenital heart disease](#9-pregnancy-in-women-with-known-congenital-heart-d) *(p. 43)*
  - [10. Pregnancy in women with pulmonary arterial hypertension](#10-pregnancy-in-women-with-pulmonary-arterial-hype) *(p. 47)*
    - [10.1. Pre-existing pulmonary arterial hypertension](#101-pre-existing-pulmonary-arterial-hypertension) *(p. 47)*
      - [10.1.1. Maternal and foetal risk](#1011-maternal-and-foetal-risk) *(p. 47)*
      - [10.1.2. Counselling and contraception](#1012-counselling-and-contraception) *(p. 47)*
      - [10.1.3. Management during pregnancy](#1013-management-during-pregnancy) *(p. 47)*
    - [10.2. New diagnosis in pregnancy](#102-new-diagnosis-in-pregnancy) *(p. 48)*
    - [10.3. Delivery in women with pulmonary arterial hypertension](#103-delivery-in-women-with-pulmonary-arterial-hype) *(p. 48)*
      - [10.3.1. Peri- and post-partum monitoring](#1031-peri--and-post-partum-monitoring) *(p. 48)*
  - [11. Venous thromboembolism in pregnancy and post-partum](#11-venous-thromboembolism-in-pregnancy-and-post-pa) *(p. 48)*
    - [11.1. Epidemiology and maternal risk](#111-epidemiology-and-maternal-risk) *(p. 48)*
    - [11.2. Risk factors for pregnancy-related venous thromboembolism](#112-risk-factors-for-pregnancy-related-venous-thro) *(p. 48)*
    - [11.3. Prevention of venous thromboembolism](#113-prevention-of-venous-thromboembolism) *(p. 49)*
      - [11.3.1. Pregnant women with no prior indications for long-term anticoagulation](#1131-pregnant-women-with-no-prior-indications-for-) *(p. 49)*
      - [11.3.2. Pregnant women with prior indication for long-term anticoagulation](#1132-pregnant-women-with-prior-indication-for-long) *(p. 49)*
    - [11.4. Management of acute venous thromboembolism](#114-management-of-acute-venous-thromboembolism) *(p. 49)*
      - [11.4.1. Clinical presentation and diagnosis](#1141-clinical-presentation-and-diagnosis) *(p. 49)*
        - [11.4.1.1. Deep vein thrombosis](#11411-deep-vein-thrombosis) *(p. 49)*
        - [11.4.1.2. Pulmonary embolism](#11412-pulmonary-embolism) *(p. 50)*
      - [11.4.2. Treatment of venous thromboembolism in pregnancy](#1142-treatment-of-venous-thromboembolism-in-pregna) *(p. 50)*
    - [11.5. Management of delivery and the post-partum period](#115-management-of-delivery-and-the-post-partum-per) *(p. 52)*
  - [12. Pregnancy in women with acquired heart disease](#12-pregnancy-in-women-with-acquired-heart-disease) *(p. 52)*
    - [12.1. Acute chest pain in pregnancy](#121-acute-chest-pain-in-pregnancy) *(p. 52)*
    - [12.2. Coronary artery disease](#122-coronary-artery-disease) *(p. 52)*
      - [12.2.1. Acute coronary syndrome](#1221-acute-coronary-syndrome) *(p. 52)*
        - [12.2.1.1. Coronary artery disease epidemiology and aetiology](#12211-coronary-artery-disease-epidemiology-and-aet) *(p. 52)*
        - [12.2.1.2. Presentation and diagnosis](#12212-presentation-and-diagnosis) *(p. 54)*
        - [12.2.1.3. Pregnancy-associated spontaneous coronary artery dissection](#12213-pregnancy-associated-spontaneous-coronary-ar) *(p. 54)*
      - [12.2.2. Coronary artery interventions](#1222-coronary-artery-interventions) *(p. 54)*
      - [12.2.3. Chronic coronary syndromes in pregnancy](#1223-chronic-coronary-syndromes-in-pregnancy) *(p. 54)*
      - [12.2.4. Management and delivery](#1224-management-and-delivery) *(p. 54)*
    - [12.3. Hypertensive disorders](#123-hypertensive-disorders) *(p. 55)*
      - [12.3.1. Definition and classification of hypertension in pregnancy](#1231-definition-and-classification-of-hypertension) *(p. 56)*
        - [12.3.1.1. Pre-eclampsia/eclampsia](#12311-pre-eclampsia/eclampsia) *(p. 56)*
      - [12.3.2. Diagnosis and risk assessment](#1232-diagnosis-and-risk-assessment) *(p. 56)*
        - [12.3.2.1. Blood pressure measurement](#12321-blood-pressure-measurement) *(p. 56)*
        - [12.3.2.2. Laboratory tests](#12322-laboratory-tests) *(p. 56)*
      - [12.3.3. Management of hypertension in pregnancy](#1233-management-of-hypertension-in-pregnancy) *(p. 56)*
        - [12.3.3.1. Non-pharmacological management](#12331-non-pharmacological-management) *(p. 56)*
        - [12.3.3.2. Pharmacological treatment](#12332-pharmacological-treatment) *(p. 57)*
          - [12.3.3.2.1. Mild hypertension (BP 140/90 – 159/109 mmHg)](#123321-mild-hypertension-(bp-140/90-–-159/109-mmhg) *(p. 57)*
          - [12.3.3.2.2. Pre-eclampsia](#123322-pre-eclampsia) *(p. 57)*
          - [12.3.3.2.3. Severe hypertension (BP ≧160/110 mmHg)](#123323-severe-hypertension-(bp-≧160/110-mmhg)) *(p. 60)*
      - [12.3.4. Hypertension and delivery](#1234-hypertension-and-delivery) *(p. 60)*
    - [12.4. Arrhythmias](#124-arrhythmias) *(p. 61)*
      - [12.4.1. Supraventricular arrhythmias](#1241-supraventricular-arrhythmias) *(p. 61)*
        - [12.4.1.1. New-onset narrow QRS tachycardia ](#12411-new-onset-narrow-qrs-tachycardia-) *(p. 61)*
        - [12.4.1.2. Atrial fibrillation including anticoagulation](#12412-atrial-fibrillation-including-anticoagulatio) *(p. 62)*
        - [12.4.1.3. Pre-existing supraventricular tachycardia](#12413-pre-existing-supraventricular-tachycardia) *(p. 63)*
      - [12.4.2. Ventricular arrhythmias](#1242-ventricular-arrhythmias) *(p. 64)*
      - [12.4.3. Cardioversion, ablation, and device implantation, and implantable cardioverter defibrillator management](#1243-cardioversion,-ablation,-and-device-implantat) *(p. 64)*
        - [12.4.3.1. Electrical cardioversion](#12431-electrical-cardioversion) *(p. 64)*
        - [12.4.3.2. Catheter ablation](#12432-catheter-ablation) *(p. 64)*
        - [12.4.3.3. Device implantation](#12433-device-implantation) *(p. 65)*
        - [12.4.3.4. Implantable cardioverter defibrillator management](#12434-implantable-cardioverter-defibrillator-manag) *(p. 66)*
      - [12.4.4. Cardiac arrest](#1244-cardiac-arrest) *(p. 68)*
      - [12.4.5. Bradycardia](#1245-bradycardia) *(p. 69)*
        - [12.4.5.1. Sinus node dysfunction](#12451-sinus-node-dysfunction) *(p. 69)*
        - [12.4.5.2. Atrioventricular block](#12452-atrioventricular-block) *(p. 69)*
        - [12.4.5.3. Management of sinus node dysfunction and atrioventricular block](#12453-management-of-sinus-node-dysfunction-and-atr) *(p. 69)*
    - [12.5. Valvular heart disease](#125-valvular-heart-disease) *(p. 69)*
      - [12.5.1. Stenotic native valve lesions](#1251-stenotic-native-valve-lesions) *(p. 69)*
        - [12.5.1.1. Mitral valve stenosis](#12511-mitral-valve-stenosis) *(p. 70)*
          - [12.5.1.1.1. Management](#125111-management) *(p. 70)*
          - [12.5.1.1.2. Interventions](#125112-interventions) *(p. 70)*
          - [12.5.1.1.3. Delivery](#125113-delivery) *(p. 70)*
          - [12.5.1.1.4. Post-partum](#125114-post-partum) *(p. 70)*
        - [12.5.1.2. Valvular aortic stenosis](#12512-valvular-aortic-stenosis) *(p. 70)*
          - [12.5.1.2.1. Management](#125121-management) *(p. 70)*
      - [12.5.2. Regurgitant native valve lesions](#1252-regurgitant-native-valve-lesions) *(p. 70)*
        - [12.5.2.1. Mitral and aortic valve regurgitation](#12521-mitral-and-aortic-valve-regurgitation) *(p. 70)*
          - [12.5.2.1.1. Management](#125211-management) *(p. 70)*
        - [12.5.2.2. Arrhythmogenic mitral valve prolapse](#12522-arrhythmogenic-mitral-valve-prolapse) *(p. 70)*
        - [12.5.2.3. Tricuspid regurgitation](#12523-tricuspid-regurgitation) *(p. 71)*
      - [12.5.3. Prosthetic valves](#1253-prosthetic-valves) *(p. 72)*
        - [12.5.3.1. Bioprosthetic valves](#12531-bioprosthetic-valves) *(p. 72)*
        - [12.5.3.2. Mechanical valves](#12532-mechanical-valves) *(p. 72)*
          - [12.5.3.2.1. Anticoagulation during pregnancy](#125321-anticoagulation-during-pregnancy) *(p. 73)*
          - [12.5.3.2.2. Mechanical valve thrombosis](#125322-mechanical-valve-thrombosis) *(p. 73)*
          - [12.5.3.2.3. Anticoagulation during delivery in women with mechanical heart valves](#125323-anticoagulation-during-delivery-in-women-wi) *(p. 73)*
      - [12.5.4. Endocarditis prophylaxis](#1254-endocarditis-prophylaxis) *(p. 75)*
    - [12.6. Heart failure](#126-heart-failure) *(p. 75)*
      - [12.6.1. Chronic heart failure](#1261-chronic-heart-failure) *(p. 75)*
      - [12.6.2. Acute heart failure (including cardiogenic shock)](#1262-acute-heart-failure-(including-cardiogenic-sh) *(p. 75)*
    - [12.7. Special populations](#127-special-populations) *(p. 77)*
      - [12.7.1. Heart transplantation](#1271-heart-transplantation) *(p. 77)*
      - [12.7.2. Cardio-oncology](#1272-cardio-oncology) *(p. 77)*
        - [12.7.2.1 Gestational cancer](#12721-gestational-cancer) *(p. 77)*
        - [12.7.2.2 Pregnancy in cancer survivors](#12722-pregnancy-in-cancer-survivors) *(p. 78)*
  - [13. Adverse pregnancy outcomes and long-term management](#13-adverse-pregnancy-outcomes-and-long-term-manage) *(p. 78)*
    - [13.1. Adverse pregnancy outcomes](#131-adverse-pregnancy-outcomes) *(p. 78)*
      - [13.1.1. Post-partum hypertensive disorders](#1311-post-partum-hypertensive-disorders) *(p. 78)*
      - [13.1.2. Gestational diabetes mellitus](#1312-gestational-diabetes-mellitus) *(p. 78)*
      - [13.1.3. Pre-term birth](#1313-pre-term-birth) *(p. 78)*
      - [13.1.4. Small for gestational age](#1314-small-for-gestational-age) *(p. 78)*
      - [13.1.5. Pregnancy loss and placental abruption](#1315-pregnancy-loss-and-placental-abruption) *(p. 78)*
    - [13.2. Breastfeeding](#132-breastfeeding) *(p. 78)*
    - [13.3. Women's Heart Clinics](#133-women's-heart-clinics) *(p. 79)*
  - [14. Key messages](#14-key-messages) *(p. 81)*
  - [15. Gaps in evidence](#15-gaps-in-evidence) *(p. 82)*
  - [16. ‘What to do’ and ‘what not to do’ messages from the Guidelines](#16-‘what-to-do’-and-‘what-not-to-do’-messages-from) *(p. 83)*
  - [17. Evidence tables](#17-evidence-tables) *(p. 83)*
  - [18. Data availability statement](#18-data-availability-statement) *(p. 83)*
  - [19. Author information](#19-author-information) *(p. 88)*
  - [Appendix](#appendix) *(p. 88)*

---

## Full Text


<!-- PAGE 1 -->

### Page 1

2025 ESC Guidelines for the management 
of cardiovascular disease and pregnancy 
Developed by the task force on the management of cardiovascular 
disease and pregnancy of the European Society of Cardiology (ESC) 
Endorsed by the European Society of Gynecology (ESG) 
Authors/Task Force Members: Julie De Backer  *†, (Chairperson) (Belgium), 
Kristina H. Haugaa  *†, (Chairperson) (Norway), Nina Eide Hasselberg  
‡, 
(Task Force Co-ordinator) (Norway), Michèle de Hosson  
‡, (Task Force 
Co-ordinator) (Belgium), Margarita Brida  
(Croatia), Silvia Castelletti  
(Italy), 
Matthew Cauldwell  
(United Kingdom), Elisabetta Cerbai  
(Italy), Lia Crotti  
(Italy), Natasja M.S. de Groot  
(Netherlands), Mette-Elise Estensen  
(Norway),  
Eva S. Goossens  
(Belgium), Bernhard Haring  
(Germany), Donata Kurpas  
(Poland), Carmel M. McEniery  
(United Kingdom), Sanne A.E. Peters  
(Netherlands), Amina Rakisheva  
(Kazakhstan), Antonia Sambola  
(Spain), 
Oliver Schlager  
(Austria), Florian S. Schoenhoff  
(Switzerland), 
Tommaso Simoncini  
1 (Italy), Françoise Steinbach (France), Isabella Sudano  
(Switzerland), Lorna Swan  
(United Kingdom), Anne Marie Valente  
(United States of America), and ESC Scientific Document Group 
* Corresponding authors: Julie De Backer, Cardiology, Ghent University Hospital, Ghent, Belgium, and Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium. 
Tel: +3293323344, E-mail: julie.debacker@ugent.be. Kristina H. Haugaa, Department of Cardiology, Oslo University Hospital, Oslo, Norway, and Institute for Clinical Medicine, 
University of Oslo, Oslo, Norway. Tel: +4723070000, E-mail: kristina.haugaa@medisin.uio.no. 
† The two Chairpersons contributed equally to the document and are joint corresponding authors. 
‡ The two Task Force Co-ordinators contributed equally to the document. 
Author/Task Force Member affiliations are listed in author information. 
1 Representing the European Society of Gynecology (ESG) 
ESC Clinical Practice Guidelines (CPG) Committee: listed in the Appendix. 
ESC subspecialty communities having participated in the development of this document: 
Associations: Association of Cardiovascular Nursing & Allied Professions (ACNAP), Association for Acute CardioVascular Care (ACVC), European Association of Cardiovascular Imaging 
(EACVI), European Association of Preventive Cardiology (EAPC), European Heart Rhythm Association (EHRA), Heart Failure Association (HFA). 
Councils: Council on Cardiovascular Genomics, Council on Hypertension. 
Working Groups: Adult Congenital Heart Disease, Aorta and Peripheral Vascular Diseases, Cardiovascular Pharmacotherapy, Cardiovascular Surgery, Myocardial and Pericardial Diseases, 
Pulmonary Circulation and Right Ventricular Function, Thrombosis. 
Patient Forum 
Disclaimer The European Society of Cardiology (ESC) Guidelines represent the views of the ESC and were produced after careful consideration of the scientific and medical knowledge and 
the evidence available at the time of their publication. The ESC is not responsible in the event of any contradiction, discrepancy and/or ambiguity between the ESC Guidelines and any other 
official recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are 
encouraged to take the ESC Guidelines fully into account when exercising their clinical judgement, as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies; however, the ESC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions 
in consideration of each patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do the ESC Guidelines exempt 
health professionals from taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the competent public health authorities, in order to 
manage each patient’s case in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s responsibility to verify the 
applicable rules and regulations relating to drugs and medical devices prior to making any clinical decision and to check whether a more recent version of this document exists. The ESC warns 
readers that the technical language may be misinterpreted and declines any responsibility in this respect. 
Permissions The content of these ESC Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC Guidelines may be 
translated or reproduced in any form without written permission from the ESC. Permissions can be obtained upon submission of a written request to Oxford University Press, the publisher 
of the European Heart Journal and the party authorized to handle such permissions on behalf of the ESC (journals.permissions@oup.com). 
© The European Society of Cardiology 2025. All rights reserved.  
https://doi.org/10.1093/eurheartj/ehaf193 
ESC GUIDELINES


<!-- PAGE 2 -->

### Page 2

Document Reviewers: Werner Budts, (CPG Review Co-ordinator) (Belgium), Karen Sliwa,  
(CPG Review Co-ordinator) (South Africa), Marianna Adamo (Italy), Elena Arbelo (Spain), Eloisa Arbustini (Italy), 
Giuseppe Boriani (Italy), Antonio Brucato (Italy), Sergio Buccheri (Sweden), Alessandra Bura Riviere (France), 
Pavel Calda1 (Czech Republic), G.-Andrei Dan (Romania), Konstantinos Dimopoulos (United Kingdom), 
Alexandra Frogoudaki (Greece), Estelle Gandjbakhch (France), Eva Gerdts (Norway), Sofie A Gevaert (Belgium), 
Bruna Gigante (Sweden), Bettina Heidecker (Germany), Borja Ibanez (Spain), Stefan James (Sweden), 
Mark Johnson (United Kingdom), Peter Jüni (United Kingdom), Jolanda Kluin (Netherlands), Lars Køber 
(Denmark), Konstantinos C. Koskinas (Switzerland), Greg Lip (United Kingdom), Emma F. Magavern  
(United Kingdom), John William McEvoy (Ireland), Borislava Mihaylova (United Kingdom), Richard Mindham 
(United Kingdom), Inge Moelgaard (Denmark), Philip Moons (Belgium), Jens Cosedis Nielsen (Denmark),  
Ntobeko A. B. Ntusi (South Africa), Agnes A. Pasquet (Belgium), Tatjana Potpara (Serbia), Eva Prescott 
(Denmark), Bianca Rocca (Italy), Jolien Roos-Hesselink (Netherlands), Xavier Rosselló (Spain), Anna Sannino 
(Germany), Felix Tanner (Switzerland), Ulf Landmesser (Germany), Ilonca Vaartjes (Netherlands), 
Christiaan Vrints (Belgium), Katja Zeppenfeld (Netherlands), and Dayenne Zwaagman (Netherlands) 
All experts involved in the development of these guidelines have submitted declarations of interest 
which are reported in a supplementary document to the guidelines. See the European Heart Journal online or  
https://www.escardio.org/Guidelines for supplementary documents as well as evidence tables.  
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 
Keywords 
Guidelines • Pregnancy • Cardiovascular • Heart failure • Arrhythmias • Genetic counselling • Risk stratification • 
Pregnancy heart team • Cardiomyopathies • Drugs in pregnancy • Aortic disease • Adult congenital heart disease • 
Peripartum cardiomyopathy • Hypertensive disorders of pregnancy • Adverse pregnancy outcomes  
Table of contents 
1. Preamble ...................................................................................................................... 7 
2. Introduction ............................................................................................................... 8 
2.1. Why we need new Guidelines on cardiovascular disease and 
pregnancy ...................................................................................................................
8 
2.2. Why these Guidelines are important ....................................................
8 
2.3. What is new .....................................................................................................
8 
2.4. What has changed ....................................................................................... 11 
3. General considerations ....................................................................................... 12 
3.1. Epidemiology .................................................................................................. 12 
3.2. Physiology of pregnancy ............................................................................ 12 
4. The Pregnancy Heart Team ............................................................................. 14 
4.1. Concept and requirements ...................................................................... 14 
4.2. Pre-pregnancy counselling and family planning ............................... 14 
4.2.1. Risk assessment ....................................................................................
14 
4.2.1.1. Maternal risk assessment .........................................................
14 
4.2.2. Genetic counselling .............................................................................
14 
4.2.2.1. Pre-natal and pre-implantation diagnosis ..........................
14 
4.2.3. Reproductive technology .................................................................
14 
4.2.4. Contraception .......................................................................................
21 
4.2.5. Termination of pregnancy including psychological  
support .................................................................................................................
21 
4.3. Diagnostic methods in pregnancy ......................................................... 23 
4.3.1. Electrocardiogram, including mobile rhythm devices ...........
23 
4.3.2. Echocardiography ................................................................................
23 
4.3.3. Cardiopulmonary exercise testing ...............................................
23 
4.3.4. Biomarkers ..............................................................................................
23 
4.3.5. Ionizing radiation exposure .............................................................
23 
4.3.5.1. Chest radiography ......................................................................
23 
4.3.5.2. Computed tomography and nuclear medicine  
imaging .............................................................................................................
23 
4.3.5.3. Cardiac catheterization .............................................................
24 
4.3.6. Cardiovascular magnetic resonance ............................................
24 
4.4. Foetal assessment ......................................................................................... 24 
4.4.1. Risk of foetal/obstetric complications .........................................
24 
4.4.2. Screening for congenital heart disease in the foetus ............
24 
4.4.3. Assessing foetal well-being ..............................................................
24 
4.4.4. Foetal assessment of heritable primary arrhythmias ............
25 
4.5. Timing and mode of delivery .................................................................. 25 
4.5.1. Timing of delivery ................................................................................
25 
4.5.2. Induction of labour .............................................................................
25 
4.5.3. Vaginal or caesarean delivery .........................................................
25 
4.5.4. Haemodynamic monitoring during delivery .............................
25 
4.5.5. Anaesthesia/analgesia .........................................................................
25 
4.5.6. Delivery in women on anticoagulants ........................................
26 
4.5.6.1. Planned delivery ...........................................................................
26 
4.5.6.2. Urgent delivery on therapeutic anticoagulation ............
26 
4.5.6.2.1. Delivery on vitamin K antagonists ...............................
26 
4.5.6.2.2. Delivery on heparin ...........................................................
26 
4.5.6.3. Restarting anticoagulation after delivery ...........................
26 
4.5.7. Endocarditis prophylaxis for delivery ..........................................
26 
4.6. Post-partum monitoring and complications ..................................... 28 
4.6.1. Monitoring ..............................................................................................
28 
4.6.2. Breastfeeding and lactation ..............................................................
28 
4.6.3. Complications .......................................................................................
28 
4.6.3.1. Haemorrhage ................................................................................
28 
4.6.3.2. Psychological reactions, post-partum depression .........
28


<!-- PAGE 3 -->

### Page 3

5. Drugs during pregnancy and lactation ......................................................... 28 
5.1. General principles ........................................................................................ 28 
5.1.1. Pharmacokinetics and pharmacodynamics in pregnancy ....
28 
5.1.2. Pharmacogenetics ................................................................................
28 
5.1.3. Newborn drug exposure in breast milk ....................................
28 
5.2. Drug classes in pregnancy ........................................................................ 28 
5.2.1. Anticoagulants .......................................................................................
28 
5.2.1.1. Vitamin K antagonists ................................................................
29 
5.2.1.2. Low-molecular-weight heparins ...........................................
30 
5.2.1.2.1. Low-molecular-weight heparin dosing ......................
30 
5.2.1.2.2. Once-daily vs twice-daily administration ..................
30 
5.2.1.3. Unfractionated heparin ............................................................
30 
5.2.1.4. Fondaparinux ................................................................................
30 
5.2.1.5. Direct oral anticoagulants .......................................................
30 
5.2.2. Antiplatelet treatment .......................................................................
31 
5.2.3. Diuretics and SGLT2 inhibitors .....................................................
31 
5.2.4. Pulmonary hypertension ...................................................................
31 
5.2.5. Anti-arrhythmic agents ......................................................................
31 
5.2.6. Calcium channel blockers .................................................................
31 
5.2.7. Renin–angiotensin–aldosterone system inhibitors ................
32 
5.2.8. Lipid-lowering agents .........................................................................
32 
5.2.9. Beta-adrenergic blocking agents ....................................................
32 
5.2.10. Immunosuppressants .......................................................................
32 
5.2.11. Neuroactive drugs ............................................................................
32 
5.2.12. Obstetric drugs in patients with cardiovascular disease ..
32 
5.3. Internet databases ........................................................................................ 32 
5.4. List of drugs .................................................................................................... 32 
6. Pregnancy in women with cardiomyopathies and primary 
arrhythmia syndromes ............................................................................................. 34 
6.1. Cardiomyopathies ........................................................................................ 34 
6.1.1. Dilated cardiomyopathy and non-dilated left ventricular 
cardiomyopathy ................................................................................................
34 
6.1.2. Arrhythmogenic right ventricular cardiomyopathy ..............
34 
6.1.3. Hypertrophic cardiomyopathy ......................................................
34 
6.1.3.1. Treatment of hypertrophic cardiomyopathy in 
pregnancy .......................................................................................................
34 
6.1.3.2. Left ventricular outflow tract obstruction .......................
34 
6.1.4. Hypertrabeculation of the left ventricle ....................................
35 
6.1.5. Labour and delivery in cardiomyopathies .................................
35 
6.2. Primary arrhythmia syndromes .............................................................. 35 
6.2.1. Long QT syndrome ............................................................................
35 
6.2.2. Brugada syndrome ..............................................................................
36 
6.2.3. Catecholaminergic polymorphic ventricular  
tachycardia ..........................................................................................................
36 
6.2.4. Short QT syndrome ...........................................................................
36 
6.2.5. Labour and delivery in primary arrhythmia syndromes ......
36 
7. Peripartum cardiomyopathy ............................................................................ 37 
7.1. Epidemiology .................................................................................................. 37 
7.2. Mechanisms ..................................................................................................... 37 
7.3. Diagnosis and clinical interventions ...................................................... 37 
7.4. Outcomes ........................................................................................................ 39 
8. Pregnancy in women with aortopathies ..................................................... 39 
8.1. Women with heritable thoracic aortic disease ............................... 39 
8.1.1. Marfan syndrome .................................................................................
40 
8.1.2. Loeys–Dietz syndrome .....................................................................
40 
8.1.3. Vascular Ehlers–Danlos syndrome ...............................................
40 
8.1.4. Non-syndromic heritable thoracic aortic diseases ................
40 
8.1.5. Aortic disease with no identifiable (likely) pathogenic 
variant ...................................................................................................................
40 
8.2. Turner syndrome ......................................................................................... 40 
8.3. Bicuspid aortic valve disease .................................................................... 40 
8.4. Aortic aneurysms other than root or ascending aorta ............... 41 
8.5. Aortic dissection ........................................................................................... 41 
8.6. Management ................................................................................................... 41 
8.7. Cardiac surgery during pregnancy ........................................................ 42 
9. Pregnancy in women with known congenital heart disease ..............
43 
10. Pregnancy in women with pulmonary arterial hypertension .......... 47 
10.1. Pre-existing pulmonary arterial hypertension ............................... 47 
10.1.1. Maternal and foetal risk ..................................................................
47 
10.1.2. Counselling and contraception ...................................................
47 
10.1.3. Management during pregnancy ...................................................
47 
10.2. New diagnosis in pregnancy ................................................................. 48 
10.3. Delivery in women with pulmonary arterial hypertension ..... 48 
10.3.1. Peri- and post-partum monitoring ............................................
48 
11. Venous thromboembolism in pregnancy and post-partum ............. 48 
11.1. Epidemiology and maternal risk .......................................................... 48 
11.2. Risk factors for pregnancy-related venous thromboembolism
48 
11.3. Prevention of venous thromboembolism ....................................... 49 
11.3.1. Pregnant women with no prior indications for long-term 
anticoagulation ..................................................................................................
49 
11.3.2. Pregnant women with prior indication for long-term 
anticoagulation ..................................................................................................
49 
11.4. Management of acute venous thromboembolism ....................... 49 
11.4.1. Clinical presentation and diagnosis ............................................
49 
11.4.1.1. Deep vein thrombosis ............................................................
49 
11.4.1.2. Pulmonary embolism ..............................................................
50 
11.4.2. Treatment of venous thromboembolism in pregnancy ...
50 
11.5. Management of delivery and the post-partum period .............. 52 
12. Pregnancy in women with acquired heart disease .............................. 52 
12.1. Acute chest pain in pregnancy ............................................................. 52 
12.2. Coronary artery disease ......................................................................... 52 
12.2.1. Acute coronary syndrome ............................................................
52 
12.2.1.1. Coronary artery disease epidemiology and aetiology
52 
12.2.1.2. Presentation and diagnosis ...................................................
54 
12.2.1.3. Pregnancy-associated spontaneous coronary artery 
dissection ........................................................................................................
54 
12.2.2. Coronary artery interventions ....................................................
54 
12.2.3. Chronic coronary syndromes in pregnancy ..........................
54 
12.2.4. Management and delivery ..............................................................
54 
12.3. Hypertensive disorders ........................................................................... 55 
12.3.1. Definition and classification of hypertension in pregnancy
56 
12.3.1.1. Pre-eclampsia/eclampsia ........................................................
56 
12.3.2. Diagnosis and risk assessment .....................................................
56 
12.3.2.1. Blood pressure measurement .............................................
56 
12.3.2.2. Laboratory tests ........................................................................
56 
12.3.3. Management of hypertension in pregnancy ..........................
56 
12.3.3.1. Non-pharmacological management ..................................
56 
12.3.3.2. Pharmacological treatment ..................................................
57 
12.3.3.2.1. Mild hypertension (BP 140/90 – 159/109 mmHg)
57 
12.3.3.2.2. Pre-eclampsia .....................................................................
57 
12.3.3.2.3. Severe hypertension (BP ≥160/110 mmHg) .......
60 
12.3.4. Hypertension and delivery ............................................................
60 
12.4. Arrhythmias ................................................................................................. 61 
12.4.1. Supraventricular arrhythmias .......................................................


<!-- PAGE 4 -->

### Page 4

12.4.1.1. New-onset narrow QRS tachycardia .............................
61 
12.4.1.2. Atrial fibrillation including anticoagulation .....................
62 
12.4.1.3. Pre-existing supraventricular tachycardia .......................
63 
12.4.2. Ventricular arrhythmias ..................................................................
64 
12.4.3. Cardioversion, ablation, and device implantation, and 
implantable cardioverter defibrillator management ..........................
64 
12.4.3.1. Electrical cardioversion ..........................................................
64 
12.4.3.2. Catheter ablation ......................................................................
64 
12.4.3.3. Device implantation .................................................................
65 
12.4.3.4. Implantable cardioverter defibrillator management ..
66 
12.4.4. Cardiac arrest .....................................................................................
68 
12.4.5. Bradycardia ..........................................................................................
69 
12.4.5.1. Sinus node dysfunction ..........................................................
69 
12.4.5.2. Atrioventricular block .............................................................
69 
12.4.5.3. Management of sinus node dysfunction and 
atrioventricular block ................................................................................
69 
12.5. Valvular heart disease .............................................................................. 69 
12.5.1. Stenotic native valve lesions .........................................................
69 
12.5.1.1. Mitral valve stenosis .................................................................
70 
12.5.1.1.1. Management .......................................................................
70 
12.5.1.1.2. Interventions ......................................................................
70 
12.5.1.1.3. Delivery ................................................................................
70 
12.5.1.1.4. Post-partum .......................................................................
70 
12.5.1.2. Valvular aortic stenosis ..........................................................
70 
12.5.1.2.1. Management .......................................................................
70 
12.5.2. Regurgitant native valve lesions ...................................................
70 
12.5.2.1. Mitral and aortic valve regurgitation ................................
70 
12.5.2.1.1. Management .......................................................................
70 
12.5.2.2. Arrhythmogenic mitral valve prolapse ............................
70 
12.5.2.3. Tricuspid regurgitation ...........................................................
71 
12.5.3. Prosthetic valves ................................................................................
72 
12.5.3.1. Bioprosthetic valves .................................................................
72 
12.5.3.2. Mechanical valves ......................................................................
72 
12.5.3.2.1. Anticoagulation during pregnancy ............................
73 
12.5.3.2.2. Mechanical valve thrombosis ......................................
73 
12.5.3.2.3. Anticoagulation during delivery in women with 
mechanical heart valves .......................................................................
73 
12.5.4. Endocarditis prophylaxis ................................................................
75 
12.6. Heart failure ................................................................................................. 75 
12.6.1. Chronic heart failure .......................................................................
75 
12.6.2. Acute heart failure (including cardiogenic shock) ...............
75 
12.7. Special populations .................................................................................... 77 
12.7.1. Heart transplantation ......................................................................
77 
12.7.2. Cardio-oncology ................................................................................
77 
12.7.2.1 Gestational cancer ....................................................................
77 
12.7.2.2 Pregnancy in cancer survivors ..............................................
78 
13. Adverse pregnancy outcomes and long-term management ............ 78 
13.1. Adverse pregnancy outcomes .............................................................. 78 
13.1.1. Post-partum hypertensive disorders ........................................
78 
13.1.2. Gestational diabetes mellitus .......................................................
78 
13.1.3. Pre-term birth ....................................................................................
78 
13.1.4. Small for gestational age .................................................................
78 
13.1.5. Pregnancy loss and placental abruption ..................................
78 
13.2. Breastfeeding ............................................................................................... 78 
13.3. Women’s Heart Clinics .......................................................................... 79 
14. Key messages ....................................................................................................... 81 
15. Gaps in evidence ................................................................................................. 82 
16. ‘What to do’ and ‘what not to do’ messages from the Guidelines
83 
17. Evidence tables .................................................................................................... 83 
18. Data availability statement .............................................................................. 83 
19. Author information ........................................................................................... 88 
20. Appendix ................................................................................................................ 88 
Tables of Recommendations 
Recommendation Table 1 — Recommendations for counselling, 
pregnancy risk assessment, contraception, assisted reproductive 
technology, and the involvement of a Pregnancy Heart Team (see 
Evidence Table 1) .................................................................................................. 22 
Recommendation Table 2 — Recommendations for diagnostic 
methods in pregnancy (see Evidence Table 2) .............................................. 24 
Recommendation Table 3 — Recommendations for timing and 
mode of delivery (see Evidence Table 3) ........................................................
26 
Recommendation Table 4 — Recommendation for direct oral 
anticoagulants and pregnancy ............................................................................... 31 
Recommendation Table 5 — Recommendations for 
cardiomyopathies and pregnancy ........................................................................ 35 
Recommendation Table 6 — Recommendations for primary 
arrhythmia syndromes and pregnancy (see Evidence Tables 4–6) ...... 36 
Recommendation Table 7 — Recommendations for peripartum 
cardiomyopathy (see Evidence Table 7) .......................................................... 39 
Recommendation Table 8 — Recommendations for aortopathies, 
cardiac surgery, and pregnancy ............................................................................ 42 
Recommendation Table 9 — Recommendations for congenital 
heart disease and pregnancy (see Evidence Table 8) ................................. 47 
Recommendation Table 10 — Recommendations for pulmonary 
arterial hypertension and pregnancy ................................................................. 48 
Recommendation Table 11 — Recommendations for venous 
thromboembolic diseases and pregnancy (see Evidence Tables 9 and 
10) .................................................................................................................................... 52 
Recommendation Table 12 — Recommendations for coronary 
artery disease and pregnancy (see Evidence Table 11) ............................. 55 
Recommendation Table 13 — Recommendations for hypertensive 
disorders and pregnancy (see Evidence Tables 12–17) ............................
60 
Recommendation Table 14 — Recommendations for 
supraventricular tachycardia and pregnancy .................................................. 64 
Recommendation Table 15 — Recommendations for ventricular 
tachycardia, device implantation, catheter ablation, and pregnancy .... 67 
Recommendation Table 16 — Recommendations for cardiac arrest 
and pregnancy ............................................................................................................. 69 
Recommendation Table 17 — Recommendation for congenital 
atrioventricular block and pregnancy ................................................................ 69 
Recommendation Table 18 — Recommendations for native valve 
disease and pregnancy ............................................................................................. 72 
Recommendation Table 19 — Recommendations for prosthetic 
valves and pregnancy (see Evidence Table 18) ............................................. 73 
Recommendation Table 20 — Recommendations for chronic and 
acute heart failure and pregnancy (see Evidence Table 19) .................... 75 
Recommendation Table 21 — Recommendations for heart 
transplantation and pregnancy ............................................................................. 77 
Recommendation Table 22 — Recommendations for 
cardio-oncology and pregnancy ........................................................................... 78 
Recommendation Table 23 — Recommendations for  
long-term effects of adverse pregnancy outcomes (see Evidence 
Tables 20 and 21) ...................................................................................................... 81


<!-- PAGE 5 -->

### Page 5

List of tables 
Table 1 Classes of recommendations .................................................................. 7 
Table 2 Levels of evidence ........................................................................................ 8 
Table 3 Updates of the 2025 Guidelines on cardiovascular disease 
and pregnancy ................................................................................................................ 9 
Table 4 New recommendations ............................................................................ 9 
Table 5 Revised recommendations .................................................................... 11 
Table 6 Modified World Health Organization 2.0 classification of 
maternal cardiovascular risk .................................................................................. 16 
Table 7 Pre-implantation and pre-natal options and implications ........ 20 
Table 8 Overview of benefits and risks of different methods of 
contraception in women with cardiovascular disease ............................... 21 
Table 9 Predictors of neonatal events in pregnancies of women with 
cardiovascular disease .............................................................................................. 25 
Table 10 List of anticoagulation regimens and disease entities in 
which they are indicated ......................................................................................... 29 
Table 11 Dosing regimens for the commonly used 
low-molecular-weight heparins ............................................................................ 30 
Table 12 Risks, monitoring, and management during pregnancy and 
delivery in women with congenital heart disease ........................................ 44 
Table 13 Reasons for antepartum/post-partum thromboprophylaxis
49 
Table 14 Hypertensive disorders of pregnancy ............................................ 55 
Table 15 Risk factors for pre-eclampsia .......................................................... 56 
Table 16 ‘What to do’ and ‘what not to do’ ................................................. 83  
List of figures 
Figure 1 Physiology of haemodynamic changes, and changes in 
electrocardiogram and echocardiography during and post pregnancy
13 
Figure 2 Central illustration. Role of Pregnancy Heart Team in 
pregnancy pathway .................................................................................................... 15 
Figure 3 Composition of the core and expanded case-based 
Pregnancy Heart Team ............................................................................................ 19 
Figure 4 Pre-conception counselling and genetic aspects ........................ 20 
Figure 5 Management of urgent delivery in women under 
anticoagulants .............................................................................................................. 27 
Figure 6 Choice of medication during pregnancy (left) and during 
lactation and breastfeeding (right) ...................................................................... 33 
Figure 7 Risk factors and management of peripartum cardiomyopathy
38 
Figure 8 Thresholds for prophylactic surgical treatment prior to 
pregnancy of aortic root/ascending aneurysm (above the line) and 
recommended mode of delivery according to aortic diameter 
(below the line) ........................................................................................................... 41 
Figure 9 Algorithm for the diagnosis and treatment of deep vein 
thrombosis during pregnancy ............................................................................... 50 
Figure 10 Algorithm for the diagnosis and treatment of pulmonary 
embolism in pregnancy in stable (A) and unstable women (B) ............. 51 
Figure 11 Management of chest pain during pregnancy and within 6 
months post-partum ................................................................................................ 53 
Figure 12A Management of hypertension and pre-eclampsia in the 
emergency ward ......................................................................................................... 57 
Figure 12B Proteinuria assessment and diagnosis of pre-eclampsia .... 58 
Figure 12C Monitoring and treatment of hypertension and pre- 
eclampsia ........................................................................................................................ 59 
Figure 13 Arrhythmogenesis in pregnant women ....................................... 61 
Figure 14 Management of narrow QRS tachycardia in pregnant 
women ............................................................................................................................ 62 
Figure 15 Management of atrial fibrillation and atrial flutter in 
pregnancy ...................................................................................................................... 63 
Figure 16 Management of ventricular tachycardias in pregnancy ......... 65 
Figure 17 Management of pacemaker and implantable cardioverter 
defibrillator and pregnancy .................................................................................... 66 
Figure 18 Management of implantable cardioverter defibrillator 
shocks in pregnancy .................................................................................................. 67 
Figure 19 Management of cardiac arrest in pregnancy .............................. 68 
Figure 20 Valvular heart disease and pregnancy ........................................... 71 
Figure 21 Management of anticoagulants during the different stages 
of pregnancy in women with mechanical heart valves .............................. 74 
Figure 22 Management of acute heart failure and cardiogenic shock 
in pregnancy and up to 6 months post-partum ........................................... 76 
Figure 23 Multidisciplinary approach of adverse pregnancy outcomes
79 
Figure 24 Algorithm for the management of new-onset post-partum 
hypertension ................................................................................................................ 80 
Figure 25 Algorithm for the management of adverse pregnancy 
outcomes ....................................................................................................................... 80  
Abbreviations and acronyms 
ACE-(I) 
Angiotensin-converting enzyme(-inhibitor) 
ACHD 
Adult congenital heart disease 
ACS 
Acute coronary syndrome 
ADR 
Adverse drug reaction 
AF 
Atrial fibrillation 
AFL 
Atrial flutter 
AHF 
Acute heart failure 
AHT 
Arterial hypertension 
ALARA 
As low as reasonably achievable 
ALT 
Alanine transaminase 
AMVP 
Arrhythmic mitral valve prolapse 
APO 
Adverse pregnancy outcomes 
aPTT 
Activated partial thromboplastin time 
ARB 
Angiotensin receptor blocker 
ARNI 
Angiotensin receptor/neprilysin inhibitor 
ARVC 
Arrhythmogenic right ventricular 
cardiomyopathy 
ASA 
Acetylsalicylic acid 
ASCVD 
Atherosclerotic cardiovascular disease 
ASD 
Atrial septal defect 
ASI 
Aortic size index 
AST 
Aspartate aminotransferase 
AV 
Atrioventricular 
AV(N)RT 
Atrioventricular (nodal) re-entry tachycardia 
AVSD 
Atrioventricular septal defect 
BAV 
Bicuspid aortic valve 
B-blocker 
Beta-blocker 
b.i.d. 
Bis in die (twice a day) 
BMI 
Body mass index 
BNP 
B-type natriuretic peptide 
BP 
Blood pressure 
b.p.m. 
Beats per minute 
BrS 
Brugada syndrome 
CABG 
Coronary artery bypass graft 
CAD 
Coronary artery disease 
CARPREG II 
Cardiac Disease in Pregnancy study II 
CCB 
Calcium channel blocker 
CCS 
Chronic coronary syndromes 
CI 
Confidence interval 
CMP 
Cardiomyopathy 
CMR 
Cardiovascular magnetic resonance  
ESC Guidelines                                                                                                                                                                                                 5


<!-- PAGE 6 -->

### Page 6

CO 
Cardiac output 
COR 
Class of recommendation 
CPG 
Clinical Practice Guidelines 
CPR 
Cardiopulmonary resuscitation 
CPVT 
Catecholaminergic polymorphic ventricular 
tachycardia 
CT 
Computed tomography 
cTnI 
Cardiac troponin I 
cTnT 
Cardiac troponin T 
CTPA 
Computed tomography pulmonary angiography 
CTRCD 
Cancer-therapy-related cardiac dysfunction 
CVD 
Cardiovascular disease 
DAPT 
Dual antiplatelet therapy 
DCM 
Dilated cardiomyopathy 
DOAC 
Direct oral anticoagulant 
DVT 
Deep vein thrombosis 
ECG 
Electrocardiogram 
ECMO 
Extracorporeal membrane oxygenation 
EF 
Ejection fraction 
EORP 
EURObservational Research Programme 
ERA 
Endothelin receptor antagonist 
ESC 
European Society of Cardiology 
ESH 
European Society of Hypertension 
FAT 
Focal atrial tachycardia 
FDA 
Food and Drug Administration 
FFP 
Fresh frozen plasma 
GDM 
Gestational diabetes mellitus 
HCM 
Hypertrophic cardiomyopathy 
HELLP 
Haemolysis, elevated liver enzymes, low platelet 
count 
HF 
Heart failure 
HFrEF 
Heart failure with reduced ejection fraction 
HLA 
Human leucocyte antigen 
HR 
Heart rate 
HTAD 
Heritable thoracic aortic disease 
ICD 
Implantable cardioverter defibrillator 
INR 
International normalized ratio 
IU 
International unit 
IUGR 
Intrauterine growth restriction 
IUD 
Intrauterine device 
i.v. 
Intravenous 
IVF 
In vitro fertilization 
LA 
Left artery 
LDL 
Low-density lipoprotein 
LDS 
Loeys–Dietz syndrome 
LMWH 
Low-molecular-weight heparin 
LQT1/2/3 
Long QT syndrome type 1, 2, or 3 
LQTS 
Long QT syndrome 
LV 
Left ventricle 
LVAD 
Left ventricular assist device 
LVEDD 
Left ventricular end-diastolic diameter 
LVEF 
Left ventricular ejection fraction 
LVH 
Left ventricular hypertrophy 
LVOT(O) 
Left ventricular outflow tract (obstruction) 
MACE 
Major adverse cardiovascular events 
MFS 
Marfan syndrome 
MHV 
Mechanical heart valve 
MINOCA 
Myocardial infarction with non-obstructive 
coronary arteries  
MR 
Mitral valve regurgitation 
MRA 
Mineralocorticoid receptor antagonist 
mU 
Milliunit 
mWHO 
modified World Health Organization 
NA 
Not applicable 
NDLVC 
Non-dilated left ventricular cardiomyopathy 
NP 
Natriuretic peptide (NT-proBNP and BNP) 
NSAID 
Non-steroidal anti-inflammatory drug 
nsHTAD 
Non-syndromic heritable thoracic aortic disease 
NSTE ACS 
Non-ST-elevation acute coronary syndrome 
NT-proBNP 
N-terminal pro-brain natriuretic peptide 
NYHA 
New York Heart Association 
o.d. 
Omni die (once a day) 
oGTT 
Oral glucose tolerance test 
OR 
Odds ratio 
P/LP 
Pathogenic/likely pathogenic 
PAH 
Pulmonary arterial hypertension 
PAP 
Pulmonary arterial pressure 
PASP 
Pulmonary arterial systolic pressure 
PCI 
Percutaneous coronary intervention 
PE 
Pulmonary embolism 
PH 
Pulmonary hypertension 
PlGF 
Placental growth factor 
p.o. 
Per os (by mouth) 
PPCM 
Peripartum cardiomyopathy 
PPH 
Post-partum haemorrhage 
PREM 
Patient-reported experience measure 
PROM 
Patient-reported outcome measure 
PV 
Pulmonary valve 
QRS 
Q, R, and S waves 
RBC 
Red blood cell 
RID 
Relative infant dose 
ROPAC 
Registry of Pregnancy and Cardiac Disease 
ROSC 
Return of spontaneous circulation 
RV 
Right ventricle 
RVEF 
Right ventricular ejection fraction 
RVH 
Right ventricular hypertrophy 
RVOT(O) 
Right ventricular outflow tract (obstruction) 
RVOT-VT 
Right ventricular outflow tract ventricular 
tachycardia 
SBP 
Systolic blood pressure 
SCAD 
Spontaneous coronary artery dissection 
SGA 
Small for gestational age 
SGLT2 
Sodium–glucose co-transporter-2 
SPAP 
Systolic pulmonary artery pressure 
SpO2 
Oxygen saturation 
SQTS 
Short QT syndrome 
STEMI 
ST-elevation myocardial infarction 
SVT 
Supraventricular tachycardia 
TAD 
Thoracic aortic disease 
TAVI 
Transcatheter aortic valve implantation 
TGA 
Transposition of the great arteries 
TOF 
Tetralogy of Fallot 
TPVI 
Transcatheter pulmonary valve implementation 
TR 
Tricuspid regurgitation 
TS 
Turner syndrome 
TTE 
Transthoracic echocardiogram 
UACR 
Urine albumin–creatinine ratio 
UFH 
Unfractionated heparin


<!-- PAGE 7 -->

### Page 7

VA-ECMO 
Veno-arterial extracorporeal membrane 
oxygenation 
VF 
Ventricular fibrillation 
VHD 
Valvular heart disease 
VKA 
Vitamin K antagonist 
VSD 
Ventricle septal defect 
VT 
Ventricular tachycardia 
VTE 
Venous thromboembolism 
WCD 
Wearable cardioverter defibrillator 
WHO 
World Health Organization 
WPW 
Wolff–Parkinson–White 
1. Preamble 
Guidelines evaluate and summarize available evidence with the aim 
of assisting health professionals in proposing the best diagnostic or 
therapeutic approach for an individual patient with a given condition. 
European Society of Cardiology (ESC) Guidelines are intended for 
use by health professionals but do not override their individual responsibility to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with the 
patient or the patient’s caregiver where appropriate and/or necessary. It is also the health professional’s responsibility to verify the 
rules and regulations applicable in each country to drugs and devices 
at the time of prescription and to respect the ethical rules of their 
profession. 
ESC Guidelines represent the official position of the ESC on a given 
topic. Guideline topics are selected for updating after annual expert review of new evidence conducted by the ESC Clinical Practice 
Guidelines (CPG) Committee. European Society of Cardiology 
Policies and Procedures for formulating and issuing ESC Guidelines 
can be found on the ESC website (https://www.escardio.org/ 
Guidelines/Clinical-Practice-Guidelines/Guidelines-development/ 
Writing-ESC-Guidelines). 
This guideline updates and replaces the previous version from 2018. 
This Task Force was selected by the ESC to include professionals 
involved with the medical care of patients with this pathology and to include patient representatives and methodologists. The selection procedure included an open call for authors and aimed to include members from 
across the whole of the ESC region and from relevant ESC Subspecialty 
Communities. Consideration was given to diversity and inclusion. 
Guidelines Task Forces perform a critical review and evaluation of 
the published literature on diagnostic and therapeutic approaches 
including assessment of the risk–benefit ratio. Recommendations 
are based on major randomized trials and relevant systematic reviews and meta-analyses, when available. Systematic literature 
searches are conducted in cases of controversy or uncertainty to 
ensure that all key studies were considered. For recommendations 
related to diagnosis and prognosis, additional types of evidence 
are included, such as diagnostic accuracy studies and studies focused 
on the development and validation of prognostic models. The 
strength of each recommendation and the level of evidence supporting it are weighed and scored according to predefined criteria as 
outlined in Tables 1 and 2. Patient-reported outcome measures 
(PROMs) and patient-reported experience measures (PREMs) are 
also evaluated when available as the basis for recommendations 
and/or discussion in these guidelines. 
Evidence tables summarizing key information from relevant studies 
are generated to facilitate the formulation of recommendations, to enhance comprehension of recommendations after publication, and to 
Table 1 Classes of recommendations  
©




	












	


	
























	





 
 	­


	





	

	


ESC Guidelines                                                                                                                                                                                                 7


<!-- PAGE 8 -->

### Page 8

reinforce transparency in the guidelines’ development process. The tables are published in their own section of ESC Guidelines and reference 
specific recommendation tables. 
After an iterative process of deliberations, a first Task Force vote on all 
recommendations is conducted prior to the initiation of rounds of review. A second Task Force vote on all recommendations is conducted 
after the final round of review and revision. For each vote, the Task 
Force follows ESC voting procedures and all recommendations require 
at least 75% agreement among voting members to be approved. 
Voting restrictions may be applied based on declarations of interests. 
The writing and reviewing panels provide declaration of interest 
forms for all relationships that might be perceived as real or potential 
sources of conflicts of interest. Their declarations of interest are reviewed according to the ESC declaration of interest rules, which can 
be found on the ESC website (http://www.escardio.org/doi) and are 
compiled in a report published in a supplementary document with the 
guidelines. Funding for the development of ESC Guidelines is derived entirely from the ESC with no involvement of the healthcare industry. 
The CPG Committee supervises and coordinates the preparation of 
new guidelines and approves their publication. In addition to review by 
the CPG Committee, ESC Guidelines undergo multiple rounds of 
double-blind peer review on a dedicated online review platform. The review is conducted by topic experts, including members from ESC 
National Cardiac Societies and from relevant ESC Subspecialty 
Communities. Guideline Task Forces consider all review comments 
and are required to respond to all those classified as major. After appropriate revisions, the Task Force and the CPG Committee members approve the final document for publication in the European Heart Journal. 
Unless otherwise stated, ESC Guidelines content refers to sex, 
understood as the biological condition of being male or female, defined 
by genes, hormones, and sexual organs. Off-label use of medication may 
be presented in this guideline if a sufficient level of evidence shows that 
it can be considered medically appropriate for a given condition. 
However, decisions on off-label use must be made by the responsible 
health professional giving special consideration to ethical rules concerning healthcare, the specific situation of the patient, patient consent, and 
country-specific health regulations. 
2. Introduction 
2.1. Why we need new Guidelines on 
cardiovascular disease and pregnancy 
Since the previous version of these Guidelines was published in 2018, 
new evidence has emerged, and clinical focus has changed in various aspects, requiring an updated discussion. These include the importance of 
the Pregnancy Heart Team, the modalities for pre-pregnancy counselling and risk stratification, and drugs during pregnancy, lactation and/or 
breastfeeding, and post-partum stages. In Table 3, the most relevant updates are listed with their respective rationale. 
2.2. Why these Guidelines are important 
Cardiovascular disease (CVD) is a major cause of maternal mortality 
and morbidity. With these new Guidelines we wish to provide updated 
evidence-based guidance for patients and caregivers. Reducing maternal 
mortality and morbidity is a key priority of the World Health 
Organization (WHO). 
In managing maternal and foetal health, it is essential to balance the 
risks and benefits of maternal and foetal therapeutic needs. Due to 
the scarcity of prospective or randomized studies within this field, 
which often cannot be performed for ethical reasons, most recommendations in these Guidelines are based on evidence level 
C. Consequently, there is an ongoing need for more registries, such 
as the Registry of Pregnancy and Cardiac Disease (ROPAC) and the 
European Surveillance of Congenital Anomalies network, and prospective studies to enhance our understanding in this area. 
2.3. What is new 
As mentioned in Section 2.1, this new version of the guidelines not only 
includes an update to several recommendations (Table 4) but also introduces a structural revision. See Supplementary data online 
(Table S1) for a detailed overview of the new recommendations. 
Below we discuss the key updates per section, highlighting a selection 
of new and revised recommendations along with their rationale. 
Table 2 Levels of evidence  










	

		

	




		
					
		
					
©


<!-- PAGE 9 -->

### Page 9

Table 3 Updates of the 2025 Guidelines on cardiovascular disease and pregnancy 
Topic 
New information 
Rationale  
Pregnancy Heart Teama 
Broader acceptance, dedicated section 
Ensure comprehensive care throughout reproductive 
stagesb 
Risk stratificationa,c 
mWHO 2.0 classification, refined and expanded 
clinical categories 
More data have emerged, necessitating more nuanced risk 
assessment for patient counselling1,2 
Clinical data and research 
ROPAC3–12 and PPCM13–17 registries 
Cardiomyopathies 
Primary arrhythmia syndromes 
New or updated clinical management 
Clinical scenarios 
Algorithms for management of clinical situations in 
pregnant women 
Provide practical information for the clinical cardiologist 
Genetic testing and counselling 
Advancements in testing and pre-implantation 
procedures 
Incorporation of latest management of genetic testing and 
counselling 
Revision of contraindications (COR III) for 
pregnancy in women classified as mWHO 
class IV 
Emphasis on the critical role of comprehensive 
counselling by the Pregnancy Heart Team (COR I) 
Recognition of a woman’s autonomy in making 
reproductive choices 
Promoting a detailed and transparent dialogue about the 
heightened risks and encouraging shared decision-making 
Adverse pregnancy outcomes (APO) 
Increased focus on long-term outcomes 
Evidence supports the need for thorough discussion and 
management of APOs18 
© ESC 2025
COR, class of recommendation; mWHO, modified World Health Organization; PPCM, peripartum cardiomyopathy; ROPAC, Registry of Pregnancy and Cardiac Disease. 
aSee Section 4. 
bSee Figure 2. 
cSee Table 6.  
Table 4 New recommendations 
Recommendations 
Classa 
Levelb  
Section 4. The Pregnancy Heart Team 
Although the concept of the Pregnancy Heart Team was previously part of the general principles, it has now been given its own dedicated section, which covers all 
aspects from pre-conception through to the postpartum period. 
A discussion by the Pregnancy Heart Team about the high risk of maternal mortality or morbidity and the related high foetal risk is 
recommended for women with mWHO 2.0 class IV conditions, including a shared decision-making process for pregnancy termination, 
involving psychological support. 
I 
C 
It is recommended that women with CVD of mWHO 2.0 class II–III and above are evaluated and managed by a Pregnancy Heart Team from 
pre-pregnancy onwards through pregnancy and post-partum. 
I 
C 
Measurement of BNP and NT-proBNP levels should be considered prior to pregnancy in women with HF of any aetiology, including 
previous PPCM, cardiomyopathy, ACHD, and PAH, and be monitored during pregnancy according to the underlying disorder and in case of 
new-onset or worsening symptoms. 
IIa 
B 
Section 5. Drugs during pregnancy and lactation 
Given the importance of medication use throughout this document, this section has been brought forward and revised. The former comprehensive medication 
table has been moved to the Supplementary data online, and we provide a summary figure (Figure 6) listing the (contra)indicated medications. 
Section 6. Pregnancy in women with cardiomyopathies and primary arrhythmia syndromes 
This section has been expanded since 2018 for advice in specific cardiomyopathies and primary arrhythmias. 
Vaginal delivery is recommended in most women with CMPs, unless there are obstetric indications for caesarean section, severe HF 
(EF <30% and/or NYHA class III/IV), uncontrolled arrhythmias, or severe outflow obstruction (≥50 mmHg) in women with HCM, or in 
women presenting in labour on VKAs. 
I 
C 
In women with DCM and worsening of EF during pregnancy, counselling on the risk of recurrence during a subsequent pregnancy is 
recommended in all cases, even after recovery of LV function. 
I 
C 
It is recommended that women with HCM with symptomatic LV dysfunction (EF <50%) and or severe LVOTO (≥50 mmHg) wishing to 
become pregnant are counselled by the Pregnancy Heart Team regarding the high risk of pregnancy-related adverse events. 
I 
C 
Myosin inhibitors are not recommended in women during pregnancy due to lack of safety data. 
III 
C                       
Continued  
ESC Guidelines                                                                                                                                                                                                 9


<!-- PAGE 10 -->

### Page 10

Beta-blockers, with pre-pregnancy dose and with nadolol and propranolol as drugs of choice, are recommended during pregnancy in 
women with LQTS. 
I 
B 
It is recommended to continue beta-blocker therapy during lactation in women with LQTS to reduce arrhythmic risk. 
I 
B 
Pre-pregnancy dose beta-blockers of nadolol or propranolol is recommended in patients with LQT2, particularly in the post-partum period, 
which represents a high-risk period for life-threatening arrhythmias. 
I 
B 
Beta-blockers, with pre-pregnancy dose and with nadolol and propranolol as drugs of choice, are recommended during pregnancy and 
lactation in women with CPVT. 
I 
C 
Flecainide, in addition to beta-blockers, is recommended in women with CPVT who experience cardiac events, such as syncope, VT, or 
cardiac arrest during pregnancy. 
I 
C 
Section 7. Peripartum cardiomyopathy 
We have provided a separate section on PPCM in these guidelines. 
Genetic counselling and testing should be considered in women with PPCM. 
IIa 
C 
When a reversible course of HF is assumed, treatment in accordance with HF guidelines should be considered for at least 12 months after 
complete LV recovery (normalization of LV volumes and EF). 
IIa 
C 
Section 8. Pregnancy in women with aortopathies 
Since 2018, significant evidence has emerged in the context of heritable thoracic aortic disease (HTAD), supporting a more gene- and variant-based approach, 
which has been incorporated in this version of the guidelines. 
It is recommended that women with a history of aortic dissection or -surgery have pre-pregnancy counselling about the high risk by an 
extended Pregnancy Heart Team considering the presence and type of genetic variant, aortic morphology, growth rate, and aetiology of 
aortic dissection. 
I 
C 
Section 9. Pregnancy in women with known congenital heart disease 
This section has undergone a major update based on recent reports, which have been summarized in a clear and concise table. 
It is recommended that all women with Fontan circulation who wish to become pregnant receive counselling from the Pregnancy Heart 
Team regarding the high risk of pregnancy-related adverse events. 
I 
C 
Section 10. Pregnancy in women with pulmonary arterial hypertension 
This subject is now covered in a separate section in these guidelines, in line with growing insights into management. 
It is recommended that women of childbearing potential with PAH wishing to become pregnant are counselled by a multidisciplinary team regarding 
the very high risk of pregnancy-related adverse events, encouraging a shared decision-making process about whether to become pregnant. 
I 
C 
Section 11. Venous thromboembolism in pregnancy and post-partum 
Guidance on the involvement of an expert team and more prompt initiation of treatment are now provided in dedicated flowcharts and recommendations. 
In pregnant women or women in the post-partum period with suspicion of venous thromboembolism (VTE) [deep vein thrombosis (DVT) 
and/or PE], an immediate formal diagnostic assessment with validated methods is recommended and should not be postponed. 
I 
B 
Section 12. Pregnancy in women with acquired heart disease 
Recommendations for emergency situations are provided for acquired heart diseases in addition to the new sections on cardio-oncology and heart transplantation. 
Recommendations for coronary artery disease and pregnancy 
In pregnant women with chest pain, it is recommended to exclude life-threatening cardiovascular conditions, including PE, ACS (including 
SCAD), and acute aortic syndrome. 
I 
C 
The duration of DAPT (aspirin and clopidogrel) in pregnant women undergoing coronary stent implantation is recommended to be the 
same as in non-pregnant women, with an individual approach considering ischaemic risk and delivery-related bleeding risks. 
I 
C 
Continuation of statins may be considered during pregnancy in women with established ASCVD. 
IIb 
C 
Recommendations for hypertensive disorders and pregnancy 
It is recommended to aim for systolic BP <140 mmHg and diastolic BP <90 mmHg in pregnant women. 
I 
B 
In severe hypertension, drug treatment with i.v. labetalol, urapidil, nicardipine, or oral short acting nifedipine or methyldopa is 
recommended for acute reduction in blood pressure. Intravenous hydralazine is a second-line option. 
I 
C 
Recommendations for supraventricular tachycardia and pregnancy 
Therapeutic anticoagulation with LMWH is recommended for pregnant women with persistent or permanent AF at elevated 
thromboembolic risk. 
I 
C 
Flecainide, in addition to beta-blockers, should be considered for long-term AF rhythm control in pregnancy. 
IIa 
C 
Recommendation for ventricular tachycardia, device implantation and catheter ablation and pregnancy 
When performing catheter ablation during pregnancy, the use of non-fluoroscopic mapping and navigation systems should be considered. 
IIa 
C                         
Continued


<!-- PAGE 11 -->

### Page 11

2.4. What has changed 
Table 5 lists the recommendations with a revised Class of 
Recommendation since the 2018 Guidelines for the management 
of cardiovascular diseases during pregnancy. See Supplementary 
data online (Table S2) for a detailed overview of all modified 
recommendations. 
Recommendations for cardiac arrest and pregnancy 
Continuous manual left uterine displacement during CPR in pregnant women (≥20 weeks) with cardiac arrest is recommended to relieve 
aortocaval compression. 
I 
C 
It is recommended to establish i.v. access above the diaphragm to ensure that the i.v. therapy is not obstructed by the gravid uterus. 
I 
C 
It is recommended that no drugs are withheld in pregnant women with cardiac arrest due to concerns of teratogenicity. 
I 
C 
Recommendation for congenital atrioventricular block and pregnancy 
In pregnant women with asymptomatic congenital AV block, normal cardiac anatomy and function, a narrow QRS complex, and ventricular 
rate (≥50 b.p.m.) a prophylactic temporary pacemaker during delivery is not recommended. 
III 
C 
Recommendation for native valve disease and pregnancy 
Valve surgery during pregnancy should only be considered when there is a maternal mortality risk and other treatment options have failed. 
IIa 
C 
Recommendation for prosthetic valves disease and pregnancy 
It is recommended that a care plan documenting the agreed anticoagulant strategy (including the decision to continue VKAs or converting to 
therapeutic-dose LMWH in the first trimester) is in place for women of childbearing age with a MHV prior to pregnancy or as soon as 
pregnancy is recognized. 
I 
C 
Recommendations for chronic and acute heart failure and pregnancy 
Inotropes and/or vasopressors are recommended in pregnant women with cardiogenic shock with levosimendan, dobutamine, and 
milrinone as recommended agents. 
I 
C 
ACE-Is, ARBs, ARNIs, MRAs, ivabradine, and SGLT2 inhibitors are not recommended during pregnancy due to adverse foetal effects. 
III 
C 
Recommendations for heart transplantation and pregnancy 
It is recommended to postpone pregnancy until at least 1 year after heart transplantation, taking individual risk factors into account. 
I 
C 
In women with a heart transplant, it is recommended that immunosuppression serum drug levels are monitored during pregnancy every 4 weeks 
until the 32nd week, then every 2 weeks until the 36th week, then weekly until delivery and for 6–12 months after delivery to guide dosing. 
I 
C 
Recommendation for cardio-oncology and pregnancy 
It is recommended that pregnant women with cancer who require cardiotoxic cancer therapy are jointly managed by the Pregnancy Heart 
Team and the cardio-oncology team. 
I 
C 
Section 13. Long-term effects of adverse pregnancy outcomes 
This is a completely new section in the guidelines, reflecting the growing recognition of the importance of APOs. 
It is recommended to undertake a cardiovascular risk assessment in women with APOs, to recognize and document APOs when CVD risk is 
evaluated in women, and to provide counselling on the importance of healthy lifestyle choices that optimize cardiovascular health. 
I 
B 
© ESC 2025
ACE-I, angiotensin-converting enzyme inhibitor; ACHD, adult congenital heart disease; ACS, acute coronary syndrome; AF, atrial fibrillation; APO, adverse pregnancy outcomes; ARB, 
angiotensin receptor blocker; ARNI, angiotensin receptor/neprilysin inhibitor; ASCVD, atherosclerotic cardiovascular disease; AV, atrioventricular; BNP, brain natriuretic peptide; BP, 
blood pressure; CMP; cardiomyopathy; CPR, cardiopulmonary resuscitation; CPVT, catecholaminergic polymorphic ventricular tachycardia; CVD, cardiovascular disease; DAPT, dual 
antiplatelet therapy; DCM, dilated cardiomyopathy; DVT, deep vein thrombosis; EF, ejection fraction; HCM, hypertrophic cardiomyopathy; HF, heart failure; HTAD, heritable thoracic 
aortic disease; i.v., intravenous; LMWH, low-molecular-weight heparin; LQT2, long QT syndrome type 2; LQTS, long QT syndrome; LV, left ventricle; LVOTO, left ventricular outflow 
tract obstruction; MHV, mechanical heart valve; MRA, mineralocorticoid receptor antagonist; mWHO, modified World Health Organization; NT-proBNP, N-terminal pro-brain 
natriuretic peptide; NYHA, New York Heart Association; PAH, pulmonary arterial hypertension; PE, pulmonary embolism; PPCM, peripartum cardiomyopathy; SCAD, spontaneous 
coronary artery dissection; SGLT2, sodium–glucose co-transporter-2; VKA, vitamin K antagonist; VT, ventricular tachycardia; VTE, venous thromboembolism. 
aClass of recommendation. 
bLevel of evidence.  
Table 5 Revised recommendations 
Recommendations in 2018 
Classa 
Levelb 
Recommendations in 2025 
Classa 
Levelb  
Section 4. The Pregnancy Heart Team 
Prophylactic antibiotic therapy to prevent endocarditis 
during delivery is not recommended. 
III 
C 
Systemic antibiotic prophylaxis may be considered for 
delivery in women at high risk. 
IIb 
C 
Section 6. Recommendations for cardiomyopathies and pregnancy 
In patients with HCM, it is recommended that 
beta-blockers are continued in women who used them 
before pregnancy. 
I 
C 
Continuation of beta-blockers should be considered 
during pregnancy in women with CMPs, with close 
follow-up of foetal growth. 
IIa 
C                       
Continued  
ESC Guidelines                                                                                                                                                                                               11


<!-- PAGE 12 -->

### Page 12

### 3 General considerations

3.1. Epidemiology 
Within high-income countries the number of pregnancies and deliveries in 
women with acquired, congenital, or inherited CVD is growing significantly.19–21 This trend originates from several factors: higher maternal age at 
first pregnancy, a growing number of women with congenital heart disease 
reaching childbearing age, and a rising prevalence of cardiovascular comorbidities.19–21 Globally, up to 4% of pregnancies are complicated by 
CVD, rising to 10% when including hypertensive disorders.22–25 
Maternal CVD is now the leading cause of non-obstetric mortality in pregnant women24,26, accounting for 33% of pregnancy-related deaths worldwide.25,27,28 In women with pre-existing CVD, up to 16% of pregnancies 
are complicated by CVD.29–32 Notably, 68% of pregnancy-related deaths 
caused by CVD are preventable.33 Women with CVD during pregnancy 
face higher risk of cardiac events later in life, making secondary prevention 
crucial.25 Adverse neonatal outcomes occur in ∼25% of these pregnancies 
in women with CVD34,35 with high rates of obstetric complications (17%) 
and maternal mortality/morbidity (11%).34,35 Of note, recent research indicates that pre-existing CVD in the mother is associated with an increased risk of CVD in her children, and this association is unlikely to be 
explained by unmeasured familial or genetic factors.36 
3.2. Physiology of pregnancy 
Pregnancy induces physiological changes in the cardiovascular system to 
meet the increased metabolic needs of the mother and foetus (Figure 1). 
These changes occur from the early stages of pregnancy onward. Starting 
at 6 weeks of gestation, stroke volume and cardiac output (CO) increase 
Section 8. Recommendations for aortopathies, cardiac surgery, and pregnancy 
Pregnancy is not recommended in patients with 
vascular Ehlers–Danlos syndrome. 
III 
C 
It is recommended that women with vascular Ehlers– 
Danlos syndrome wishing to become pregnant are 
counselled regarding the very high risk of 
pregnancy-related adverse events by a multidisciplinary 
team, considering family history, genetic variant, and 
previous vascular events. 
I 
C 
Beta-blocker therapy throughout pregnancy should be 
considered in women with Marfan syndrome and other 
heritable thoracic aortic diseases. 
IIa 
C 
Beta-blocker therapy throughout pregnancy and in the 
post-partum period is recommended in women with 
MFS and other HTADs. 
I 
C 
Section 9. Recommendations for congenital heart disease and pregnancy 
Patients with a systemic right ventricle (Mustard/ 
Senning or congenitally corrected TGA), in NYHA class 
III/IV, systemic ventricular dysfunction (EF <40%), or 
severe TR should be advised against pregnancy. 
IIa 
C 
It is recommended that women with a systemic RV 
(Mustard/Senning or congenitally corrected TGA), in 
NYHA class III/IV, systemic ventricular dysfunction 
(EF <40%), or severe TR wishing to become pregnant 
are counselled by the Pregnancy Heart Team regarding 
the high risk of pregnancy-related adverse events. 
I 
C 
Section 12. Recommendations for acquired heart disease and pregnancy 
An invasive management strategy should be considered 
for NSTE ACS with high-risk criteria. 
IIa 
C 
It is recommended to manage pregnant women with 
ACS in the same way as non-pregnant women, including 
diagnostic investigations and interventions. 
I 
C 
Catheter ablation with electro-anatomical systems 
should be considered in experienced centres in cases of 
drug-refractory and poorly tolerated SVT. 
IIa 
C 
Catheter ablation may be considered in pregnant 
women with recurrent, long symptomatic SVT or with 
contraindications to pharmacological therapies. 
IIb 
C 
Balloon aortic valvuloplasty should be considered 
during pregnancy in patients with severe aortic stenosis 
and severe symptoms. 
IIa 
C 
In very selected symptomatic pregnant women with 
severe aortic stenosis not responding to medical 
therapy, non-surgical options such as balloon 
valvuloplasty or TAVI may be considered. 
IIb 
C 
A bioprosthesis should be considered in young women 
contemplating pregnancy. 
IIa 
C 
A bioprosthetic valve is recommended (over a 
mechanical valve) in young women contemplating 
pregnancy requiring a valve prosthesis. 
I 
B 
During the second and third trimesters, LMWH with 
anti-factor Xa level monitoring and dose adjustment 
(see separate recommendations) may be considered in 
women who need a high dose of VKA after patient 
information and consent. 
IIb 
C 
During the second and third trimesters until the 36th 
week, continuing VKAs should be considered in women 
with prosthetic heart valves at higher risk of thrombosis. 
IIa 
C 
© ESC 2025
ACS, acute coronary syndrome; CMP, cardiomyopathy; EF, ejection fraction; HCM, hypertrophic cardiomyopathy; HTAD, heritable thoracic aortic disease; LMWH, low-molecular-weight 
heparin; MFS, Marfan syndrome; NSTE ACS, non-ST-elevation myocardial infarction; NYHA, New York Heart Association; RV, right ventricle; SVT, supraventricular tachycardia; TAVI, 
transcatheter aortic valve implantation; TGA, transposition of the great arteries; TR, tricuspid regurgitation; VKA, vitamin K antagonist. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 13 -->

### Page 13

by 30%–50%, and heart rate increases by 10–20 beats per minute. 
Peripheral vascular resistance decreases by 20%–50%.37 
Left and right atrial and ventricular diameters and volumes increase 
while ventricular function is preserved.38 Blood pressure and CO increase during labour.39 After delivery, the uterus contracts, and CO 
drops rapidly to ∼15%–25% above normal. A gradual decrease of 
CO follows over the next 3–4 weeks and reaches pre-pregnancy levels 
at ∼6 weeks post-partum. 
In women with heart disease, left and right ventricular adaptation to 
pregnancy can be suboptimal and can lead to heart failure (HF) and 
atrial and ventricular tachyarrhythmias. Atrial arrhythmias may develop 
in response to cardiac stretch and hormonal changes in pregnancy and 
may not be well tolerated in women with CVD. The haemodynamic 
and hormonal changes during pregnancy are risk factors for aortic dissection in women with aortopathy.40 Pregnancy is a hypercoagulable 
state associated with an increased risk of thromboembolism.41 
Increased activity of gastrointestinal–hepatic metabolism, liver enzyme 
systems, glomerular filtration rate and plasma volume, changes in protein binding, and decreased serum albumin levels all contribute to 
changes in the pharmacokinetics of many drugs.42 











		



	



	





	
	

	
		












	


 
­
 









	



























Figure 1 Physiology of haemodynamic changes, and changes in electrocardiogram and echocardiography during and post pregnancy. BP, blood pressure; 
ECG, electrocardiogram; LA, left atrium; LV, left ventricle; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; RV, right 
ventricle; RVEF, right ventricular ejection fraction; SPAP, systolic pulmonary artery pressure.   
ESC Guidelines                                                                                                                                                                                               13


<!-- PAGE 14 -->

### Page 14

### 4 The Pregnancy Heart Team

4.1. Concept and requirements 
The central role of the Pregnancy Heart Team is illustrated in  
Figure 2. The concept of the Pregnancy Heart Team was first introduced in the 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy.43 It has become an established 
component in the care of women with CVD or those who develop 
cardiovascular problems during pregnancy.44–49 This care provision 
commences prior to pregnancy and persists through the post- 
partum period. Research has shown that management by a 
Pregnancy Heart Team is associated with favourable maternal, foetal, 
and healthcare services outcomes, including lowered maternal mortality and readmission rates and subsequently improved patient 
safety.50 Institutional Pregnancy Heart Teams should be established 
in referral hospitals, taking into account the geographical regions, 
disciplines represented, and numbers of births, as well as sociocultural aspects.44,45,47–49 Maintaining a balance between the need for 
follow-up by such teams and the workload on these teams is crucial, 
emphasizing the importance of carefully selecting women who should 
be directed to a Pregnancy Heart Team. Patient selection is best accomplished by a risk assessment using the modified World Health 
Organization (mWHO) 2.0 classification (Table 6). The Pregnancy 
Heart Team should encompass a core team that can be expanded 
with other experts (see Figure 3), tailored to women’s physical and 
mental health or emerging complications.53 
The primary responsibilities of the Pregnancy Heart Team encompass 
risk assessment, collaborative care plan development, continuous 
progress monitoring, coordination, patient education, and psychological counselling. A staged approach is recommended, from 
pre-conception and pregnancy through to labour, delivery, and 
post-partum care. Promoting shared decision-making is essential 
at all stages. Not every hospital needs to establish a dedicated 
Pregnancy Heart Team, but each hospital should establish communication and collaboration with nearby expert teams, optimizing 
emergency and elective referral pathways within a shared-approach 
care model. 
4.2. Pre-pregnancy counselling and family 
planning 
Women should receive pre-pregnancy counselling and education about 
the maternal, foetal, and transmission risk(s).54 In adolescents diagnosed 
with congenital or inherited heart disease, tailored discussions about reproductive health should start early, ideally from menarche. Girls and women with congenital heart disease may not demonstrate appropriate 
understanding of safe contraception and pregnancy risk. High rates of unintended pregnancies (up to 45%) have been reported in adolescents 
with congenital heart disease.55 Transition programmes showed improved disease-related knowledge levels in adolescents with congenital 
heart disease.56–58 
4.2.1. Risk assessment 
A personalized pregnancy-related risk assessment is needed in all women with CVD and should encompass the specific cardiovascular diagnosis, functional status, and medication regimen, as well as non-cardiac 
risk factors such as maternal age, smoking history, comorbidities, body 
mass index (BMI), obstetric history, logistical care aspects, maternal 
ethnicity, and socioeconomic status. It is also crucial to integrate foetal 
and obstetric outcomes with specific cardiovascular considerations. 
Maternal preferences should be thoroughly explored as part of the 
shared decision-making process. 
4.2.1.1. Maternal risk assessment 
Depending on the diagnosis, a cardiovascular assessment may include imaging, biomarker-level assessment, and functional testing. Cardiopulmonary 
exercise testing can be useful for pre-pregnancy risk stratification.59,60 
Assessment may include re-evaluation after discontinuation of teratogenic 
medications and whether pre-pregnancy intervention is required. 
Various scoring systems are available to assess maternal risk and foetal 
risk. These do not fully explore the interaction with non-cardiac risk factors, 
only focus on maternal cardiac events, and have mainly been validated in 
higher-income countries. Further adaptation and validation in other countries may be required.51 Despite these limitations, disease-specific risks can 
be effectively assessed using the mWHO classification, validated as the 
best-available risk assessment model.1,61 However, the mWHO classification is oriented towards adult congenital heart disease (ACHD) and identifying those at the highest risk. Therefore, the mWHO 2.0 classification has 
now been expanded with other CVDs and refined by integrating the 
Cardiac Disease in Pregnancy study (CARPREG) II (Table 6).52 Specific expertise and collaborative management by a Pregnancy Heart Team is mandatory for all women with a condition of mWHO 2.0 class II–III or above. 
4.2.2. Genetic counselling 
Several CVDs have a genetic basis, including heritable cardiac conditions 
such as some aortopathies, channelopathies, cardiomyopathies, congenital 
heart disease, and subsets of pulmonary arterial hypertension (PAH) and 
thromboembolic disease. Most show autosomal dominant inheritance 
with a 50% transmission risk. Knowledge of an underlying pathogenic/likely 
pathogenic (P/LP) variant (adjusted terminology for mutation) is of increasing importance to better assess pregnancy-related outcomes and to adjust 
management (Figure 4).62,63 Therefore, it is recommended that genetic 
testing for CVD is performed pre-pregnancy in a specialized cardiogenetic 
centre or a network model with access to a multidisciplinary team, involving appropriately trained professionals with expertise in genetic testing 
methodology, sequence variant interpretation, clinical application of genetic testing, and pre- and post-testing genetic counselling about the transmission risk and the variable expression of an inherited genetic condition.64,65 
4.2.2.1. Pre-natal and pre-implantation diagnosis 
A timely discussion about pre-implantation (or pre-gestational) genetic 
testing and pre-natal testing should be offered to every woman and/or 
couple when there is a known parental monogenic or chromosomal abnormality. Pre-implantation genetic testing requires in vitro fertilization 
(IVF). The modalities of pre-natal and pre-implantation testing, including 
precautions, are summarized in Table 7. The decision whether to pursue pre-implantation or pre-natal genetic testing should include consideration of a spectrum of aspects related to the disease, including 
cultural, religious, and legal issues, but also accessibility of required techniques and expertise.67 Counselling should be provided at an experienced centre with an expert multidisciplinary team. An individualized 
approach is required to ensure autonomous choice and informed 
decision-making within the local ethical and legal framework. Several 
of these options take time and require early referral. 
4.2.3. Reproductive technology 
Infertility rates in most women with CVD are similar to 
those in the general population, but managing infertility and 
medically assisted reproductive treatment is more complex.68


<!-- PAGE 15 -->

### Page 15








	






















 	

­





	
	
­
	
­
	


	
­
­
	
	

	

	


	
Figure 2 Central illustration. Role of Pregnancy Heart Team in pregnancy pathway. CMP, cardiomyopathy; mWHO, modified World Health Organization.   
ESC Guidelines                                                                                                                                                                                               15


<!-- PAGE 16 -->

### Page 16

Table 6 Modified World Health Organization 2.0 classification of maternal cardiovascular risk  
mWHO 2.0 I 
mWHO 2.0 II 
mWHO 2.0 II–III 
mWHO 2.0 III 
mWHO 2.0 IV  
Diagnosis 
Ventricular (dys)function + pulmonary hypertension   
Mild left ventricular 
impairment: EF >45%. 
Significantly impaired 
RV (subpulmonary) 
function. 
Moderate left 
ventricular impairment: 
EF 30%–45%. 
Previous PPCM with 
not more than mild 
residual left ventricular 
impairment. 
Severe left ventricular 
impairment: EF <30% 
or NYHA class III/IV. 
Previous PPCM with 
more than mild left 
ventricular 
impairment.  
PAH. 
Arrhythmias 
Atrial or ventricular 
ectopic beats, isolated. 
Most 
supraventricular 
arrhythmias. 
Bradycardia 
requiring 
pacemaker. 
Low-risk LQTS: no 
previous events + on 
full dose beta-blocker 
therapy. 
Low-risk CPVT: well 
controlled by medical 
therapy. 
BrS with no previous 
events. 
Sustained ventricular 
tachycardia from any 
aetiology. 
LQT2 (post-partum). 
Symptomatic CPVT 
and LQTS not 
adequately controlled 
by therapy. 
BrS with previous 
events.  
Cardiomyopathy 
HCM: genotype-positive 
+ phenotype-negative.  
Low-risk ARVC: 
genotype-positive + no 
or mild phenotype. 
HCM without 
complications. 
DCM/NDLVC with 
normal or mild left 
ventricular 
impairment: EF >45%. 
ARVC with moderate/ 
severe disease. 
HCM with arrhythmic 
and/or moderate 
haemodynamic 
complications. 
DCM/NDLVC with 
moderate left 
ventricular impairment: 
EF 30%–45%. 
DCM/NDLVC with 
severe left ventricular 
impairment: EF <30% 
or NYHA class III/IV. 
HCM with 
symptomatic severe 
outflow tract 
obstruction: 
≥50 mmHg. 
HCM with severely 
symptomatic LV 
dysfunction (EF <50%). 
Congenital heart disease 
Successfully repaired 
simple lesions without 
significant residual 
(haemodynamic) 
complications (atrial or 
ventricular septal defect, 
patent ductus arteriosus, 
anomalous pulmonary 
venous drainage). 
Unoperated 
uncomplicated 
atrial or ventricular 
septal defect. 
Repaired tetralogy 
of Fallot without 
significant residual 
haemodynamic/ 
arrhythmic lesions. 
Transposition of 
the great arteries 
with arterial switch 
without significant 
residual lesions. 
Repaired 
atrioventricular septal 
defect without 
significant residual 
lesions. 
Uncomplicated 
Ebstein anomaly: mild 
to moderate TR, no 
tricuspid stenosis, no 
accessory pathway. 
Unrepaired cyanotic 
heart disease (not 
Eisenmenger). 
Systemic RV with good 
or mildly decreased 
ventricular function. 
Uncomplicated Fontan 
circulation: good 
ventricular function, no 
significant valve disease 
or arrhythmias, good 
exercise tolerance, and 
normal arterial 
saturations. 
Ebstein anomaly with 
any complication. 
Systemic RV with 
moderate or severely 
decreased ventricular 
function. 
Fontan with any 
complication. 
Eisenmenger 
syndrome.                                       
Continued


<!-- PAGE 17 -->

### Page 17

mWHO 2.0 I 
mWHO 2.0 II 
mWHO 2.0 II–III 
mWHO 2.0 III 
mWHO 2.0 IV  
Valvular heart disease 
Small or mild 
• pulmonary stenosis 
• mitral valve prolapse 
without significant 
regurgitation.  
Native, homograft or 
tissue valve disease not 
considered mWHO 
2.0 I or IV: mild mitral 
stenosis, moderate 
aortic stenosis. 
Moderate valvular 
regurgitation. 
Uncomplicated 
mechanical valve with 
stable well controlled 
INRs. 
Moderate mitral stenosis. 
Severe asymptomatic 
aortic stenosis. 
Severe left-sided valvular 
regurgitation. 
Severe mitral stenosis. 
Severe symptomatic 
aortic stenosis. 
Aortopathy 
Non-HTAD mild aortic 
dilatation (<40 mm). 
Turner syndrome 
without 
cardiovascular 
features (BAV, 
coarctation, AHT, 
aortic dilatation). 
Marfan or other 
HTAD syndrome 
without aortic 
dilatation. 
Aorta <45 mm in BAV 
pathology. 
Repaired coarctation. 
Moderate aortic 
dilatation: 40–45 mm in 
Marfan syndrome or 
other HTAD; 
45–50 mm in BAV, 
Turner syndrome ASI 
20–25 mm/m2, other 
aortic dilatation 
<50 mm. 
Marfan with previous 
aortic root replacement. 
Previous aortic 
dissection with stable 
diameter. 
Severe aortic 
dilatation: >45 mm in 
Marfan syndrome or 
other HTAD, 
>50 mm in BAV, 
ASI >25 mm/m2 in 
Turner syndrome, 
other aortic dilatation 
>50 mm. 
Vascular Ehlers– 
Danlos syndrome. 
Severe (re)coarctation. 
Previous aortic 
dissection with 
increasing diameter. 
Acquired + coronary heart disease + other    
Prior SCAD. 
Prior ischaemic cardiac 
event (STEMI/NSTE 
ACS). 
Prior adverse pregnancy 
outcome requiring 
hospitalization. 
Prior adverse 
cardiovascular effects of 
cancer treatment.  
Risk 
No detectable increased 
risk of maternal mortality 
and no/mild increased risk 
in morbidity. 
Small increased risk 
of maternal 
mortality or 
moderate increase 
in morbidity. 
Intermediate increased 
risk of maternal 
mortality or moderate 
to severe increase in 
morbidity. 
Significantly increased 
risk of maternal 
mortality or severe 
morbidity. 
Extremely high risk of 
maternal mortality or 
severe morbidity. 
Average 
maternal 
cardiac 
event 
ratesa 
Van Hagen 
et al. 
(2016)51 
9.9% 
7.7% 
17.7% 
28.9% 
50.3% 
Silversides 
et al. 
(2018)52 
3.1% 
21.7% 
12.8% 
21.1% 
35.6% 
Individualize each maternal risk with the modifiers belowb (derived from CARPREG II)52 
CARPREG II score: 1 point 
• No prior cardiac intervention indicated 
• Late pregnancy assessment 
CARPREG II score: 2 points 
• Ventricular dysfunction 
• High-risk left-sided valve disease or outflow 
tract obstruction 
• Pulmonary hypertension 
• Coronary artery disease 
• High-risk aortopathy 
CARPREG II score: 3 points 
• Prior cardiac event or arrhythmias 
• Baseline NYHA III/IV or cyanosis 
• Mechanical valve                                                                
Continued  
ESC Guidelines                                                                                                                                                                                               17


<!-- PAGE 18 -->

### Page 18

mWHO 2.0 I 
mWHO 2.0 II 
mWHO 2.0 II–III 
mWHO 2.0 III 
mWHO 2.0 IV  
Involvement of the 
Pregnancy Heart 
Team 
No 
No 
Yes 
Yes 
Yes 
Counselling 
Yes (by regular healthcare 
professional) 
Yes (by regular 
healthcare 
professional) 
Yes: expert counselling 
by Pregnancy Heart 
Team is required 
Yes: expert counselling 
by Pregnancy Heart 
Team is required 
Yes: expert 
counselling by 
Pregnancy Heart 
Team is required, with 
clear and thorough 
discussion of very high 
pregnancy risk and 
shared 
decision-making 
process for 
termination if 
pregnancy occurs 
Obstetric and cardiac 
care during 
pregnancy 
Local hospital 
Local hospital 
Shared care with local 
hospital + Pregnancy 
Heart Team 
Care led by Pregnancy 
Heart Team 
Care led by Pregnancy 
Heart Team 
Location of delivery 
Local hospital 
Local hospital 
Shared care with local 
hospital + Pregnancy 
Heart Team. Location 
depends on CV status 
and evolution of 
pregnancy 
Expert centre, care led 
by Pregnancy Heart 
Team 
Expert centre, care led 
by Pregnancy Heart 
Team 
© ESC 2025
AHT, arterial hypertension; ARVC, arrhythmogenic right ventricular cardiomyopathy; ASI, aortic size index; BAV, bicuspid aortic valve; BrS, Brugada syndrome; CARPREG II, Cardiac Disease 
in Pregnancy study II; CPVT, catecholaminergic polymorphic ventricular tachycardia; CV, cardiovascular; DCM, dilated cardiomyopathy; EF, ejection fraction; HCM, hypertrophic 
cardiomyopathy; HTAD, heritable thoracic aortic diseases; INR, international normalized ratio; LQTS, long QT syndrome; LQT2, long QT syndrome type 2; LV, left ventricle; mWHO, 
modified World Health Organization; NDLVC, non-dilated left ventricular cardiomyopathy; NSTE ACS, non-ST-elevation acute coronary syndrome; NYHA, New York Heart 
Association; PAH, pulmonary arterial hypertension; PPCM, peripartum cardiomyopathy; RV, right ventricle; SCAD, spontaneous coronary artery dissection; STEMI, ST-elevation 
myocardial infarction; TR, tricuspid regurgitation. 
aDefinition of cardiac events: cardiac arrest, cardiac death, arrhythmia requiring treatment, left/right heart failure, thromboembolic event, aortic dissection, acute coronary syndrome, or 
hospitalization for cardiac reason. Endocarditis only in van Hagen et al.51 




	

	

	

	

	










 



bEstimation of maternal adverse cardiac event rate with integration of CARPREG II score. Reprinted from Silversides et al.52 with permission from Elsevier.


<!-- PAGE 19 -->

### Page 19

Nevertheless, women with CVD requesting reproductive treatment 
should not be turned down based on assumed cardiovascular risk until their case has been discussed in a multidisciplinary setting involving 
the Pregnancy Heart Team. 
Assisted reproduction has added risks above those of pregnancy 
alone; superovulation is pro-thrombotic and can be complicated by ovarian hyperstimulation syndrome, with marked fluid shifts and a high 
thrombosis risk. All women with CVD who are embarking on fertility 
treatment should have an individual risk assessment for venous thromboembolism (VTE) given the risk associated with these techniques.69 The 
risk of ovarian hyperstimulation syndrome can be reduced by careful cycle monitoring, using a low-dose follicle-stimulating hormone in combination with a gonadotropin-releasing hormone antagonist. Transferring 
a single embryo is strongly advised in women with CVD, as carrying 
multiple gestations is associated with greater cardiovascular changes 
and more maternal and foetal complications.70,71 
In women with mWHO 2.0 class III conditions or those who are anticoagulated (Table 6), the risk of complications from superovulation is 
very high. It is therefore recommended that these women have a full 
pre-pregnancy assessment by a Pregnancy Heart Team prior to the 




















	







	




	

	





	





	















































	








Figure 3 Composition of the core and expanded case-based Pregnancy Heart Team. MDT, multidisciplinary team.   
ESC Guidelines                                                                                                                                                                                               19


<!-- PAGE 20 -->

### Page 20















	





 ­

­ ­­
­



­
	




	

	


Figure 4 Pre-conception counselling and genetic aspects. ARVC, arrhythmogenic right ventricular cardiomyopathy; CPVT, catecholaminergic polymorphic 
ventricular tachycardia; DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; LQTS, long QT syndrome; PAH, pulmonary arterial 
hypertension.  
Table 7 Pre-implantation and pre-natal options and implications  
Pre-implantation genetic 
diagnosis 
IVF procedure followed by biopsy and genetic testing of a single cell of the embryo. Embryo transfer with success rate of 
25%–30% (dependent on mother’s age and fertility). 
Risks to mother and offspring of IVF, such as multiple birth, premature labour and low birth weight, as well as side effects of 
hormonal treatment. 
Availability, expense and methods differ across countries. 
Chorionic villus sampling 
Transcervical or transabdominal sampling of the chorionic villi at the end of the first trimester. 
Procedure-related foetal loss rate ∼0.2%.66 
Amniocentesis 
Direct sampling of amniotic fluid after 15 weeks of gestation. 
Procedure-related foetal loss rate ∼0.1%.66 
© ESC 2025
Adopted from the 2023 ESC Guidelines for the management of cardiomyopathies.60 
IVF, in vitro fertilization.


<!-- PAGE 21 -->

### Page 21

procedure, including an evaluation of the risk of hormonal treatment. 
The option of natural cycle IVF should be considered. Hysteroscopy 
and laparoscopy can be life-threatening procedures in women with specific cardiac conditions, such as a Fontan circulation, and should only be 
undertaken in an experienced centre with appropriate support. 
Fertility treatment should be avoided in women with mWHO 2.0 
class IV conditions. 
4.2.4. Contraception 
To ensure informed decision-making about pregnancy, accurate 
counselling about contraception should be provided to all girls 
and women of childbearing age with CVD, starting from menarche, 
to prevent unplanned pregnancies. An overview of the benefits and 
risks of different types of contraception in women with CVD is provided in Table 8. 
4.2.5. Termination of pregnancy including 
psychological support 
It is strongly recommended to consider and discuss termination of 
pregnancy with women whose risk is classified as mWHO 2.0 class 
IV due to the exceptionally elevated risk of maternal and foetal mortality or severe morbidity.83 Efforts should be made to minimize delays for women seeking pregnancy termination because the risk of 
procedure-related complications increases as gestational age advances. Surgical methods are often preferred, but pharmacological 
methods remain an option until the ninth week of pregnancy.83 
Given the emotional and psychological impact of pregnancy termination, it is crucial to provide professional psychosocial support, which 
plays a significant role in reducing adverse mental health outcomes.89 
At the same time a discussion should be held regarding appropriate 
contraception. 
Table 8 Overview of benefits and risks of different methods of contraception in women with cardiovascular disease 
Method 
Benefits 
Cardiovascular 
risks 
Cautious use and contraindications 
Contraceptive 
efficacy  
Hormonal oral contraceptives 
Progestin-only oral 
contraceptives 
Minimal/no impact 
on coagulation 
factors 
Safe CV risk 
profile72,73 
Mild fluid retention 
LQTS not on beta-blockers74,75 
++ (general) 
+++ (for 
drospirenone)73 
Combined oral 
contraceptives76,77 
Regular 
menstruation with 
reduced blood loss 
VTE, hypertension 
and altered lipid 
profilea 
Known dyslipidaemia78 
Pre-existing hypertension79 
Obesity80 
Cyanosis 
MHV 
Fontan circulation 
Risk factors for ACS81 
+++ 
Long-acting reversible contraceptives 
Levonorgestrel-releasing 
IUD 
↓ Menstrual bleeding 
and iron loss 
None specified 
Vasovagal responses on insertion and 
removal (done by gynaecologist) → caution 
and monitoring with availability of 
anaesthesiologist recommended in PAH and 
Fontan circulation82 
Safest and most 
effective option 
+++ 
Smaller levonorgestrel IUD 
↓ Menstrual bleeding 
and iron loss 
Easier to insert 
↓ Risk of vasovagal 
responses 
None specified 
— 
+++ 
Copper IUD 
↓ Cost 
— 
↑ Intensity of menstrual bleeding 
+++ 
Etonogestrel-releasing 
subcutaneous implants 
No pelvic infection 
risk 
None specified 
Surgical subcutaneous insertion (in the 
forearm with local anaesthesia—outpatient 
procedure) 
+++ 
Depot 
medroxyprogesterone 
acetate injection83 
Lighter menses 
Increased VTE risk, 
weight gain 
Irregular bleeding 
++ 
Barrier methods 
— 
↓ Pelvic infection risk84 
— 
None specified 
+                                                 
Continued  
ESC Guidelines                                                                                                                                                                                               21


<!-- PAGE 22 -->

### Page 22

Permanent sterilization 
Tubal ligation 
Vasectomy 
Permanent 
Anaesthetic and 
procedural risks 
Non-reversible 
+++ 
Emergency contraception 
Oral contraceptive pills to delay ovulation 
Ulipristal acetate 
↑ Effectiveness than 
levonorgestrel 
No ↑ thrombosis 
risk85–87 
None specified 
+++ (only if taken 
before ovulation) 
Levonorgestrel 
single dose of 1.5 mg <72 h after 
unprotected intercourse 
— 
No ↑ thrombosis risk 
None specified 
++ (only if taken before 
ovulation) 
Contraceptive device 
Copper IUD 
<120 h after unprotected intercourse 
— 
— 
None specified 
+++ (in addition to 
ongoing 
contraception)85–88 
© ESC 2025
ACS, acute coronary syndrome; CV, cardiovascular; IUD, intrauterine device; LQTS, long QT syndrome; mg, milligram; MHV: mechanical heart valve; PAH, pulmonary arterial hypertension; 
VTE, venous thromboembolism. 
↑ increase ↓ decrease. 
aHigher in combined oral contraceptive pills containing ethyniloestradiol compared to natural oestradiol or oestetrol.  
Recommendation Table 1 — Recommendations for counselling, pregnancy risk assessment, contraception, assisted reproductive technology, and the involvement of a Pregnancy Heart Team (see Evidence Table 1) 
Recommendations 
Classa 
Levelb  
Maternal risk assessment 
It is recommended to perform a risk assessment in all women with CVD of childbearing age using the mWHO 2.0 classificationc.44,45,47–49,54 
I 
C 
A discussion by the Pregnancy Heart Team about the high risk of maternal mortality or morbidity and the related high foetal risk is 
recommended for women with mWHO 2.0c class IV conditions, including a shared decision-making process for pregnancy termination, 
involving psychological support.65 
I 
C 
It is recommended that women with CVD of mWHO 2.0c class II–III and above are evaluated and managed by a Pregnancy Heart Team 
from pre-pregnancy onwards through pregnancy and post-partum.44,45,47–49,54 
I 
C 
Methods of contraception 
It is recommended that women with CVD of mWHO 2.0c class II and above, or those at risk of developing CVD, receive individualized 
advice to determine the most suitable contraception method, including emergency contraception.90,91 
I 
C 
Progestin-only treatment, contraceptive implants, and/or levonorgestrel IUDs should be considered when there is any risk of 
thromboembolic events.73,92–94 
IIa 
B 
Genetic counselling 
Assessment by a clinical geneticist prior to pregnancy is recommended in women fulfilling diagnostic criteria for inherited cardiovascular 
disease to guide risk stratification and pre-natal genetic testing.63,95 
I 
C 
Pre-conception genetic counselling is recommended in couples with heritable CVD, whether genetic testing is being considered or not. It is 
recommended that this counselling is provided by an appropriately trained healthcare professional within a multidisciplinary team that offers 
psychological support and education to encourage decision-making.63,95 
I 
C 
Reproductive technology 
It is recommended that single embryo transfer is performed in women with CVD.70,71 
I 
C 
Pregnancy termination 
It is recommended to offer women with CVD access to termination of pregnancy that is tailored to their cardiac condition to minimize the 
risks of the procedure.83 
I 
C 
© ESC 2025
CVD, cardiovascular disease; IUD, intrauterine device; mWHO, modified WHO. 
aClass of recommendation. 
bLevel of evidence. 
cThe mWHO 2.0 classification is the updated mWHO classification from the 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy43 and described in Table 6.


<!-- PAGE 23 -->

### Page 23

4.3. Diagnostic methods in pregnancy 
The pros and cons of the primary cardiovascular diagnostic methods 
for diagnosing cardiovascular disease in pregnancy are described here. 
Pre-pregnancy evaluation is covered in the risk assessment section 
(Section 4.2.1). 
4.3.1. Electrocardiogram, including mobile rhythm 
devices 
Pregnant women may present changes in their surface electrocardiogram (ECG), including increased heart rate, minor leftward QRS axis 
shift (15–20 degrees), slightly decreased (20 ms) PR interval, prominent 
Q waves in II, III, and aVF, and flat or inverted T-waves in III, aVF, V1, V2, 
and V3 (Figure 1).96–98 
A 12-lead ECG is part of the standard evaluation of pregnant women 
presenting with new-onset cardiac signs or symptoms or suspected arrhythmia. In pregnant women presenting with syncope or palpitations, 
long-term Holter monitoring or implantable loop recorders should be 
considered as additional diagnostic tools. As pregnant women are more 
prone to arrhythmias, the threshold to perform long-term ambulatory 
rhythm monitoring should be low. 
4.3.2. Echocardiography 
Transthoracic echocardiography (TTE) is the first-line imaging method 
used in pregnancy.99,100 Physiological changes in cardiac geometry and 
functioning are expected during pregnancy (Figure 1).99,101–103 These 
are greatest early in the third trimester and resolve early post-partum. 
Agitated saline contrast should not be used during pregnancy, given 
the risk of placental infarction due to microbubble embolism, resulting 
in foetal distress.99,104 Relevant foetal exposure to intravenous (i.v.) 
echocardiographic contrast agents is not expected due to their very 
short half-life.105 Nevertheless, these agents should only be used selectively because studies during pregnancy or lactation are lacking.99 
Transoesophageal echocardiography is relatively safe, but the potential 
risks and benefits must be weighed individually, including the risk of emesis/aspiration and sudden increase in intra-abdominal pressure. 
Speckle-tracking echocardiography is a useful method to detect subclinical myocardial abnormalities in pregnancy.106,107 
4.3.3. Cardiopulmonary exercise testing 
If there is suspicion of new-onset CVD during pregnancy, submaximal 
exercise testing (at 80% of predicted maximal heart rate) can be useful 
to assess cardiovascular response to exercise. There is no evidence that 
exercise testing increases the risk of spontaneous miscarriage.108,109 
Stress echocardiography using bicycle ergometry may improve diagnostic specificity. The use of pharmacologic stress agents (e.g. dobutamine) 
should be avoided.99,110 There is no evidence supporting a preference 
for treadmill over bicycle exercise testing during pregnancy. The choice 
should be based on women’s individual risk factors, contraindications, 
pregnancy stage, and local availability of testing and expertise. 
4.3.4. Biomarkers 
Throughout pregnancy and the early post-partum stages, natriuretic 
peptide [NP: B-type natriuretic peptide (BNP) and N-terminal pro- 
brain natriuretic peptide (NT-proBNP)] values within the normal range 
have a strong negative predictive value for heart failure whereas the 
positive predictive value tends to be lower.111,112 In women with pre- 
existing cardiomyopathy, ACHD, or valvular heart disease, baseline as a 
minimum and serial NP measurements on an individualized basis should 
be considered to diagnose cardiac complications during pregnancy and 
post-partum.113–118 
Although cardiac troponin I (cTnI) and cardiac troponin T (cTnT) are 
essential in diagnosing myocardial ischaemia, standardized values in pregnancy and post-partum have not been established.112,119 Therefore, routine use of troponins alone during pregnancy is not recommended. 
D-dimer testing has relevance in the diagnosis of VTE (see Section  
11), taking into account the physiological increase during pregnancy, 
particularly in the third trimester. 
4.3.5. Ionizing radiation exposure 
Risks of ionizing radiation exposure are highest during organogenesis 
and decrease with time.120,121 Exposing the foetus to radiation doses 
>150–200 mGy may result in intrauterine growth restriction (IUGR), 
congenital malformations (in particular of the central nervous system), 
and malignancies. If possible, procedures should be delayed at least until 
the completion of major organogenesis (>12 weeks of gestation). 
However, the safety of the woman is important and should guide the 
clinical decision. All radiation doses to the foetus must be kept ‘as 
low as reasonably achievable’ (ALARA) (preferably <50 mGy) and 
should be clearly documented. Manoeuvres to minimize radiation are: 
(i) use echo guidance when possible; (ii) place the source as far and 
the receiver as close as possible to the patient; (iii) use only low-dose 
fluoroscopy (7.5 frames per second or lower); (iv) favour anteroposterior projections; (v) avoid direct radiation of the abdominal region (abdominal shielding is of limited benefit due to internal scatter from 
thoracic tissues rather than direct foetal irradiation); (vi) collimate as 
tightly as possible to the area of interest; (vii) minimize fluoroscopy 
time; and (viii) ensure the procedure is performed by an experienced 
cardiologist.122–126 Iodinated contrast can cross the placenta, but has 
not been reported to have teratogenic effects.127 The potential risk 
of congenital hypothyroidism is unclear but no abnormalities of foetal 
thyroid function after application have been reported.122,128,129 
4.3.5.1. Chest radiography 
The chest radiograph is a practical and readily available diagnostic tool 
for evaluating cardiopulmonary diseases. The foetal dose from chest 
radiography is <0.01 mGy. Nevertheless, it should only be performed 
in symptomatic women if other methods fail to clarify the cause of 
the symptoms. 
Lung ultrasound is a valuable tool for diagnosing pleural effusion, pulmonary oedema, pneumothorax, and pneumonia. However, there is 
currently a lack of data about the regular ultrasound pattern during 
pregnancy,130,131 and lung ultrasound is therefore not recommended 
as an alternative to chest radiography. 
Protection of the foetus is governed by radiological standards. Both 
the technician and the radiologist should act accordingly. 
4.3.5.2. Computed tomography and nuclear medicine  
imaging 
The radiation dose to the foetus from a chest computed tomography 
(CT) or pulmonary CT angiography is estimated at 0.02 mGy.121 
Technetium-99m, used for ventilation–perfusion lung scanning for detection of pulmonary embolism, results in an embryonic or foetal exposure of <5 mGy, which is considered a safe dose in pregnancy. 
Computed tomography or nuclear medicine techniques are generally  
ESC Guidelines                                                                                                                                                                                               23


<!-- PAGE 24 -->

### Page 24

not recommended during pregnancy. However, if such techniques are 
necessary because other diagnostic tools are insufficient or not readily 
available for the diagnosis in question, they should not be withheld from 
a pregnant patient.100,132 
4.3.5.3. Cardiac catheterization 
Cardiac catheterization is seldom needed during pregnancy but may be 
necessary for specific diagnostic and interventional purposes. Foetal 
compromise decreases with gestational age. The highest risk is <20 
weeks gestation and is proportional to the radiation dose, with no reports of foetal anomalies or loss when exposure is <50 mGy.133,134 
Most coronary procedures can be performed within these dose limits 
and radiation exposure to the foetus itself is estimated to be lower than 
20%. The radial approach by an experienced operator is preferable and 
every effort to reduce radiation exposure should be made. 
4.3.6. Cardiovascular magnetic resonance 
Cardiovascular magnetic resonance (CMR) is advised if other non-invasive 
diagnostic measures are insufficient to provide a clinical diagnosis and is 
preferable to radiation-based imaging modalities.99,100,135 It seems prudent 
to avoid a scanner strength higher than 1.5 tesla due to the greater energy 
deposition in tissue. Evidence regarding gadolinium-based contrast in pregnancy is controversial and its use should be avoided unless absolutely necessary.135–137 Excretion of gadolinium-based agents into breast milk is 
limited (<0.04% of an i.v. dose within the first 24 h, with 1%–2% absorption).138 Lactating women receiving intravascular gadolinium should discontinue lactation for 24 h.133,138,139 
4.4. Foetal assessment 
4.4.1. Risk of foetal/obstetric complications 
The typical increase in CO during pregnancy may not occur optimally in some women with CVD, potentially affecting uteroplacental 
blood flow. These and other cardiovascular risk factors contribute 
to an increased risk of obstetric and foetal complications, including 
foetal loss, stillbirth, pre-term birth, pre-eclampsia, and IUGR.140 
Furthermore, the severity of obstetric and foetal outcomes varies 
depending on the maternal risk as defined in the mWHO 2.0 classification. Adverse outcomes are more frequent in women with a 
higher mWHO 2.0 classification, emphasizing the importance of 
risk stratification, comprehensive counselling, and multidisciplinary 
management, including neonatology expertise.2,134,140 Notably, pulmonary hypertension (PH) represents one of the highest risks for 
obstetric and foetal complications.141 The main predictors of neonatal complications are indicated in Table 9. 
4.4.2. Screening for congenital heart disease in the 
foetus 
Foetal echocardiography should routinely be offered at 18–22 weeks 
when parents have congenital heart disease. This will detect up to 
80% of significant congenital cardiac defects.142–144 
4.4.3. Assessing foetal well-being 
Detailed anatomical foetal assessment is required in women using cardiac 
medication with teratogenic effects (see Section 5 for more details).145 
Recommendation Table 2 — Recommendations for diagnostic methods in pregnancy (see Evidence Table 2) 
Recommendations 
Classa 
Levelb  
Echocardiography 
Transthoracic echocardiography is recommended as first-line imaging tool in any pregnant woman with unexplained or new cardiovascular 
signs or symptoms.99 
I 
C 
Biomarkers 
Measurement of BNP and NT-proBNP levels should be considered prior to pregnancy in women with HF of any aetiology, including 
previous PPCM, cardiomyopathy, ACHD, and PAH, and be monitored during pregnancy according to the underlying disorder and in case of 
new-onset or worsening symptoms.114 
IIa 
B 
Ionizing radiation 
It is recommended to limit exposure to all medical ionizing radiation doses to ALARA levels.121 
I 
C 
It is recommended to keep the radiation dose to the foetus as low as possible (preferably <50 mGy), particularly if the foetus is in the field of 
view.120,121 
I 
C 
A CT scan should be considered for PE when clinical benefits outweigh the risks to the mother and foetus.100,121,132 
IIa 
C 
A chest radiograph may be considered as a first-line imaging tool if other methods are not successful in clarifying the cause of dyspnoea. 
IIb 
C 
Coronary angiography with minimal radiation may be considered during pregnancy if potential benefits outweigh the risks. 
IIb 
C 
Cardiovascular magnetic resonance 
Discontinuation of lactation for 24 h should be considered in women in whom i.v. gadolinium is required.133,139 
IIa 
C 
CMR imaging without gadolinium contrast should be considered for a definitive, clinically relevant diagnosis during pregnancy, if other 
non-invasive diagnostic measures are not sufficient.135,136 
IIa 
C 
© ESC 2025
ACHD, adult congenital heart disease; ALARA, as low as reasonably achievable; BNP, B-type natriuretic peptide; CMR, cardiovascular magnetic resonance; CT, computed tomography; HF, 
heart failure; i.v., intravenous; NT-proBNP, N-terminal pro-brain natriuretic peptide; PAH, pulmonary arterial hypertension; PE, pulmonary embolism; PPCM, peripartum cardiomyopathy. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 25 -->

### Page 25

In women with beta-blocker exposure, higher small for gestational age 
(SGA) rates and, more rarely, bradycardia have been reported, indicating the need for appropriate foetal monitoring.12,146 Foetal ductus venosus Doppler velocity is a useful adjunct to evaluate foetal well-being and 
determine the time to delivery in cases of increased risk of IUGR.147 
4.4.4. Foetal assessment of heritable primary 
arrhythmias 
In families with primary arrhythmia, the foetus may present with arrhythmias. Therefore, the foetal heart rate should be assessed at baseline 
and during each pre-natal visit and compared against gestation-specific 
norms. In pregnancies complicated by suspected primary arrhythmia- 
related foetal arrhythmias, complete foetal echocardiography, typically 
performed at 20–22 weeks, is recommended to evaluate heart anatomy, 
ventricular function, and the arrhythmia mechanism.148 Foetal magnetocardiography, if available, offers valuable insights into arrhythmia type and 
severity and monitors anti-arrhythmic drug therapy, as it captures all cardiac time intervals (P, QRS, T-wave) between 17 and 24 weeks of gestation. It is currently the only method to detect repolarization 
abnormalities, such as QT interval prolongation.149 
4.5. Timing and mode of delivery 
An individualized delivery plan should be made that covers the needs 
for induction of labour, labour management, delivery, and post-partum 
surveillance, in shared decision-making with the pregnant women. This 
delivery plan should be widely accessible to the patient, her partner, and 
relevant health professionals, and should be placed in the patient’s 
(electronic) health record. 
4.5.1. Timing of delivery 
Pregnant women with CVD are more likely to have comorbidities and 
experience adverse events during delivery than those without CVD, 
and require additional monitoring and care.150 Any maternal benefit 
of early term delivery (from 37 weeks 0 days to 38 weeks 6 days of gestation) should be weighed against the increased likelihood of adverse 
foetal outcomes.151 Induction of labour between 39 and 40 weeks reduces the risk of emergency caesarean section by 12% and the risk of 
stillbirth by 50% in women without CVD. The benefit is likely to be 
greater for women with CVD who have higher rates of obstetric complications.152,153 In the absence of maternal or foetal indications for 
early birth, induction of labour before 39 weeks should be reserved 
for obstetrical indications.154 
4.5.2. Induction of labour 
Mechanical methods, prostaglandin E1 analogue (misoprostol), 
slow-release formulation of 10 mg prostaglandin E2 (dinoprostone), 
oxytocin, and artificial rupture of membranes are all considered safe 
to induce labour.4,155,156 High-dose (600 mg) misoprostol does not affect cardiac parameters in women without heart disease, although 
there remains a theoretical risk of coronary vasospasm and arrhythmias.155 Dinoprostone may cause profound hypotension, but only 
when injected blindly into the myometrium, and this route of administration should be avoided.157 The use of an additional 2 IU of oxytocin 
for the management of the third stage in women with CVD has no cardiac consequences and is associated with significantly lower blood 
loss.158 In women at high risk (mWHO 2.0 classes III–IV), oxytocin is 
generally considered as a first-line uterotonic, misoprostol and carboprost are second line (see Supplementary data online, Table S3).159 
Mechanical methods such as a cervical ripening balloon might be preferable in women where a drop in systemic vascular resistance would be 
detrimental.160 If membranes are ruptured, augmentation of labour 
should be immediate to reduce the risk of infection and should be undertaken with oxytocin to minimize the number of vaginal examinations.4 
4.5.3. Vaginal or caesarean delivery 
Vaginal delivery is associated with less blood loss and lower risk of infections and venous thromboembolism and should be advised for 
most women.161 Planned caesarean section does not confer any advantage over planned vaginal delivery in terms of maternal outcomes and 
may be associated with adverse foetal outcomes.162,163 
Caesarean section is the preferred mode of delivery for obstetric indications and for women presenting in labour who use or have used 
vitamin K antagonist (VKA) within the past 2 weeks, with high-risk aortopathy (mWHO 2.0 class III), with hypertrophic cardiomyopathy 
(HCM) and severe left ventricle outflow tract obstruction, or in acute 
intractable HF.43 
4.5.4. Haemodynamic monitoring during delivery 
Pulse oximetry, blood pressure monitoring, and continuous ECG monitoring may help detect early signs of decompensation, arrhythmias, and 
ischaemia in women with significant CVD and identify those in whom 
delivery should be expedited.164 Arterial lines should be reserved for 
those women who have haemodynamic instability or are at risk of it. 
A right-heart catheter is of uncertain benefit, is associated with complications, and should be avoided in most cases. Minimally invasive CO 
monitoring is preferable, where possible.110 
4.5.5. Anaesthesia/analgesia 
Analgesia is crucial for labour in pregnant women with CVD to reduce 
physical stress. Neuraxial methods are very effective analgesic blocks. 
The onset of conventional epidural analgesia is relatively slow (±15 min) 
and allows for careful titration of a local anaesthetic–opioid mix.165 
Spinal analgesia is suitable for women with high-risk CVD, where a faster 
onset of sympathetic block is desirable.166 Combined spinal–epidural 
analgesia typically has a faster onset time (±5 min). However, adverse 
effects such as hypotension and foetal heart rate abnormalities occur 
more quickly and are more pronounced. Different techniques for administering low-concentration, high-volume local anaesthetic–opioid regimens allow maintenance of epidural analgesia through the epidural 
Table 9 Predictors of neonatal events in pregnancies of women with cardiovascular disease 
Predictors of neonatal events  
NYHA class III/IV or cyanosis during baseline pre-natal visit 
Maternal left heart obstruction 
Low maternal oxygen saturation (<90%) 
Multiple gestations 
Use of anticoagulants 
Cardiac medication before pregnancy 
Mechanical valve prosthesis 
Maternal cardiac event during pregnancy 
Maternal decline in CO during pregnancy 
© ESC 2025
Derived from the 2018 ESC Guidelines for the management of cardiovascular 
diseases during pregnancy.43 
CO, cardiac output; NYHA, New York Heart Association.   
ESC Guidelines                                                                                                                                                                                               25


<!-- PAGE 26 -->

### Page 26

catheter. Whenever an epidural catheter is in situ in a high-risk woman, 
higher doses can be administered for conversion to caesarean section, 
avoiding airway and other complications of general anaesthesia. In women 
at risk of dural ectasia, including Marfan syndrome, extra caution and management in an expert centre is essential. Furthermore, a pre-delivery consultation with the anaesthesia team is needed.167 When neuraxial analgesia 
is contraindicated due to conditions such as systemic anticoagulation or 
spinal deformities, opioids (i.v. remifentanil) are an alternative despite 
the risk of hypoventilation and apnoea.168,169 Single-shot spinal analgesia 
is common in caesarean delivery for its simplicity and effectiveness.167 
4.5.6. Delivery in women on anticoagulants 
4.5.6.1. Planned delivery 
In women with mechanical heart valves (MHVs) taking VKAs, suspension of VKAs and bridging with heparin [either therapeutic-dose 
low-molecular-weight heparin (LMWH) or i.v. unfractionated heparin 
(UFH)] is recommended at least 2 weeks before planned delivery 
(see also Section 5 and Section 12). This is because of the slow metabolism of VKA in the foetus. If therapeutic-dose LMWH is used, one 
strategy is to switch to i.v. therapeutic UFH at least 36 h before planned 
delivery.170 In these settings the target activated partial thromboplastin 
time (aPTT) is ≥2 times control values. UFH can then be stopped 4–6 h 
before surgery (in case of caesarean section) or before insertion of regional anaesthesia or anticipated vaginal delivery. For women who are 
on therapeutic-dose LMWH for non-MHV indications, dosing can be 
omitted for 24 h prior to caesarean section or anticipated vaginal delivery with no need for bridging. In women with MHVs who are on 
LMWH and aspirin in combination, consideration should be given to 
stopping aspirin 4 days before delivery.170 
4.5.6.2. Urgent delivery on therapeutic anticoagulation 
Managing women who are anticoagulated during delivery is complex 
and needs an individualized approach. Figure 5 gives an overview, but 
again each scenario may need a more tailored solution. 
4.5.6.2.1. Delivery on vitamin K antagonists. If women require urgent delivery and have been taking VKAs within the last 2 weeks, 
then delivery by caesarean section is recommended to reduce the 
risk of foetal intracranial bleeding. When urgent delivery is required, 
preventing bleeding complications with administration of i.v. four-factor 
prothrombin complex concentrate (4F-PCC), depending on the international normalized ratio (INR) (25 U/kg for a therapeutic INR range of 
2–4) is the preferred method for rapid INR normalization. If necessary, 
vitamin K should be given.171,172 If 4F-PCC is not available, fresh frozen 
plasma (FFP) is an alternative, but it takes longer to reverse an elevated 
INR and requires a larger fluid challenge.171,173. The involvement of an 
expert haematologist in these scenarios is essential, in addition to the 
Pregnancy Heart Team. The foetus may remain anticoagulated for 8– 
10 days after discontinuation of maternal VKAs, and may need to be given FFP and higher doses of vitamin K.170 
4.5.6.2.2. Delivery on heparin. If delivery occurs after recent administration of heparin (e.g. within 4–6 h of UFH, with non-normalized aPTT, 
or within 12 h of therapeutic LMWH) protamine sulfate should be given. 
Neutralization of LMWH varies between products and may be less effective.174 Protamine dosage depends on timing after the last dose of 
LMWH (1 mg/1 mg enoxaparin <8 h; 0.5 mg/1 mg enoxaparin >8 h). 
For UFH, 1 mg of protamine per 100 units of heparin is needed.175 
In addition to the level of anticoagulation, the decision to reverse anticoagulation should also be related to the bleeding risk, which is higher 
with conditions such as placental abruption, placenta previa, and multiple previous caesarean sections. 
4.5.6.3. Restarting anticoagulation after delivery 
The decision to restart anticoagulation post-delivery is challenging and 
must balance risk of bleeding and risk of thrombosis. Anaesthetic, cardiac, 
haematology, and obstetric teams may have different priorities, but all 
need to be actively involved in decision-making, which should also involve 
the patient. Late obstetric bleeding (>24 h) is common,176 as was also 
confirmed in recent data from the ROPAC III trial177 (bleeding on 
mean post-partum day 3.6), suggesting that these events occur at a 
time when heparin is being used at the same time as the VKA is being reintroduced. Restarting UFH (aPTT levels ≥2 times the control) or low/ 
intermediate doses of LMWH are all valid options.170 Techniques to reduce bleeding risk include active management of the third stage of labour 
with oxytocin. Recently, the effect of adding 2 IU oxytocin over 10 min to 
a standard treatment of low-dose infusion for 4 h [10 IU of oxytocin in 
500 mL of normal saline given i.v. at 36 mL/h for 4 h (12 mU/min)] was 
analysed. The addition of 2 IU of oxytocin was not associated with any 
greater derangement in cardiovascular measures, but with a significantly 
lower volume of blood loss.158 VKA should only be started 7–14 days 
or later post-partum to reduce the risk of late bleeding.170 
4.5.7. Endocarditis prophylaxis for delivery 
Systemic antibiotics according to the 2023 ESC Guidelines for the management of endocarditis may be considered for delivery in women at 
high risk of endocarditis.178 
Recommendation Table 3 — Recommendations for timing and mode of delivery (see Evidence Table 3) 
Recommendations 
Classa 
Levelb  
Timing and mode of delivery 
Vaginal delivery is recommended in most women with CVD.161–163 
I 
B 
Systemic antibiotic prophylaxis may be considered for delivery in women at high riskc.178 
IIb 
C 
Routine induction of labour prior to 39 weeks is not recommended in women with stable CVD.44,154 
III 
C 
Delivery in women on anticoagulants 
It is recommended that the timing of delivery is planned to ensure safe and effective peripartum anticoagulation. 
I 
C 
It is recommended to discontinue VKAs and start therapeutic-dose LMWH or adjusted-dose i.v. UFH at the 36th week of gestation or 2 
weeks before the planned delivery.179 
I 
C 
In women at low riskd on therapeutic-dose LMWH, neuraxial anaesthesia and vaginal delivery (or caesarean section for obstetric 
indications) is recommended 24 h after the last dose of LMWH.180 
I 
C                         
Continued


<!-- PAGE 27 -->

### Page 27

Woman on therapeutic anticoagulants arriving in established labour 
After delivery,  postpone the switch from heparin back to oral anticoagulants until 7–14 days post-partum when the wound area has healed, in consultation with the Pregnancy Heart Team
(Class I)
Post-delivery
If  neuraxial anaesthesia catheter insertion was traumatic do not start therapeutic dose anticoagulation for at least 24 h after removal 
VKA
Stop VKA and check INR
i.v. UFH
LMWH
Stop LMWH 
Prepare RBC
Give 4F-PCC
(FFP if 4F-PCC not available)
Consider vitamin K
Caesarean section with general anaesthesia for foetal protection  
(Class I)
Stop UFH 
Delivery in next 
24 h
Delivery in next 
4–6 h and aPTT 
not normalized
Consider protamine sulfate
Proceed with neuraxial anaesthesia and vaginal delivery unless obstetric indication for caesarean section
(Class I)
Actively manage the third stage with oxytocin to reduce risk of PPH
(Class IIa)
Consider caesarean section with general anaesthesia
Figure 5 Management of urgent delivery in women under anticoagulants. aPTT, activated partial thromboplastin time; FFP, fresh frozen plasma; INR, international normalized ratio; i.v., intravenous; LMWH, low-molecular-weight heparin; 4F-PCC, four-factor prothrombin complex concentrate; N, no; PPH, 
post-partum haemorrhage; RBC, red blood cell; UFH, unfractionated heparin; VKA, vitamin K antagonist; Y, yes.  
In women at high riskd, it is recommended to convert LMWH to i.v. UFH at least 36 h prior to delivery and stop the UFH infusion 4–6 h 
prior to anticipated delivery. The aPTT should be normal before regional anaesthesia.180 
I 
C 
If delivery starts while the mother is on VKAs or <2 weeks after discontinuation of VKAs, caesarean section is recommended for foetal 
protection. 
I 
C 
Post-delivery, it is recommended that the decision to restart LMWH or UFH is made after discussion with the Pregnancy Heart Team and 
the woman who gave birth.170 
I 
C 
It is recommended to postpone the switch from heparin back to oral anticoagulants until 7–14 days post-partum when the wound area has 
healed, in consultation with the Pregnancy Heart Team.177 
I 
C 
In women on therapeutic-dose LMWH, planned delivery should be considered at around 39 weeks to avoid the risk of spontaneous labour 
while fully anticoagulated. 
IIa 
C 
In women who are on antenatal anticoagulation, active management of the third stage of labour with oxytocin should be considered.158 
IIa 
C 
© ESC 2025
aPTT, activated partial thromboplastin time; CVD, cardiovascular disease; i.v., intravenous; LMWH, low-molecular-weight heparin; UFH, unfractionated heparin; VKA, vitamin K antagonist. 
aClass of recommendation. 
bLevel of evidence. 
cPatients with prosthetic cardiac valves or a history of infective endocarditis, or cardiac transplant patients with residual valve defects. 
dSee Table 10.   
ESC Guidelines                                                                                                                                                                                               27


<!-- PAGE 28 -->

### Page 28

4.6. Post-partum monitoring and 
complications 
4.6.1. Monitoring 
The post-partum period is associated with significant haemodynamic 
changes and fluid shifts. Hence, women are at risk of adverse outcomes, 
such as hypertension, HF, or stroke.181,182 Post-partum management 
must be individualized and depends on the woman’s underlying CVD, 
risk or presence of arrhythmias and HF symptoms, and the course during pregnancy and delivery. For women at the highest HF risk or with 
HF symptoms during pregnancy or delivery, admission to an intensive 
(cardiac) care unit during the first 24–48 h for haemodynamic monitoring should be considered.183 Early ambulation is important to reduce 
the thromboembolism risk. 
In women with hypertensive disorders of pregnancy, blood pressure 
should be monitored in hospital (or with an equivalent level of outpatient surveillance) for 72 h after birth and checked again 7–10 days 
post-partum. Optimizing blood pressure levels from the immediate 
post-partum period until the first post-natal months could help prevent 
the development of hypertension and improve long-term cardiovascular health.184 
4.6.2. Breastfeeding and lactation 
Throughout these Guidelines, the term ‘lactation’ (including not only 
breastfeeding but also other methods such as pumping) is used as the 
default term in most sections, especially where it encompasses a broader scope, such as in medication-related contexts. We use ‘breastfeeding’ specifically in sections where the focus is on the act of nursing or 
direct feeding at the breast, particularly when discussing its physiological 
and long-term health outcomes. 
Breastfeeding is a global priority because interruption of lactation is 
associated with adverse health outcomes for the woman and her child, 
including higher maternal risks of breast cancer, ovarian cancer, diabetes, and hypertension, and greater infant risks of infectious and metabolic disease.185,186 
Inhibition of lactation can be obtained with standard doses of cabergoline in general, or bromocriptine in peripartum cardiomyopathy (PPCM). 
Several drugs are contraindicated during lactation (see Figure 6 in 
Section 5 and Supplementary data online, Table S4). 
4.6.3. Complications 
4.6.3.1. Haemorrhage 
Post-partum haemorrhage (PPH) is more frequently reported in women with CVD.187 To reduce the risk of PPH, an active third stage of 
labour with early cord clamping and administration of oxytocin to deliver the placenta should be pursued. Maternal anaemia is a known risk 
factor for PPH, so anaemia should be managed aggressively in the antenatal period. 
At the time of delivery, a slow i.v. infusion of 2 IU oxytocin over 10 
min immediately after birth, followed by 12 mU/min for 4 h, reduces 
the PPH risk and has a minimal impact on cardiovascular parameters.158 
In cases of PPH that are refractory to medical treatment, additional devices may be used, such as the Bakri intrauterine balloon, uterine compression sutures, or further haemostatic measures including uterine 
artery embolization or hysterectomy. 
4.6.3.2. Psychological reactions, post-partum depression 
Although the general risk of post-partum depression among new 
mothers in the general population is ∼10%–20%, this risk increases 
with underlying health conditions such as CVD, where ∼1 in 
3 mothers have reported symptoms of depression in the post- 
partum period.188 Those with PPCM are particularly vulnerable to 
depression.189–191 These findings emphasize the critical need for 
early detection, regular mental health screening and the necessity 
of holistic care models with psychological support and tailored 
interventions.191,192 
5. Drugs during pregnancy and 
lactation 
5.1. General principles 
5.1.1. Pharmacokinetics and pharmacodynamics in 
pregnancy 
Physiological adaptation of maternal organ systems to pregnancy 
affects the pharmacokinetics and pharmacodynamics of potentially 
all medical treatments, including cardiovascular drugs (see Section  
3.2).146,193,194 
5.1.2. Pharmacogenetics 
An overlap between individual genotypes associated with drug effects 
and pregnancy-induced modifications (e.g. liver enzymes) may unmask 
adverse effects or require careful titration, in particular for drugs that 
lead to severe adverse drug reactions (ADRs). As an example, warfarin can cause severe ADR at the maternal (bleeding, thrombosis) 
and/or foetal level (embryotoxicity, teratogenesis).195 The most notable cases refer to the polymorphisms of CYP2D6, associated with different phenotypes (extensive, ultrarapid, or poor metabolizers), 
leading to diverse pharmacokinetics/pharmacodynamics of drugs 
used in pregnancy such as beta-blockers (e.g. labetalol, metoprolol), 
antidepressants (e.g. fluoxetine, paroxetine), and analgesic drugs 
(e.g. tramadol, codeine).194 Poor and ultrarapid metabolizers may experience extreme variations in drug plasma level and bioavailability, 
and hence in their effects.195 
5.1.3. Newborn drug exposure in breast milk 
The exposure of the newborn to maternal drugs via breast milk is expressed as a percentage value, calculated as the dose taken by the infant compared either to the therapeutic dose of the same drug (often 
unknown for newborns) or the maternal weight-adjusted dose.196 
The ‘relative infant dose’ (RID) depends on the relative amount of 
drug secreted in the milk (milk-to-plasma concentration ratio) and 
the quantity of milk intake (the standard is 150 mL/kg/day) on a 
body weight basis.196 The dose per kg of the infant is compared to 
the maternal dose per kg over the same period. A RID lower than 
5%–10% is generally considered safe (see Figure 6; Supplementary 
data online; Table S4; and LactMed database).197 
5.2. Drug classes in pregnancy 
5.2.1. Anticoagulants 
The use of anticoagulants during pregnancy represents a complex 
balance of risks and benefits, influenced by specific indications, 
and hampered by low-quality evidence. Indications for anticoagulation in pregnancy are diverse and covered in different sections in 
these Guidelines. In this section, we cover drug-specific aspects 
and dosing regimens that explicitly pertain to the setting of 
pregnancy.


<!-- PAGE 29 -->

### Page 29

Low-molecular-weight heparin treatment regimen glossary 
To ensure consistency throughout these Guidelines, we apply the following wording about LMWH treatment—any deviations from these 
standards are clearly indicated in the specific sections: 
• Prophylactic-dose LMWH refers to low fixed doses with adjustment 
for extremes of body weight.198 
• Therapeutic-dose LMWH refers to high doses typically reserved for 
treatment of VTE (Section 11) and thrombosis prevention in 
MHVs (Section 12).  
An individualized shared decision-making approach with careful consideration of maternal thrombosis risk vs foetopathy is needed, and 
strategies will vary from prophylactic dosing of LMWH to correctly 
dosed VKAs. Regional differences, also related to lower availability of 
anti-factor Xa level monitoring in low- and middle-income countries 
as indicated by the ROPAC III study, also need to be taken into account. 
Interestingly, this study shows that despite higher monitoring and better resource availability, the risk of thrombosis was higher in high- 
income countries, specifically due to higher use of treatment regimens 
with therapeutic LMWH.177 Haemorrhagic complications in the 
mother can occur with all regimens.199 Table 10 lists the regimens 
and disease entities in which anticoagulants are indicated. 
5.2.1.1. Vitamin K antagonists 
Vitamin K antagonists cross the placenta and are associated with embryopathy and foetopathy risk, even at low doses. They will therefore 
be switched to LMWHs in most pregnant women, with the only exception being women with atrial fibrillation (AF) in the context of moderate to severe mitral valve stenosis or MHVs, given the lower thrombosis 
risk with VKAs compared to LMWH in the latter (see Section 12).179,200 
Women receiving chronic VKAs who are contemplating pregnancy 
need counselling regarding avoidance of the potential teratogenic effects. When switching (usually to LMWH) is desired, this should take 
place as soon after conception as possible. 
Vitamin K antagonist embryopathy is thought to be related to interference with embryonic ossification.201,202 Adverse impact is highest in 
the first trimester (0.6%–12% of embryopathy) and much lower but 
persisting in later stages of pregnancy (0.7%–2% risk of foetopathy, 
e.g. central nervous anomalies, intracranial haemorrhage).200,203,204 
The risk of embryopathy in the first trimester depends on the VKA 
dose. The risk was 0.45%–0.9% in pregnancies with low-dose warfarin 
according to two systematic reviews.199,205 In this setting, low-dose refers to the dose necessary to maintain the appropriate INR (according 
to current guidelines this equals doses of ≤5 mg of warfarin, ≤2 mg/day 
acenocoumarol, ≤3 mg/day phenprocoumon).43 This approach may be 
seen as a reasonable balance between the risks to the mother with 
Table 10 List of anticoagulation regimens and disease entities in which they are indicated 
Indication 
Type of 
anticoagulant 
Dosing 
Timing  
Low thrombosis risk 
VTE prevention/no indication for oral 
anticoagulationa 
LMWH 
Prophylactic dose 
o.d. 
Uncomplicated Fontan circulationb 
LMWH  
Prophylactic dose 
o.d. 
Intermediate thrombosis risk 
VTE (DVT/PE) during pregnancya 
LMWH 
Therapeutic dose 
o.d. or 
b.i.d. 
Persistent/permanent AF at elevated 
thromboembolic riskc 
LMWH 
Therapeutic dose 
o.d. or 
b.i.d. 
Decreased ventricular function (EF <35%) and/ or 
intracardiac thrombusd 
LMWH 
Therapeutic dose 
o.d. or 
b.i.d. 
High thrombosis risk 
Mechanical heart valvese 
1. First trimester 
Low VKA dose to achieve required INRf 
First trimester: VKA or 
LMWH 
INR: weekly to every 2 weeks 
LMWH: dose adjusted to peak anti-factor Xa level 
b.i.d. 
High VKA dose to achieve required INR 
Switch to LMWH 
Dose adjusted to peak anti-factor Xa level (weekly until 
threshold, every 2–4 weeks thereafter) 
b.i.d. 
2. From week 13: shared decision  
(a) 
Continue/switch to VKA with weekly to every 2 weeks INR  
(b) 
Continue LMWH with dose adjustment as above 
Delivery: refer to Section 4.5.6.2. (for urgent delivery) and Section 4.5.6.1 (for planned delivery) 
© ESC 2025
AF, atrial fibrillation; b.i.d., is in die (twice a day); DVT, deep vein thrombosis; EF, ejection fraction; INR, international normalized ratio; LMWH, low-molecular-weight heparin; o.d., omni die 
(once a day); PE, pulmonary embolism; VKA, vitamin K antagonist; VTE, venous thromboembolism. 
aRefer to Section 11 Venous thromboembolism. 
bRefer to Section 9 Pregnancy in women with congenital heart disease. 
cRefer to section 12.4.1.2. Atrial fibrillation including anticoagulation. 
dRefer to section 12.6 Heart failure. 
eRefer to Section 12.5.3.2 Mechanical heart valves. 
f≤5 mg of warfarin; ≤2 mg/day acenocoumarol, ≤3 mg/day phenprocoumon.43   
ESC Guidelines                                                                                                                                                                                               29


<!-- PAGE 30 -->

### Page 30

MHV and the foetus.170,200,204,206,207 Due to incomplete development 
of liver metabolism, the INR takes longer to normalize in the foetus and 
neonate than in the mother, which is why VKA should be discontinued 
2 weeks before delivery (see Section 4). 
If the indication of anticoagulation is non-MHV, such as 
pregnancy-related VTE, VKAs are not recommended. In case of pre- 
existing VKA or direct oral anticoagulant (DOAC) therapy due to previous VTE, VKAs and DOACs should be replaced by LMWH when 
pregnancy is planned or at recognition of pregnancy.208 
Vitamin K antagonists are safe during lactation209 and are recommended in all women with MHVs given their superior anticoagulant 
properties in avoiding valve thrombosis.179,200 
5.2.1.2. Low-molecular-weight heparins 
Embryopathy or foetopathy has not been reported with LMWHs, even 
in therapeutic doses, but thromboembolic complications in women 
with MHVs are higher than with VKAs (8.7%, 5.8%, and 2.7% for 
LMWH, UFH, and VKA, respectively).179,200 LMWHs appear less likely 
to induce heparin-induced thrombocytopenia compared with UFH, although this has not been studied in pregnancy.210 
Data on optimal dosing and frequency of administration in pregnancy 
are scarce and mostly limited to the setting of VTE and MHV. 
5.2.1.2.1. Low-molecular-weight heparin dosing. In women with 
MHVs, slightly higher starting doses are suggested to ensure minimal 
delay in reaching the target range (See Table 11).176 
For prophylactic-dose LMWH, a fixed low-dose LMWH regimen can 
be used in most cases.207 In women with acute VTE requiring therapeutic LMWH dose, routine anti-factor Xa monitoring has not been 
shown to affect clinical outcomes despite fluctuations of anti-factor 
Xa levels during pregnancy, and should only be considered in women 
with renal insufficiency or obesity, where adjustment for body weight 
may result in overdosing.211–213 Underweight patients show a low 
prevalence of antepartum or post-partum VTE214 and do not require 
specific recommendations compared to patients with normal 
weight.215 
Monitoring of anti-factor Xa levels is essential in women with MHVs 
on therapeutic-dose LMWH: at least weekly until target level is 
achieved or when there is a below target level at any stage, and regular 
monitoring thereafter (e.g. every 2–4 weeks depending on stability) 
(see Section 12.5.3.2). Recommended peak anti-factor Xa levels should 
be individualized based on type and location of the valve (between 1.0 
and 1.2 U/mL) and additional trough level measurement may be indicated in selected cases with increased thrombosis risk (see Section  
12.5.3.2).216 
5.2.1.2.2. Once-daily vs twice-daily administration. In pregnant women with confirmed acute VTE, no clear benefit of a twice-daily 
LMWH administration vs a once-daily administration has been demonstrated.217,218 Thus, either using a once- or twice-daily regimen, each 
one resulting in a therapeutic dose, is reasonable. 
Twice-daily administration at slightly higher doses is the usual therapeutic dosing regimen for pregnant women with MHVs.177 There is insufficient evidence for the use of LMWH injections more frequently 
than twice daily. 
5.2.1.3. Unfractionated heparin 
Intravenous UFH, although not crossing the placenta, is associated with 
higher risks of thrombocytopenia and osteoporosis compared with 
LMWH. The risk of valve thrombosis during pregnancy with subcutaneous UFH is unacceptably high and its use is not recommended.219 
In women with MHVs in whom VKAs cannot be continued, intravenous UFH is only indicated when anti-factor Xa monitoring is not possible during the first trimester and at the time of delivery (see Section  
4.5.6). However, intravenous heparin dosing is challenging, requiring 
hospitalization and multiple daily blood tests to achieve an aPTT ≥2 
times control values. 
5.2.1.4. Fondaparinux 
In women requiring prophylaxis of VTE, good outcomes with subcutaneous fondaparinux were reported in an observational study of 65 
pregnancies and a retrospective analysis in 84 women with one or 
more previous pregnancies.220,221 Its use can be considered if there is 
an allergy or adverse response to LMWH (prophylactic dose: 2.5 mg 
daily; therapeutic dose: up to 10 mg daily)221–223 (see Section 11). 
5.2.1.5. Direct oral anticoagulants 
Direct oral anticoagulants have shown better bleeding profiles than a 
LMWH or VKA regimen across diverse indications in non-pregnant populations. Outcome data on their use in pregnancy are scarce and inconsistently captured in pharmacovigilance databases, indicating a 
need for a more robust system of reporting.224,225 The foetal effects 
of DOACs are controversial.226,227 Animal and in vitro studies showed 
that dabigatran, rivaroxaban, and apixaban crossed the placenta.228–230 
Prescription information based on these data reported variable adverse 
effects in pregnant rodents and rabbits: post-implantation loss, maternal bleeding, or malformation at >4 times the recommended maternal 
doses (see Supplementary data online, Table S4). Counselling women 
on DOACs who are planning a pregnancy is advised, considering the 
complexity of pre- and post-conceptional switches to alternative 
Table 11 Dosing regimens for the commonly used low-molecular-weight heparins  
Enoxaparin 
Dalteparin 
Tinzaparin 
Target  
Prophylactic LMWH 
Body weight 
50–100 kg 
4000 IU o.d. 
5000 IU o.d. 
4500 IU o.d. 
NA 
Therapeutic LMWH 
(non-MHV) 
150 IU/kg o.d. 
200 IU/kg o.d. 
175 IU/kg o.d. 
NA 
Therapeutic LMWH 
MHV 
125 IU/kg b.i.d. (starting dose) 
then 100 IU/kg b.i.d. 
125 IU/kg (starting dose) b.i.d. 
then 100 IU/kg b.i.d. 
250 IU /kg (starting dose) 
then 175 IU/kg o.d. 
0.8–1.2 U/mL anti-factor Xa 
(4–6 h post administration) 
© ESC 2025
b.i.d., bis in die (twice a day); IU, international units; LMWH, low-molecular-weight heparin; MHV, mechanical heart valve; NA, not applicable; o.d., omni die (once a day).


<!-- PAGE 31 -->

### Page 31

regimens (LMWH, VKA) and the risk of VTE recurrence.227 DOACs 
may have an edge over VKAs, such as rapid reversal in case of premature delivery and a short antepartum interruption period, due to their 
reversible inhibition of procoagulant factors. The oral route is an advantage over LMWHs. However, evidence of safety is lacking for specific 
DOAC antidotes (andexanet alfa, idarucizumab) in pregnant women 
and can only be inferred from pre-clinical studies. After uncertain initial 
reports on foetotoxicity,224 a recent retrospective cohort study (mainly in women exposed to rivaroxaban) does not support a high risk of 
embryotoxicity.231 It should be highlighted that despite promising studies, clinical evidence on the benefits and risks of DOACs for the mother 
and foetus is scarce and needed, and their foetal safety over VKAs during the second and third trimesters has not been established. DOACs 
are not recommended in pregnancy and they should only be used in the 
absence of any other option in consultation with the Pregnancy Heart 
Team and the haematology team. Based on current data there is no absolute indication to interrupt pregnancy in the case of accidental 
exposure.227,232 
During lactation, alternative drugs should be preferred to DOACs 
due to the paucity of data. However, there are relevant differences between the agents. In studies on lactating women treated with apixaban, 
the concentration in milk was significantly higher than that of rivaroxaban: the milk-to-plasma ratio was >12%,233 and the weight-adjusted infant doses 14%–20%.234 Dabigatran etexilate mesylate, the orally 
available prodrug, is poorly excreted to the milk after biotransformation to dabigatran, and its oral absorption by the neonatal gastrointestinal tract is likely negligible. In two breastfed neonates of women 
receiving dabigatran, the maximum drug concentrations in the neonates’ plasma were 100 000 times below the levels that would have a 
significant effect on coagulation indices.235 In lactating women treated 
with 15–20 mg/day rivaroxaban, the breastfed infant would receive a 
low dose, corresponding to 1.3%–5% of the maternal weight-adjusted 
dosage.233,236–238 Therefore, dabigatran and rivaroxaban may be taken 
cautiously during lactation. Signs of bleeding should be monitored in 
neonates of lactating mothers taking dabigatran. 
5.2.2. Antiplatelet treatment 
No teratogenic effect is reported for aspirin doses up to 300 mg daily. 
Clopidogrel is considered safe if dual antiplatelet therapy (DAPT) is 
needed for the shortest possible duration.239,240 Ticagrelor is contraindicated due to embryotoxicity. Prasugrel may be considered during 
pregnancy in special populations including poor metabolizers in 
whom the prodrug clopidogrel has limited effect.241,242 The use of 
glycoprotein IIb/IIIa inhibitors (eptifibatide and tirofiban) should only 
be used in pregnancy if strictly necessary.240 
5.2.3. Diuretics and SGLT2 inhibitors 
Diuretics may be used in pregnancy to treat systemic hypertension especially in emergencies or HF-related volume overload conditions. 
Care must be taken to monitor for reduction in plasma volume or 
CO, and decrease in placental perfusion. 
Pre-clinical data on SGLT2 inhibitors showed that they cross the placenta243 and exposure to these drugs may cause foetal damage in rodents, especially during the second and third trimesters.244 SGLT2 
inhibitors should be stopped before pregnancy and during lactation. 
5.2.4. Pulmonary hypertension 
Parenteral prostaglandin analogues (i.v. epoprostenol, treprostinil) can 
be used in pregnant women with significant right ventricle (RV) dysfunction, while recognizing that these agents may interfere with platelet aggregation and may promote bleeding.245 Oral phosphodiesterase 5 
inhibitors (e.g. sildenafil, tadalafil) can also be used, while recognizing 
the potential side effects of pre-term delivery and SGA babies.246 
Combination therapy with sildenafil and inhaled iloprost has also 
been reported.247 Calcium channel blockers should be continued during pregnancy for women with vasodilator-responsive PAH and normal 
RV function. Endothelin receptor antagonists (ERAs, e.g. bosentan, ambrisentan, macitentan) should not be used in pregnancy due to their 
teratogenic potential. There are few data on the safety of agents 
such as bosentan and sildenafil in the post-partum period for lactating 
mothers; however, successful cases have been reported.248,249 
5.2.5. Anti-arrhythmic agents 
For women without structural heart disease, anti-arrhythmic drugs (such 
as flecainide, sotalol, and ibutilide) can be used for the prevention or termination of AF and atrial flutter (AFL).250,251 Beta-blockers are considered safe, especially lipophilic compounds (labetalol, metoprolol, and 
propranolol). In pregnant women with AF and concomitant congestive 
HF, digoxin may be an alternative option for rate control. Amiodarone 
can cause foetal abnormalities, bradycardia, and thyroid dysfunction, 
and its routine use is contraindicated during pregnancy, but may be 
used as single dose in emergencies like ventricular tachycardia (VT) 
storm. There are no restrictions on amiodarone use in cardiac arrest.252 
5.2.6. Calcium channel blockers 
The safety and efficacy of nifedipine [the originator of dihydropyridine 
calcium channel blockers (CCBs)] as an antihypertensive in pregnancy 
has largely been proved in comparison with other antihypertensive 
treatments (see Section 12.3). A meta-analysis of 22 randomized control trials with 2595 participants found that nifedipine was significantly 
more effective at reducing patients’ high blood pressure compared 
with other antihypertensive drugs (labetalol, hydralazine, methyldopa) 
in hypertensive patients.253 Foetal, neonatal, and maternal safety 
outcomes were not statistically different between nifedipine and comparators, except for maternal headache and flushing.253 A randomized 
controlled trial compared oral regimens with nifedipine, labetalol, 
or methyldopa in women requiring antihypertensive therapy due to 
severe hypertension. It found that the primary outcome of blood pressure control within 6 h with no adverse outcome was more common 
with nifedipine or labetalol than with methyldopa254. Amlodipine 
showed safety and efficacy similar to nifedipine.255 Studies on the non- 
dihydropyridine CCB diltiazem are inadequate and significant potential 
teratogenic effects have been demonstrated in rodents and rabbits. 
The drug passes in milk, reaching relevant infant concentrations. 
Therefore, diltiazem is not recommended in pregnancy and lactation. 
Oral verapamil is considered safe; no teratogenicity has been observed. 
The drug is excreted at low levels in milk, <1% of the mother’s weight- 
adjusted dosage. 
Recommendation Table 4 — Recommendation for direct oral anticoagulants and pregnancy 
Recommendation 
Classa 
Levelb  
DOACs are not recommended during pregnancy. 
III 
C 
© ESC 2025
DOAC, direct oral anticoagulants. 
aClass of recommendation. 
bLevel of evidence.   
ESC Guidelines                                                                                                                                                                                               31


<!-- PAGE 32 -->

### Page 32

5.2.7. Renin–angiotensin–aldosterone system 
inhibitors 
Angiotensin-converting enzyme inhibitors (ACE-Is), angiotensin receptor blockers (ARBs), angiotensin receptor/neprilysin inhibitors 
(ARNIs), and renin inhibitors can cause foetal malformations, 
IUGR and death, and are contraindicated in pregnancy. Caution 
should be recommended to childbearing women, especially in the 
absence of effective contraception. Captopril, enalapril, and benazepril are safe during lactation,146 whereas ARBs are not recommended. Candesartan may be an exception.256 Aldosterone 
antagonists, canrenone, and spironolactone can have anti- 
androgenetic effects and are contraindicated in pregnancy. 
Spironolactone is considered safe during lactation because of extensive metabolism to canrenone, thus the infant would receive less 
than 1% of the mother’s daily dosage of canrenone.257 Case reports 
of eplerenone in pregnant women with resistant hypertension identified no adverse effects.258–261 
5.2.8. Lipid-lowering agents 
Diagnosis of maternal hypercholesterolaemia at the first trimester or 
familial hypercholesterolaemia have adverse consequences for both 
foetus and mother.262 Low-density lipoprotein (LDL) levels increase 
by ∼30%–50%, high-density lipoprotein cholesterol by 20%–40%, 
and triglycerides by 50%–100% during pregnancy262, so referring 
to reference range as for routine testing is of limited clinical use. 
Previously, lipid-lowering treatment was usually discontinued during 
pregnancy because of limited safety data.43 Having been contraindicated in pregnancy since 1987, statins now remain contraindicated 
only during lactation. In July 2021 the United States Food and 
Drug Administration (FDA)263 stated that the evidence was insufficient to conclude that a risk of miscarriage is increased with statins 
and requested removal of the contraindication.264 Continuing 
with statins may therefore be considered during pregnancy in women with familial hypercholesterolaemia or established atherosclerotic cardiovascular disease (ASCVD) (see Section 12.2).265 
Furthermore, inadvertent conception during statin therapy does 
not require pregnancy termination but should prompt close follow- 
up. Bile acid binding sequestrants265 and LDL apheresis265 can be 
considered in women with familial hypercholesterolaemia. PCSK9 
inhibitors and ezetimibe are not recommended during pregnancy 
due to lack of clinical data.266 Bempedoic acid has a strong contraindication and therefore women are recommended contraception 
during its use. 
5.2.9. Beta-adrenergic blocking agents 
Beta-blocker use during early pregnancy has not been associated with 
an increased risk of congenital malformations.250,267,268 Recent data 
from ROPAC indicate higher SGA rates in women with beta-blocker 
exposure (15.3% vs 9.3%, P < .001). With metoprolol as reference, labetalol (0.2, 95% CI 0.1–0.4) was the least likely to cause SGA, and 
atenolol (2.3, 95% CI 1.1–4.9) the most.12 Labetalol and lipophilic 
drugs (metoprolol, propranolol, carvedilol) are preferred due to 
high first-pass metabolism, as well as beta-1-selective drugs (bisoprolol, metoprolol), which reduce the risk of hypoglycaemia in addition to 
reduced IUGR. Nadolol and pindolol are also safe in the case of arrhythmic events in cardiomyopathies and channelopathies (see 
Section 6).269–271 Of note, the metabolism of metoprolol (and perhaps 
other oral lipophilic beta-blockers) was significantly higher in mid and 
late pregnancy than post-partum, likely due to enzymatic induction 
during pregnancy.272 Changes in dosage (dose and frequency) are likely required if inadequate clinical responses are encountered.272 
Atenolol causes severe growth restriction, bradycardia, and hypoglycaemia and is not recommended.250,268,272,273 
Propranolol, metoprolol (combined with hydralazine), and labetalol 
had the lowest and sotalol the highest risk of neonatal bradycardia during lactation.274 For the lipophilic beta-blockers, milk level was <1% of 
the maternal weight-adjusted dose, thus reducing the risks associated 
with neonatal exposure during lactation.272 
5.2.10. Immunosuppressants 
The balance between maternal and foetal safety is challenging for immunosuppressant therapy, especially for women with heart transplantation. Medication can pass to the milk and expose neonates 
and infants to adverse drug effects. Changes in maternal physiology 
impact the pharmacokinetics of immunosuppressant drugs (see 
Section 3.2).275 Calcineurin inhibitors (e.g. cyclosporine, tacrolimus), 
mammalian target of rapamycin inhibitors (e.g. everolimus, sirolimus), 
and azathioprine are the drugs of choice during pregnancy and lactation, which should not be discouraged. Mycophenolate derivatives increase the risk of miscarriage and foetal malformations especially 
during the first trimester and should be discontinued at least 6 weeks 
before conception.276,277 
5.2.11. Neuroactive drugs 
Selective serotonin reuptake inhibitors, including sertraline, can be taken safely during pregnancy and lactation.278 Zuranolone, a synthetic 
form of the neurosteroid allopregnanolone, has recently been approved for the treatment of post-partum depression. No information 
is available on its safety in patients with CVD. Zuranolone is excreted in 
the milk and lactation should be avoided in the absence of safety 
data.279 
5.2.12. Obstetric drugs in patients with 
cardiovascular disease 
Drugs for inducing ovulation, including follicle-stimulating hormone and 
luteinizing hormone or combinations, are associated with an increased 
risk of deep vein thrombosis (DVT) and PE, due to the sharp rise in oestrogen levels during follicle recruitment,280 but no other immediate cardiovascular side effects are known. 
5.3. Internet databases 
See Supplementary data online, Internet databases. 
5.4. List of drugs 
See Supplementary data online, Table S4.


<!-- PAGE 33 -->

### Page 33







	



 ­





	



 ­
	






	
	

	





	



















	









































 ­


































 




		
	



	
	

	


	


	

Figure 6 Choice of medication during pregnancy (left) and during lactation and breastfeeding (right). ACE-I, angiotensin-converting enzyme inhibitor; ARB, 
angiotensin receptor blocker; ARNI, angiotensin receptor/neprilysin inhibitor; ASA, acetylsalicylic acid; ASCVD, atherosclerotic cardiovascular disease; DOAC, 
direct oral anticoagulant; LMWH, low-molecular-weight heparin; MRA, mineralocorticoid receptor antagonist; PCSK9-I, proprotein convertase subtilisin/kexin 
type 9 inhibitor; SGLT2-I, sodium–glucose co-transporter-2 inhibitors; UFH, unfractionated heparin; VKA, vitamin K antagonist; wk, week. 
First/safest choice in pregnancy, lactation and breastfeeding. 
Second choice in pregnancy, lactation, and breastfeeding. 
Evidence of foetal or infant 
toxicity or no data on safety. aExcept candesartan. bSee text for details.   
ESC Guidelines                                                                                                                                                                                               33


<!-- PAGE 34 -->

### Page 34

### 6 Pregnancy in women with

cardiomyopathies and primary 
arrhythmia syndromes 
6.1. Cardiomyopathies 
Cardiomyopathies are characterized by disease-specific structural abnormalities and increased risk of ventricular and supraventricular arrhythmias. The risk associated with pregnancy in a woman with 
cardiomyopathy can be estimated using the mWHO 2.0 classification 
(Table 6). Pre-pregnancy, women with cardiomyopathies should be 
clinically evaluated to optimize treatment, avoid contraindicated drugs, 
and assess the risk of heart failure and arrhythmias. Indicated procedures, including implantable cardioverter defibrillator (ICD) implantation, should be performed before pregnancy. 60 
Genetic counselling is recommended before pregnancy to explain 
the probability of genetic transmission, risks for the mother, foetus, 
and child, and the possibilities of pre-implantation and pre-natal genetic 
testing (Table 7).60,281 Women with cardiomyopathies should be managed by the Pregnancy Heart Team, including a cardiologist with expertise in cardiomyopathies and arrhythmias. 
6.1.1. Dilated cardiomyopathy and non-dilated left 
ventricular cardiomyopathy 
In women with dilated cardiomyopathy (DCM) and non-dilated left ventricle (LV) cardiomyopathy (NDLVC), severe systolic LV dysfunction, 
New York Heart Association (NYHA) functional class III/IV, RV failure, 
sustained ventricular arrhythmias, AF, and/or severe mitral valve regurgitation (MR) are high-risk criteria for major adverse cardiovascular events 
during pregnancy.282 In contrast, women with mild LV dysfunction, good 
functional status, no arrhythmias, and no history of cardiac events are 
likely to have an uncomplicated pregnancy.282 
Therapy should be modified before pregnancy. ACE-Is, ARBs, 
mineralocorticoid receptor antagonists (MRAs), sacubitril/valsartan, and 
SGLT2 inhibitors are all contraindicated during pregnancy. Pre-pregnancy 
risk stratification should include temporary withdrawal of contraindicated 
medication with close monitoring (see Section 12.6 Heart failure). 
Beta-blockers should be continued with close monitoring of foetal growth. 
If anticoagulation is needed for AF or evidence of an intracardiac thrombus, 
LMWH should be used (see Section 5 for dosing regimens). 
Data about genotype-specific management during pregnancy are 
scarce but one study evaluated the risk of pregnancy and progression 
of cardiomyopathy in women with lamin A/C (LMNA) P/LP variants.283 
A small subset of women experienced arrhythmias during pregnancy although a history of pregnancy was not associated with long-term adverse disease progression.283 
More information is included in Sections 7, 12.4, and 12.6. 
6.1.2. Arrhythmogenic right ventricular 
cardiomyopathy 
Several observational studies and registries have shown that pregnancies in women with arrhythmogenic right ventricular cardiomyopathy 
(ARVC) are generally well tolerated with good foetal outcomes and 
no cardiac mortality when receiving optimal surveillance and therapy.284,285 Delivery was usually vaginal and appeared safe. Sustained 
ventricular arrhythmias were reported in 5% of pregnancies and HF 
in 13%. Neither increased arrhythmia burden or ICD shocks were observed.284 Beta-blocker therapy should be continued during pregnancy 
(with the exception of atenolol) or could be started in pregnancy if 
needed. The two most used anti-arrhythmic drugs in previous studies, 
beside beta-blockers, were flecainide and sotalol. Both drugs have a 
long record of safety. However, sotalol should be used with caution 
in women with reduced ejection fraction (EF) and with careful corrected QT interval (QTc) monitoring.60 Sotalol also has a beta-blocker 
effect, necessitating monitoring of foetal growth.286,287 Amiodarone is 
contraindicated in pregnancy. In women at high arrhythmic risk, an ICD 
should be implanted, preferably before pregnancy (see Section 12.4). 
Two large studies of women with ARVC showed that pre-pregnancy 
phenotypical severity, rather than pregnancy itself, was the primary risk 
factor. Pregnancy was uneventful in the overwhelming majority.288,289 
Pregnancy did not seem to accelerate long-term progression of the 
ARVC phenotype.288 
6.1.3. Hypertrophic cardiomyopathy 
Hypertrophic cardiomyopathy290 is the most common inherited cardiomyopathy and is often caused by variants in sarcomeric genes.60 Phenocopies 
such as Anderson–Fabry disease and Danon disease290 are X-linked and 
therefore the cardiac phenotype tends to be milder and occurs later in 
life in females than males, making pregnancy usually uneventful.291–293 
Despite higher maternal mortality in women with HCM compared 
with the general population, absolute maternal mortality is low (0.5%) 
and confined to women at particularly high risk (Table 6).294,295 Data 
from the ROPAC registry showed that despite overall good outcomes, 
23% of pregnant women with HCM developed major cardiac events, including VT (10%) and AF (1.7%), mostly in women already identified as 
high risk prior to pregnancy.296 A recent systematic review including 
1624 women confirmed low neonatal mortality (0.2%) and stillbirths 
(1%) in pregnant women with HCM.297 A study including 242 women 
with HCM found that pregnancy was not a modifier of the long-term 
outcomes and pregnancy was well tolerated.298 Risk factors for major adverse cardiovascular events were advanced NYHA class and 
higher age at diagnosis.298 Left atrium diameter as a risk factor has 
been reported with conflicting results.298,299 
6.1.3.1. Treatment of hypertrophic cardiomyopathy in pregnancy 
Ongoing beta-blocker therapy should be continued during pregnancy. 
Atenolol should be replaced before pregnancy (Section 5.2.6). Atrial fibrillation is poorly tolerated in HCM patients in general due to the risk of 
haemodynamic decompensation, and medical or electrical cardioversion of AF during pregnancy should be considered. Beta-blockers 
should be started during pregnancy when new symptoms occur [e.g. 
due to left ventricular outflow tract obstruction (LVOTO)], for rate 
control in AF, and to suppress ventricular arrhythmias. Verapamil is 
the second choice of drug when beta-blockers are not tolerated. 
6.1.3.2. Left ventricular outflow tract obstruction 
Left ventricular outflow tract (LVOT) gradients may increase slightly 
during pregnancy and were previously associated with increased cardiac events including arrhythmias and HF.300 However, subsequent 
studies have not confirmed this association.296,298 
In women with obstructive HCM, it is recommended to evaluate gradient in basal condition, with exercise and the Valsalva manoeuvre, before pregnancy and with only the medications allowed during 
pregnancy, to identify those needing septal reduction therapy before 
pregnancy.60 Disopyramide may cause uterine contractions and is not 
recommended in pregnancy and should be discontinued unless the benefits outweigh foetal risk. Data on the safety of alcohol septal ablation 
during pregnancy are limited to a few case reports.60,301,302


<!-- PAGE 35 -->

### Page 35

Myosin inhibitors (e.g. mavacamten) have not been tested in pregnancy and animal studies have shown foetal toxicity.303 Therefore, 
contraception is recommended while on this treatment. Mavacamten 
may interact with hormonal contraception and therefore adding intrauterine or barrier contraception to hormonal contraception may be 
considered. Myosin inhibitor treatment should be discontinued at least 
6 months before planning pregnancy304 (see Supplementary data 
online, Table S4). 
6.1.4. Hypertrabeculation of the left ventricle 
Hypertrabeculation in isolation identified during pregnancy can be the 
simple consequence of an increased preload, can resolve after pregnancy, and cannot be used to make a diagnosis of cardiomyopathy.60 
Patients with hypertrabeculation and associated HCM, DCM, or 
NDLVC should follow the same recommendation as patients with 
the specific cardiomyopathy.60 
6.1.5. Labour and delivery in cardiomyopathies 
Labour and delivery may be associated with acute pain, adrenaline release, and need for urgent administration of anaesthetic drugs, and 
therefore haemodynamic monitoring and continuous telemetry monitoring during and after delivery is often warranted. In the absence of obstetric contraindications, vaginal delivery is generally recommended. 
Neuraxial anaesthesia reduces pain and therefore reduces adrenergic 
activation and arrhythmic risk. 
In HCM, peripheral vasodilatation is poorly tolerated in women 
with severe LVOT obstruction (LVOTO) and therefore epidural 
and spinal anaesthesia should be applied cautiously. Low-risk 
LVOTO cases may have a spontaneous labour and vaginal delivery. 
Caesarean section may be the preferred option in women with severe 
LVOTO. 
6.2. Primary arrhythmia syndromes 
In general, women with primary arrhythmia syndromes tolerate pregnancy well. Genetic counselling is recommended before pregnancy, 
as discussed in Section 6.1. A complete clinical re-evaluation, optimization of treatment, and ICD evaluation should be undertaken prior to 
pregnancy.252 Indicated treatment should be continued throughout 
pregnancy and in the post-partum period. 
6.2.1. Long QT syndrome 
Long QT syndrome (LQTS) is the most common channelopathy.307 All patients with LQTS should take beta-blockers, with propranolol and nadolol 
being the most effective.308 Additional therapies include left cardiac sympathetic denervation309 and mexiletine for LQT3252 and LQT2.310,311 The 
foetal risk of mexiletine treatment is unknown, and decisions on treatment 
during pregnancy should be a shared decision with the woman. 
Retrospective studies312–316 show that women with LQTS were not at 
higher risk of cardiac events during pregnancy itself, but had an increased risk 
Recommendation Table 5 — Recommendations for 
cardiomyopathies and pregnancy 
Recommendations 
Classa 
Levelb  
Clinical cardiological surveillance (ECG, 
echocardiogram, and Holter ECG monitoring) is 
recommended during pregnancy in women with 
CMPs, depending on individual risk. 
I 
C 
Vaginal delivery is recommended in most women 
with CMPs, unless there are obstetric indications for 
caesarean section, severe HF (EF <30% and/or 
NYHA class III/IV), uncontrolled arrhythmias, or 
severe outflow obstruction (≥50 mmHg) in women 
with HCM, or in women presenting in labour on 
VKAs.60 
I 
C 
Continuation of beta-blockersc should be considered 
during pregnancy in women with CMPs, with close 
follow-up of foetal growth.60 
IIa 
C 
Dilated cardiomyopathy 
In women with DCM and worsening of EF during 
pregnancy, counselling on the risk of recurrence 
during a subsequent pregnancy is recommended in all 
cases, even after recovery of LV function.43 
I 
C                                                                                                   
Continued 
Arrhythmogenic right ventricular cardiomyopathy 
Flecainide, in addition to beta-blockers, should be 
considered as the anti-arrhythmic drug of choice in 
pregnant women with ARVC.148 
IIa 
C 
Sotalol may be considered as an anti-arrhythmic drug 
in pregnant women with ARVC, with careful 
evaluation of QTc and while monitoring for foetal 
bradycardia and foetal growth and neonate 
hypoglycaemia. 
IIb 
C 
Hypertrophic cardiomyopathy 
It is recommended to use the same risk stratification 
protocol for ventricular arrhythmias in pregnant 
women with HCM as for non-pregnant women with 
HCM.43 
I 
C 
It is recommended to start beta-blockersc in women 
with HCM who develop symptoms due to outflow 
tract obstruction or arrhythmia during pregnancy.43 
I 
C 
It is recommended that women with HCM with 
symptomatic LV dysfunction (EF <50%) and or 
severe LVOTO (≥50 mmHg) wishing to become 
pregnant are counselled by the Pregnancy Heart 
Team regarding the high risk of pregnancy-related 
adverse events.294,295 
I 
C 
Cardioversion for AF should be considered in 
pregnant women with HCM.43,305 
IIa 
C 
Disopyramide may be considered in pregnant 
women with HCM only when the potential benefits 
outweigh the risk of uterine contractions.305,306 
IIb 
C 
Myosin inhibitors are not recommended in women 
during pregnancy due to lack of safety data.303,304 
III 
C 
© ESC 2025
AF, atrial fibrillation; ARVC, arrhythmogenic right ventricular cardiomyopathy; CMP, 
cardiomyopathy; DCM, dilated cardiomyopathy; ECG, electrocardiogram; EF, ejection 
fraction; HCM, hypertrophic cardiomyopathy; HF, heart failure; LV, left ventricular; 
LVOTO, left ventricular outflow tract obstruction; NYHA, New York Heart 
Association; QTc, corrected QT interval; VKA, vitamin K antagonist. 
aClass of recommendation. 
bLevel of evidence. 
cExcept for atenolol.   
ESC Guidelines                                                                                                                                                                                               35


<!-- PAGE 36 -->

### Page 36

in the post-partum period (up to 12 months), especially for those with 
LQT2. Beta-blocker therapy was associated with risk reduction in all the 
studies. Women with LQTS should therefore start beta-blockers at pregnancy or continue beta-blockers at pre-pregnancy dose, with propranolol 
or nadolol as drugs of choice. Beta-blockers should be continued in the post- 
partum period, particularly in the case of women with LQT2 due to the increased arrhythmic risk. It should be noted that nadolol has a higher excretion in breast milk than propranolol, with a relative infant dose of 4%–7%.317 
Therefore, nadolol is generally not the preferred beta-blocker during lactation. However, arrhythmic risk can be high in LQTS, and nadolol is one of the 
drugs of choice; thereofore, a careful weighting of benefit against harm is appropriate. Change of beta-blocker therapy after delivery should be avoided, 
as this is a vulnerable phase. Therefore, a change from nadolol to propranolol should ideally be evaluated before pregnancy. High dosages of nadolol 
during lactation may require monitoring of the infant for bradycardia. 
Women with LQTS should always avoid QT-prolonging drugs (see  
www.crediblemeds.org)318. Women with LQTS should be promptly 
treated for hypokalaemia and hypomagnesaemia, which is relevant in 
pregnancy-related hyperemesis, causing electrolyte disturbances and 
failure to absorb oral medications. All anti-emetic medications are 
QT-prolonging. Electrocardiogram monitoring should be performed 
if anti-emetic therapy is absolutely required. 
Long QT syndrome can manifest very early in life, even during the foetal period, and can be a cause of stillbirth319,320 (Section 4.5.1). A neonatal 
ECG should be performed post-delivery and after 2 weeks to avoid overdiagnosis due to transiently prolonged QT interval during the first 7–10 
days of life.321 Genetic screening for familiar genetic variants should be 
performed as soon as possible (e.g. from chordal blood). If the newborn 
is affected by LQTS, beta-blocker therapy should be started immediately. 
6.2.2. Brugada syndrome 
Men with Brugada syndrome (BrS) are more often symptomatic than 
women.322 The only retrospective study on pregnant women with 
BrS did not show an increased risk of cardiac events during pregnancy 
and the post-partum period.323 All patients with BrS should avoid contraindicated drugs (see www.brugadadrugs.org),324 large meals, or excess alcohol, and promptly treat fever and its causes.325 If there are 
symptoms during pregnancy, quinidine therapy should be considered 
with monitoring of hepatic function and blood count in the mother. 
6.2.3. Catecholaminergic polymorphic ventricular  
tachycardia 
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is 
mainly caused by P/LP in the RYR2 gene.252 The only retrospective 
study published, involving 96 women and 228 pregnancies, did not 
show an increased risk of cardiac events during pregnancy and the post- 
partum period.326 
Beta-blockers are the mainstay of therapy, with additive flecainide if 
needed.322,327 Nadolol and propranolol are beta-blockers of choice and 
should be continued during pregnancy and lactation. As in LQTS, the 
higher excretion of nadolol in breast milk should be noted (Section  
6.2.1). Left cardiac sympathetic denervation is a valuable anti- 
arrhythmic option that should be performed in experienced centres 
before pregnancy if indicated.328 Implantable cardioverter defibrillators 
are indicated in a minority of patients with CPVT. 
6.2.4. Short QT syndrome 
Short QT syndrome (SQTS) is a rare channelopathy characterized by 
short QT and increased risk of life-threatening arrhythmias and 
AF.329 There are no case reports or studies published on pregnancy 
in women with SQTS. When choosing an anti-arrhythmic drug during 
pregnancy, quinidine is the best option in the absence of more robust 
data.330 
6.2.5. Labour and delivery in primary arrhythmia 
syndromes 
In all primary arrhythmia syndromes, delivery should be planned with 
heart rhythm monitoring, electrolyte control, and post-operative 
ECG monitoring until all anaesthetic drugs have been eliminated. 
Labour and delivery may be associated with acute pain, adrenaline 
release, and urgent administration of anaesthetic drugs, and therefore 
continuous telemetry monitoring is often warranted. In the absence 
of obstetric contraindications, vaginal delivery is generally recommended. Neuraxial anaesthesia reduces pain and therefore adrenergic 
activation which is specifically important in LQTS and CPVT. Women 
with LQTS and CPVT should continue beta-blocker therapy during labour and delivery. In women with CPVT, it is reasonable to keep 
the heart rate under the threshold for premature ventricular contraction onset during delivery, typically 100–110 b.p.m.331,332 Anaesthetic 
drugs for LQTS should be selected according to the CredibleMeds 
website (www.crediblemeds.org). 
In BrS, propofol and local anaesthetics with sodium-blocking agents 
(e.g. lidocaine) carry a theoretical risk of triggering arrhythmias. Case 
reports have indicated uneventful delivery with neuraxial anaesthesia 
in women with BrS.333 Thiopental and inhalation anaesthesia have so 
far not been associated with adverse events.324,333 Anaesthestic drugs 
should be chosen according the BrugadaDrugs website (www. 
brugadadrugs.org). 
Recommendation Table 6 — Recommendations for primary arrhythmia syndromes and pregnancy (see Evidence 
Tables 4–6) 
Recommendations 
Classa 
Levelb  
Monitoring and treatment of hypokalaemia and hypomagnesaemia is recommended in pregnant women with primary arrhythmia 
syndromes suffering from hyperemesis.334 
I 
C 
Long QT syndrome 
Beta-blockersc, with pre-pregnancy dose and with nadolol and propranolol as drugs of choice, are recommended during pregnancy in 
women with LQTS.312–316,335 
I 
B 
It is recommended to continue beta-blocker therapy during lactation in women with LQTS to reduce arrhythmic risk.148,336 
I 
B 
Pre-pregnancy beta-blocker dose of nadolol or propranolol, is recommended in women with LQT2, particularly in the post-partum period, 
which represents a high-risk period for life-threatening arrhythmias.148,313,315 
I 
B                         
Continued


<!-- PAGE 37 -->

### Page 37

### 7 Peripartum cardiomyopathy

7.1. Epidemiology 
Peripartum cardiomyopathy is a potentially life-threatening condition 
defined as HF with reduced left ventricular ejection fraction (LVEF) 
<45%, without any other cause of HF, that occurs mainly during the 
peripartum period or in the months following delivery, termination, 
or miscarriage.339 Peripartum cardiomyopathy is essentially a diagnosis 
of exclusion and requires urgent management. 
Worldwide, PPCM is a complication of 1 of 2000 births,340 but incidence rates vary depending on the geographical region, ethnicity, and 
socioeconomic factors, with an incidence of 1–4/1000 births in the 
United States of America341,342 and 10/1000 births in the north- 
western region of Nigeria.343 Recent data from 49 countries showed 
that most women presented with PPCM in the post-partum 
stage.344–346 Risk factors for PPCM are shown in Figure 7. 
7.2. Mechanisms 
Recent trials suggest a ‘multiple hit’ theory for developing PPCM, with 
an accumulation of genetic and environmental risk factors (Figure 7). An 
overrepresentation of genetic variants in TTN, FLNC, BAG3, and DSP 
genes have been found in up to 15% of women with PPCM, with 
TTN truncating variants being the most common.347,348 The prevalence 
of these four genes in women with PPCM was comparable to the 
prevalence in DCM cohorts, supporting the similarity between PPCM 
and DCM. Genetic testing should therefore be considered in women 
with PPCM. 
There is growing evidence that several pathophysiological mechanisms in PPCM converge on a common pathway, which involves inflammation, unbalanced oxidative stress, and the generation of the 
anti-angiogenic 16 kDa prolactin. The 16 kDa prolactin induces 
endothelial dysfunction and damage, and subsequently leads to HF. 
Blocking prolactin with the dopamine D2 receptor agonist bromocriptine has emerged as a potential disease-specific therapy for 
PPCM.344,349–352 Additionally, the systemic or local increase in other 
anti-angiogenic factors, such as the soluble fms-like tyrosine kinase-1 
(sFlt-1) receptor, contributes to both local and widespread vascular 
dysfunction.353 
7.3. Diagnosis and clinical interventions 
Peripartum cardiomyopathy may present as subtle manifestations 
but most women with PPCM present with acute heart failure 
(AHF) with severe symptoms (NYHA III/IV). Mild to moderate symptomatic cases of PPCM are often mistaken for physiological changes 
associated with pregnancy, especially in the post-partum period. 
Myocarditis is a differential diagnosis and should be excluded by 
CMR.354 Women with PPCM and pre-eclampsia had a higher risk 
of adverse neonatal outcome but also a higher likelihood of left ventricular recovery (LVEF ≥50%).15 Diagnostic measures in a woman 
with suspected PPCM should include ECG, NPs, and echocardiography. The management strategy should be discussed within the 
Pregnancy Heart Team, considering maternal and foetal outcomes 
(Figure 7). Foetal prematurity and low birth weight are common in 
mothers with PPCM, and children of these mothers have a 3.4 times 
higher incidence of cardiovascular disease and 5 times higher 
mortality.355 
Treatment of AHF caused by PPCM follows the main principles 
of AHF management during and after pregnancy (Section 12.6). 
Mechanical circulatory support should be considered in women with 
persistent cardiogenic shock despite medical treatment.356,357 
Most medications used in the management of HF are foetotoxic and 
thus contraindicated during pregnancy (i.e. ACE-Is, ARBs, MRAs, and 
SGLT2 inhibitors).339 In the post-partum period, full HF treatment 
In women carrying a LQTS P/LP variant and who are phenotype-negative, use of beta-blockersc during pregnancy, post-partum, and 
lactation should be considered.148 
IIa 
C 
Left cardiac sympathetic denervation should be considered before pregnancy in high-risk woman with LQTS who are not adequately 
protected by pharmacological therapies or who have appropriate ICD shocks despite optimal medical therapy.252 
IIa 
C 
Brugada syndrome 
Quinidine therapy should be considered in pregnant women with BrS who have arrhythmic events during pregnancy.337,338 
IIa 
C 
Catecholaminergic polymorphic ventricular tachycardia 
Beta-blockersc, with pre-pregnancy dose and with nadolol and propranolol as drugs of choice, are recommended during pregnancy and 
lactation in women with CPVT.43,148,252 
I 
C 
Flecainide, in addition to beta-blockers, is recommended in women with CPVT who experience cardiac events such as syncope, VT, or 
cardiac arrest during pregnancy. 
I 
C 
It is recommended that women with CPVT who are stable on beta-blockers (nadolol or propranolol as drugs of choice) and flecainide 
before pregnancy continue both drugs during pregnancy and post-partum. 
I 
C 
The use of beta-blockersc during pregnancy and lactation should be considered in phenotype-negative women with a CPVT P/LP variant.148 
IIa 
C 
Left cardiac sympathetic denervation should be considered before pregnancy in high-risk women with CPVT who are not adequately 
protected by pharmacological therapies or with appropriate ICD shocks despite optimal medical therapy.252 
IIa 
C 
Short QT syndrome 
It should be considered to continue quinidine therapy in women with SQTS throughout pregnancy and the post-partum period.148 
IIa 
C 
Quinidine therapy should be considered in pregnant women with SQTS and arrhythmic events during pregnancy.148 
IIa 
C 
© ESC 2025
BrS, Brugada syndrome; CPVT, catecholaminergic polymorphic ventricular tachycardia; ICD, implantable cardioverter defibrillator; LQTS, long QT syndrome, LQT2, long QT syndrome type 
2; P/LP, pathogenic/likely pathogenic; SQTS, short QT syndrome; VT, ventricular tachycardia. 
aClass of recommendation. 
bLevel of evidence. 
cExcept for atenolol.   
ESC Guidelines                                                                                                                                                                                               37


<!-- PAGE 38 -->

### Page 38

can be initiated, except if lactation and breastfeeding are necessary for 
nutritional reasons, in which case ARBs and SGLT2 inhibitors should be 
avoided. Spironolactone is considered safe (see Section 5.2.7 and  
Figure 7). 
In addition to HF treatment, the prolactin production suppressing 
agent bromocriptine may be considered in women with PPCM 
(Figure 7).358–360 A secondary effect of bromocriptine is stopping 
lactation, which enables the possibility of full HF treatment of the 
mother that is not breastfeeding. The downsides of stopping lactation 
as PPCM treatment include psychological implications for the mother 
and the source of nutrition for the infant. These considerations indicate 
that women with moderate and severe HF in PPCM are the preferred 
candidates for bromocriptine treatment. A recent multi-centre randomized study comparing two different bromocriptine dosages in women 



	
















	



	
	







		
	



	

	
 


­





	






	



	







	
	
	

	


 




	 

	

	
	


	







	


	







­




	

			


	






	
	
	

Figure 7 Risk factors and management of peripartum cardiomyopathy. CMR, cardiac magnetic resonance imaging; HF, heart failure; LVEF, left ventricular 
ejection fraction; P/LP, pathogenic/likely pathogenic; PPCM, peripartum cardiomyopathy. aIn specific cases.


<!-- PAGE 39 -->

### Page 39

with severe PPCM (2.5 mg daily for 1 week vs 5 mg daily for 2 weeks 
followed by 2.5 mg daily for 6 weeks) observed a high LV recovery 
rate at 6 months. No significant differences were observed between 
treatment over 1 week and 8 weeks, suggesting that a 1 week addition 
of bromocriptine to standard heart failure treatment would be beneficial.358 There are limited data on the use of bromocriptine in pregnant 
women with PPCM and cardiogenic shock.339,361 Personalized bromocriptine treatment, with dose adjustments to effectively suppress prolactin, may be a viable therapeutic option in these specific cases. Adding 
LMWH (in prophylactic doses at a minimum) to bromocriptine should 
be considered to reduce the thromboembolic risk.362 
7.4. Outcomes 
Risk stratification is crucial to determine the appropriate level of care for 
women diagnosed with PPCM (Figure 7). Key indicators to identify individuals at risk of complications include LVEF <30%, LV end-diastolic 
diameter >60 mm, biventricular dysfunction, ECG QT interval prolongation, delayed diagnosis, and Middle Eastern or African ethnicity and/or 
geography.344 Additional parameters such as age (>40 or <20 years), 
antepartum diagnosis, haemodynamic parameters at presentation, and 
cardiac biomarkers can further refine risk stratification. 
PPCM may cause ventricular tachyarrhythmias and patients should 
therefore be monitored.363,364 As ∼50% of women with PPCM recover 
within 1 year after delivery, a wearable cardioverter defibrillator (WCD) 
for pregnant women with LVEF <35% at risk of sudden cardiac death 
may be considered to provide bridging therapy to recovery.365,366 
Myocardial recovery after PPCM, defined as LVEF >50%, has been 
shown to occur in 46% (25%–62% according to geographical region) 
of women at 6 months.16 Full HF treatment should be given during the 
first year after complete LV function recovery. Stepwise discontinuation 
of HF therapy may be considered after 1 year if complete myocardial recovery is achieved, assuming that no genetic predisposition has been 
identified.339,367 However, recent data indicated higher risk of LVEF relapse during subsequent pregnancies in PPCM women who had discontinued their HF medication.368 Left ventricular assist device (LVAD) or 
heart transplantation have been reported in up to 10% of PPCM cases, 
with inferior survival rates compared to other age-adjusted heart transplant recipients.340 
Outcomes after PPCM differ globally.344 The EURObservational 
Research Programme’s (EORP) PPCM registry reported low mortality 
rates369 of 2.4% 1 month after diagnosis.370 However, the mortality 
rate at 6 months was 6%, with HF and cardiac arrest as the most frequent causes of death.16 At 1 year follow-up, death from any cause occurred in 8% of women, with regional variations (Europe 5%, Africa 6%, 
Asia–Pacific 9%, Middle East 19%; P < .001).17 
Women with a previous PPCM diagnosis face a notably elevated risk 
of poor outcomes. In the most recent EORP paper following women 
with subsequent pregnancies after PPCM, risk of maternal mortality 
was lower than in previous reports, at 2% at 198 days after delivery.368 
More than mild LV dysfunction before a new pregnancy increases the risk 
of LVEF deterioration, but also women with recovered LV functions remained at risk of relapse.368 In women planning a new pregnancy after a 
previous PPCM and with only mild LV dysfunction, stress echo without 
contraindicated HF medication may be helpful to further stratify risk. 
Having a good contractile reserve after HF medication has been discontinued may be an encouraging prognostic sign.371 If planning a new pregnancy after PPCM, discontinuation of beta-blocking therapy may not be 
advisable, and restarting beta-blocking therapy may be beneficial at a subsequent pregnancy, irrespective of baseline LV systolic function.368 
8. Pregnancy in women with 
aortopathies 
Acute arterial dissection during pregnancy occurs in 5.5/100 000 live 
births, with the aorta being the third most frequent location (19.8%) 
after coronary artery dissection (38.2%) and vertebral artery dissection 
(22.9%).378 A large cohort study reported an aortic dissection rate of 
5.5 per million women during pregnancy and post-partum, compared 
with 1.4 per million during the equivalent period 1 year later.40 
Although rare, acute aortic syndromes carry high foetal and maternal 
morbidity and mortality risks.378,379 Arterial dissections occur antenatally in 15%, intrapartum in 23%, and post-partum in 62% of cases.378 
Most pregnancy-related aortic dissections occur in women who are unaware of their underlying aortic disease380 and events rarely occur in 
women who have been monitored according to guidelines.7 The risk 
of peripartum dissection in more distal aortic segments remains after 
prior aortic root replacement.381 The mechanism for dissection during 
pregnancy is unclear. Given the high post-partum prevalence, haemodynamic changes alone do not fully explain the increased risk and hormonal influences are likely involved. 
8.1. Women with heritable thoracic aortic 
disease 
The number of genes associated with heritable thoracic aortic disease 
(HTAD) is steadily increasing. Although there is clear evidence for an 
increased risk of aortic dissection in HTAD, recent data from the 
Recommendation Table 7 — Recommendations for 
peripartum cardiomyopathy (see Evidence Table 7) 
Recommendations 
Classa 
Levelb  
Counselling for women with PPCM about the risk of 
recurrence during a subsequent pregnancy and about 
contraception is recommended in all cases, even 
after recovery of LV function (LVEF >50%).355,369 
I 
C 
Adding at least prophylactic LMWH treatment to 
bromocriptine treatment in women with PPCM 
should be considered.358,362,372,373 
IIa 
C 
Genetic counselling and testing should be considered 
in women with PPCM.60 
IIa 
C 
When a reversible course of HF is assumed, 
treatment in accordance with HF guidelines should 
be considered for at least 12 months after complete 
LV recovery (normalization of LV volumes and 
EF).339,345,368,374 
IIa 
C 
Bromocriptine treatment may be considered in 
addition to optimal HF treatment to enhance 
recovery of LV function in women with PPCM.358– 
360,366,375,376 
IIb 
B 
The use of a WCD may be considered in women 
with PPCM and LVEF <35%.377 
IIb 
C 
© ESC 2025
EF, ejection fraction; HF, heart failure; LMWH, low-molecular-weight heparin; LV, left 
ventricle; LVEF, left ventricular ejection fraction; PPCM, peripartum cardiomyopathy; 
WCD, wearable cardioverter defibrillator. 
aClass of recommendation. 
bLevel of evidence.   
ESC Guidelines                                                                                                                                                                                               39


<!-- PAGE 40 -->

### Page 40

ROPAC III study showed that the aortic dissection incidence rate (3.5%) 
in pregnant women with HTAD was lower than previously reported.382 
Phenotypes and outcomes between different genes and variants vary, 
are of clinical importance, and impose differences in management with 
regard to the extent of imaging, surveillance, and referral for surgery.62,383 Clinical and genetic entities for which data are available are 
discussed below and included in Figure 8. 
8.1.1. Marfan syndrome 
Marfan syndrome (MFS) is caused by P/LP variants in FBN1. 
Pregnancy-associated cardiovascular events include aortic and coronary 
artery dissection as well as rapid aortic growth necessitating surgery.384 
Aortic event rates can reach up to 10%. Although type A dissections 
mainly occur in undiagnosed women, often with aortic diameters exceeding surgical thresholds,389 type B dissections remain unpredictable 
and can occur even after prophylactic root replacement.390 Women diagnosed earlier in life have a lower risk of dissection.391 More dissections 
occur during the post-partum period than during pregnancy or at delivery.384,392 Event rates and overall maternal mortality are low in women 
under guidelines-based follow-up.7,390 Studies have shown stable aortic 
root diameters during pregnancy in women with diameters between 40 
and 45 mm.384,393 No significant difference in aortic events is noted between ever-pregnant and never-pregnant women,384,392 but most data 
come from patients in highly controlled environments. 
8.1.2. Loeys–Dietz syndrome 
Loeys–Dietz syndrome (LDS) is linked to P/LP variants in six genes: 
TGFBR1, TGFBR2, SMAD2, SMAD3, TGFB2, and TGFB3. Aortic outcomes 
in LDS vary by gene and variant,64 leading to gene-specific recommendations for aortic root surgery thresholds.62,383,388 Planned pregnancy is a 
known risk factor, but data on dissection risk during pregnancy, including 
diameters at dissection, are limited. Cases of type B dissection after aortic 
root replacement have been reported.394 A higher incidence of haemorrhagic events, reported in earlier studies,395 was not corroborated in a 
recent ROPAC III study.382 Although pregnancy data for women with 
LDS are sparse, recent reports suggest favourable maternal and foetal 
outcomes with appropriate counselling and surveillance.395 The lack of 
data about aortic diameters at dissection during pregnancy limits high- 
level recommendations for prophylactic aortic root surgery thresholds. 
8.1.3. Vascular Ehlers–Danlos syndrome 
With a reported pregnancy-related mortality rate of 5% and life- 
threatening vascular events in up to 10% of pregnancies, women with 
vascular Ehlers–Danlos syndrome undeniably have high-risk pregnancies.396 Pregnancy-related complications include vascular dissection 
or rupture, uterine rupture, perineal tears, haemorrhage, and premature birth. However, pregnancy and delivery do not seem to affect 
overall survival rates in women with vascular Ehlers–Danlos syndrome.397 The risk may be lower for some women with specific genetic 
variants, null mutations, and normal vascular imaging.398,399 Celiprolol is 
recommended (also in normotensive women), given the very high risk 
of dissections and the benefit demonstrated in non-pregnant populations.7 Shared decision-making is crucial for these women. A ROPAC 
study included four women with vascular Ehlers–Danlos syndrome 
who experienced pregnancy without adverse maternal events.7 Based 
on data from a recent systematic review, caesarean section at 37 weeks 
should be scheduled to avoid obstetrical complications.400 Women 
with vascular Ehlers–Danlos syndrome should be counselled on pregnancy risk and monitored by a Pregnancy Heart Team. 
8.1.4. Non-syndromic heritable thoracic aortic 
diseases 
The number of genes linked to non-syndromic heritable thoracic aortic 
diseases (nsHTAD) is growing, including those rarely associated with 
extra-aortic features such as MYLK, ACTA2, MYH11, and PRKG1.401,402 
For most cases, specific pregnancy management recommendations are 
limited. Pragmatically, prophylactic surgery in nsHTAD is recommended 
at a diameter >45 mm. In women with variants in PRKG1, certain ACTA2 
variants, or additional risk factors that carry a high dissection risk at small 
diameters, such as hypertension or family history of dissection at smaller 
diameters, surgery may be considered at lower diameters (>40 mm).386 
8.1.5. Aortic disease with no identifiable (likely) 
pathogenic variant 
It is unclear whether young women with known aortic disease in whom 
genetic screening fails to identify a P/LP variant truly have a lower dissection risk than those with a known variant. The term ‘sporadic aneurysm’ is discouraged, as an aneurysm may stem from a heritable disorder 
even without a family history. Recent data from a large cohort of type A 
aortic dissection patients <30 years of age showed a near dichotomy 
between HTAD and unknown hypertension as probable dissection 
causes.403 
8.2. Turner syndrome 
Approximately 50% of women with Turner syndrome (TS) have 
cardiovascular manifestations, including aortic dilatation, bicuspid aortic 
valve (BAV), aortic coarctation, elongated aortic arch, and partial abnormal pulmonary venous return.404,405 All women with TS present 
a generalized arteriopathy and TS itself is an independent risk factor 
for thoracic aortic dilatation. Aortic dissection risk (85% type A and 
15% type B) increases with increasing diameters and can be reduced 
by following treatment guidelines.406–409 Risk factors include hypertension, BAV, and coarctation. In women with TS and an aortic size index 
(ASI) ≥25 mm/m2, aortic height index ≥25 mm/m or a z-score >4, the 
increased dissection risk and the option of surgery before pregnancy 
should be discussed with the patient and the Pregnancy Heart Team, 
taking the other risk factors into account.410–412 Spontaneous pregnancy can occur in women with mosaic TS, but assisted fertility techniques are now more common. Timely cardiovascular evaluation 
before fertility treatment is very important. Higher rates of adverse 
events during pregnancy and post-partum have been reported 
including hypertensive disease, gestational diabetes, haemorrhage, and 
SGA babies.413,414 Caesarean section rates of up to 67% have been 
reported.414 
8.3. Bicuspid aortic valve disease 
Available data for patients with BAV indicate a low risk of aortic events 
if the aorta is <45 mm. Data on pregnancy in women with diameters of 
45–50 mm are limited.7,415 Recent data on patients with BAV demonstrate a higher risk of dissection in those with a ‘root phenotype’ compared to those with a primarily ascending aorta involvement.416,417 
When counselling these patients, it is important to note that BAV 
does not exclude the possibility of nsHTAD.


<!-- PAGE 41 -->

### Page 41

8.4. Aortic aneurysms other than root or 
ascending aorta 
Currently there are no recommendations for prophylactic surgery before conceiving except for the aortic root and ascending aorta. Recently 
published guidelines recommended surgery for the undissected aortic 
arch, descending and abdominal aorta at 50 mm in patients with 
Marfan syndrome,62 but no specific guidelines for management in pregnancy are available. 
8.5. Aortic dissection 
Data about pregnancy in women with a history of aortic dissection are 
scarce. ROPAC II and III included 11 and 9 women, respectively, with a 
previous dissection and reported no maternal mortality. However, two 
women in ROPAC III had a recurrent aortic event.7,382 Adverse events 
are likely low in women with a history of traumatic or iatrogenic dissection and probably also for those with a maximum aortic diameter of 
<40 mm and documented stable follow-up. Obviously there is a selection bias, as many women with complex aortic disease choose not to 
have children independent of the risk of progression of aortic disease. 
8.6. Management 
Women with aortic disease should be managed by a multidisciplinary 
team with experts from both the Pregnancy Heart Team and the aortic team who are experienced in diagnostic pathways, medical and surgical management of aortopathies in the ante-, peri-, and post-partum 
periods. Institutional protocols for the management of pregnancy- 
related aortic events should be available and a shared-decision model 
needs to be applied. Imaging of the entire aorta (CT or CMR) in women with known or suspected aortic disease is recommended and 
can reasonably be performed for most clinical scenarios within the 
6 months prior to pregnancy. CMR without gadolinium is recommended in pregnant women with known aortopathy, without pre- 
pregnancy imaging. In all women with aortic disease, strict blood 
pressure control is recommended. Specific target values for this specific situation have not been studied—in the general population 
it is recommended that treated systolic blood pressure values be targeted to 120–129 mmHg to reduce CVD, provided the treatment is 
well tolerated.388,418 In women with genetic aortopathies, treatment 
with beta-blockers throughout pregnancy should be considered 
with foetal growth monitoring. Women who used beta-blockers 





		





 ­


­












­

 ­

 ­





		

		


Figure 8 Thresholds for prophylactic surgical treatment prior to pregnancy of aortic root/ascending aneurysm (above the line) and recommended mode of 
delivery according to aortic diameter (below the line). BAV, bicuspid aortic valve; LDS, Loeys–Dietz syndrome; MFS, Marfan syndrome, nsHTAD, non- 
syndromic heritable thoracic aortic disease; P/LP, pathogenic/likely pathogenic; TAD, thoracic aortic disease; w/o, without. aRisk factors: family history of 
dissection, rapid aortic growth (≥3 mm/year), uncontrolled hypertension. bRoot phenotype to be added to the other risk factors. Based on Narula 
et al.,384 Wallace et al.,385 Regalado et al.,386 Jondeau et al.,387 Mazzolai et al.,388 and Isselbacher et al.62.   
ESC Guidelines                                                                                                                                                                                               41


<!-- PAGE 42 -->

### Page 42

throughout pregnancy in the ROPAC III study gave birth to infants 
with a significantly lower birth weight than women who did not.382 
Specific thresholds for pre-conception aortic root surgery are illustrated in Figure 8. 
The mode of delivery needs to be informed by the patient’s history, 
presence and type of gene/variant, and aortic diameter. The primary 
aim of intrapartum management in women with aortic disease is to reduce the cardiovascular stress of labour and delivery. Caesarean section 
may be considered in women with a maximum diameter of >45 mm 
and those with a history of dissection. In women with an aortic diameter <40 mm, vaginal delivery is recommended. In women with MFS, 
LDS, and vascular Ehlers–Danlos syndrome, pre-delivery anaesthesiology consultation is recommended to consider precautions for dural 
ectasia and scoliosis (including possible previous surgery).419 In general, 
an individualized approach is favoured.383 Given the peak risk of a dissection at day 6 post-partum, it may be appropriate for women to stay 
in hospital for 1 week post-partum.420 
8.7. Cardiac surgery during pregnancy 
Prophylactic cardiac surgery in women who are planning a pregnancy is far 
more common than urgent or emergency surgery during pregnancy. 
Aortic surgery is the most frequently performed procedure during pregnancy, followed by surgery for aortic and mitral valve disease. Key 
pregnancy-related pathologies include prosthetic valve thrombosis and 
endocarditis. The decision to perform surgery with extracorporeal circulation and cardioplegic arrest during pregnancy is highly individualized with no 
specific guidelines available. A recent meta-analysis421 reported a maternal 
mortality rate of 7.3% consistent across trimesters, and no difference in maternal mortality if caesarean section was performed. Overall foetal mortality was 26.5%, lowest during third trimester surgeries (10.3%). Caesarean 
section before surgery significantly reduces foetal mortality. The decision 
to perform a caesarean section prior to surgery should be based on foetal 
viability and the level of medical care available rather than on a fixed gestational age. This is particularly crucial in acute type A aortic dissection. 
Hypothermic distal circulatory arrest increases foetal mortality.422 
Recommendation Table 8 — Recommendations for aortopathies, cardiac surgery, and pregnancy 
Recommendations 
Classa 
Levelb  
Counselling 
It is recommended that women with aortic disease have counselling about the risk of aortic dissection in pregnancy and the post-partum 
period.404,423 
I 
C 
It is recommended that women with a history of aortic dissection or -surgery have pre-pregnancy counselling about the high risk by an 
extended Pregnancy Heart Teamc considering the presence and type of genetic variant, aortic morphology, growth rate, and aetiology of 
aortic dissection.7,381,424 
I 
C 
It is recommended that women with vascular Ehlers–Danlos syndrome wishing to become pregnant are counselled regarding the very high 
risk of pregnancy-related adverse events by a multidisciplinary team, considering family history, genetic variant, and previous vascular 
events.7,396,397,425 
I 
C 
Imaging 
Imaging of the entire aortad (CT or CMR) is recommended before pregnancy in women with known or suspected aortic disease.390,424,426 
I 
C 
In women with aortic dilatation related to BAV, imaging (with TTE, and CMR/CT if needed) of the aortic root, ascending aorta, and 
descending aorta (to rule out coarctation) is recommended before pregnancy.427,428 
I 
C 
In women with low-risk aortic disease (mWHO 2.0 classes II and II–III), one-time echocardiographic imaging between 20 and 30 weeks of 
gestation and imaging at 6 months post-partum is recommended.393,429 
I 
C 
In women with moderate to high-risk aortic disease (mWHO 2.0 classes III and IV), repeated echocardiographic imaging every 4–12 weeks 
(depending on diagnosis and severity of dilatation) is recommended during pregnancy and until 6 months post-partum.393,429,430 
I 
C 
CMR (without gadolinium) imaging of the entire aorta is recommended in pregnant women at risk of or with known aortic dilatation who 
have not had recent pre-pregnancy cross sectional imaging.135 
I 
C 
Treatment—medical 
When a woman with known aortic dilatation, history of dissection, or P/LP variant associated with aortic disease becomes pregnant, strict 
and individualized BP control is recommended.431,432 
I 
C 
Beta-blocker therapye throughout pregnancy and in the post-partum period is recommended in women with MFS and other HTADs.433 
I 
C 
Celiprolol is recommended in women with vascular Ehlers–Danlos syndrome during pregnancy and lactation.434 
I 
C 
Treatment—intervention/surgical 
It is recommended that indications for pre-pregnancy aortic root and/or ascending aortic surgery are guided by aortic morphology, 
underlying pathology, family history, genetic variant, previous vascular events, and patient’s preference.62,383 
I 
C 
It is recommended that centres managing pregnancies in women with moderate to high-risk aortic disease (mWHO 2.0 class III/IV) can 
provide cardiovascular surgery in case of peripartum adverse events.435,436 
I 
C 
Specific conditions 
In women with MFS and aortic root diameters >45 mm, surgery before pregnancy is recommended.380,424 
I 
C 
In women with LDS with P/LP variants in TGFBR1, TGFBR2, and aortic root diameters ≥45 mm, surgery before pregnancy is 
recommended.437–439 
I 
C                         
Continued


<!-- PAGE 43 -->

### Page 43

### 9 Pregnancy in women with known

congenital heart disease 
Congenital heart disease is present in 0.8%–0.9% of live births, with significant geographical variation.448,449 Nowadays, most children born with congenital heart disease reach fertile age, even those with complex lesions, 
making adult congenital heart disease (ACHD) one of the most frequent 
CVDs during pregnancy.450 Discussions about family planning, contraception, pregnancy risk (mWHO 2.0—see Table 6), and life expectancy are essential and should start early, preferably during the transition to adult life.2 
In the prospective ROPAC registry, most women with ACHD (n =  
3295) had a relatively favourable pregnancy outcome, with an overall 
mortality rate of 0.2% and trends improving from 2007 to 2017.2 
Heart failure rates were low in ROPAC, with differences according 
to disease complexity (13% in severe, 5%–6% in less-complex lesions). 
Arrhythmia rates were low overall (2%). Women with uncorrected 
ACHD more often have maternal and foetal complications.451 
Women with ACHD experiencing complications during pregnancy 
and post-partum may also be at higher risk of late cardiac events.451 
Pre-pregnancy evaluation should at least include routine blood tests, 
ECG, TTE, and cardiopulmonary exercise testing. As mentioned in 
Section 4, the increased transmission risk should be discussed, and genetic counselling should be offered.452 The level and timing of the pre- 
pregnancy cardiovascular evaluation and follow-up during pregnancy 
depend on the mWHO 2.0 class (see Table 6), taking the anatomical 
and functional status into account. 
Optimization of cardiac status and any comorbidities should take place 
prior to pregnancy. This includes guideline-directed elective surgery or/and 
In women with nsHTAD with P/LP variants in MYH11, ACTA2, PRKG1, or MYLK, and aortic root diameters ≥45 mm, surgery before 
pregnancy is recommended.385,386,440 
I 
C 
In women with BAV and aortic root or ascending aortic diameter ≥50 mm, surgery before pregnancy is recommended.441,442 
I 
C 
In women without an identifiable P/LP variant with aortic root or ascending aortic diameters ≥50 mm, surgery before pregnancy is 
recommended. 
I 
C 
In women with HTAD and aortic arch, descending aortic, or abdominal aortic diameters ≥50 mm, surgery before pregnancy should be 
considered.392,443 
IIa 
C 
In women with LDS with P/LP variants in TGFB2, TGFB3, SMAD2, and SMAD3, and aortic root diameters ≥45 mm, surgery before pregnancy 
should be considered.437–439 
IIa 
C 
In women with BAV and root phenotype or family history of aortic aneurysm or dissection, surgery before pregnancy should be considered 
if the aorta is ≥45 mm. 
IIa 
C 
In women without an identifiable P/LP variant with aortic root or ascending aortic aneurysm ≥45 mm, surgery before pregnancy should be 
considered in the presence of a family history of aortic aneurysm, aortic dissection, uncontrolled arterial hypertension, or on patient’s 
preference. 
IIa 
C 
In women with MFS and aortic root diameters between 40 and 45 mm, surgery before pregnancy may be considered if risk factors (growth 
>3 mm/year, family history of aortic dissection) are present.444 
IIb 
C 
In women with LDS with P/LP variants in TGFBR1 or TGFBR2 and aortic root diameters ≥40 mm, surgery before pregnancy may be 
considered.387,437,445,446 
IIb 
C 
In women with nsHTAD and aortic root diameters ≥40–44 mm, surgery before pregnancy may be considered depending on the genetic 
variant, family history, and aortic growth rate.385,386,440 
IIb 
C 
Delivery 
In women with an aorta <40 mm, vaginal delivery is recommended.163 
I 
C 
In women with vascular Ehlers–Danlos syndrome, caesarean section at 37 weeks is recommended for obstetrical reasons.400 
I 
C 
In women with an aorta 40–45 mm, vaginal delivery with epidural anaesthesia and an expedited second stage should be considered. 
IIa 
C 
In women with an aorta ≥45 mm, caesarean section should be considered. 
IIa 
C 
In women with acute, subacute, or chronic aortic dissection, caesarean section should be considered. 
IIa 
C 
In women with an aorta 40–45 mm, caesarean section may be considered. 
IIb 
C 
The use of ergometrine post-delivery is not recommended in women with aortopathy. 
III 
C 
Cardiac surgery during pregnancy 
Delivery before cardiac surgery should be considered as soon as the foetus is viable, taking gestational age, comorbidities, and the available 
level of neonatal care into account.163,421,435,447 
IIa 
C 
Cardiac surgery may be considered during pregnancy when conservative and medical therapy has failed, and in situations that threaten the 
mother’s life or that are not amenable to percutaneous treatment. 
IIb 
C 
© ESC 2025
BAV, bicuspid aortic valve; BP, blood pressure; CMR, cardiovascular magnetic resonance imaging; CT, computed tomography; HTAD, heritable thoracic aortic disease; LDS, Loeys–Dietz 
syndrome; MFS, Marfan syndrome; mWHO, modified World Health Organization; nsHTAD, non-syndromic heritable thoracic aortic disease; P/LP, pathogenic/likely pathogenic; TTE, 
transthoracic echocardiogram. 
aClass of recommendation. 
bLevel of evidence. 
cExtended Pregnancy Heart Team: regular team + multidisciplinary aortic team—see also Section 4.1. 
dIn women with vascular Ehlers–Danlos syndrome and LDS, imaging should encompass the entire aorta, including supra-aortic vessels as well as iliac and femoral arteries. 
eSee Section 5.2.9 for beta-blocker choice.   
ESC Guidelines                                                                                                                                                                                               43


<!-- PAGE 44 -->

### Page 44

intervention of significant haemodynamic lesions (native or residual),21 as 
well as optimizing medical therapy and healthy lifestyle choices. 
The timing and mode of delivery should be decided by the 
Pregnancy Heart Team, for all women with a condition of mWHO 
2.0 class II–III or above. In general, vaginal delivery is the preferred delivery mode in women with ACHD.163 Post-partum monitoring should 
be individualized based on the woman’s underlying ACHD, risk or 
presence of arrhythmias and/or HF, and the course during pregnancy 
and delivery. High-risk women or those with HF symptoms during 
pregnancy or delivery should be considered for intensive (cardiac) 
care admission for haemodynamic monitoring.183 For more details 
about managing the various delivery stages, including post-partum, 
see Sections 4.5 and 4.6.1. 
A summary of relevant disease-specific considerations, maternal and 
foetal complications, monitoring, and management during pregnancy 
are listed in Table 12. 
Table 12 Risks, monitoring, and management during pregnancy and delivery in women with congenital heart disease 
ACHD 
Maternal Risk 
Obstetric and foetal 
risk 
Monitoring 
Pregnancy management and 
delivery  
Left ventricular outflow tract obstruction (LVOTO) 
Coarctation of the 
aorta 
• ↑ Complication risk if residual 
obstruction (gradient 
>20 mmHg, aortic lumen 
<12 mm), clinical signs of HF, 
LVEF <40%, NYHA class>19 
• ↑ Risk of aortic dissection 
(if aneurysm present) 
• Uncontrolled hypertension9 
• ↑ Miscarriage rate453 
• Pre-term birth and low 
birth weight in 9%9 
• Close BP monitoring 
—also early 
post-partum 
• Pre-pregnancy CMR 
and treatment of 
residual lesions454 
• Treat hypertensiona 
• Consider bed rest, hospital 
admission and stenting in case of 
severe symptomatic 
(re)coarctation (including 
refractory hypertension or 
maternal/foetal compromise)455 
• Vaginal delivery preferred unless 
aneurysm, HF, severe hypertension 
Subvalvular, valvular and supravalvular aortic stenosis: see Section 12.5.1b and Section 8.3c for BAV related aortic disease. 
Women with serial left heart obstructive lesions have higher maternal cardiovascular event rates.456 
Shunt lesions 
ASD 
• Low risk in (un)repaired ASD 
(if no PAH)457 
Unrepaired ASD: 
• ↑ Risk of arrhythmia (4%)457 
• Paradoxical embolism 
(2%–5%)457,458 
• Rare457 
• Unrepaired ASD 457,458: 
• SGA (21%) 
• Foetal/perinatal 
mortality (2%–3%) 
• Pre-eclampsia (7%) 
Unrepaired and 
uncomplicated ASD: 
consider TTE at 
28–32 weeks457 
• Large and/or haemodynamically 
significant ASD: closure 
pre-pregnancy21 
• Unrepaired ASD: 
• Consider ASA or prophylactic 
LMWHd for paradoxical 
embolism prevention 
• Consider device closure in 
pregnancy only for recurrent 
stroke on medical therapy 
VSD and patent 
ductus arteriosus 
Low risk in small or repaired 
lesions with normal LV and no 
PAHe 
No evidence for ↑ risk 
Unrepaired and 
uncomplicated VSD: 
consider TTE at 
28–32 weeks 
Vaginal delivery is preferred 
AVSD 
• Low risk in repaired AVSD 
without significant residual 
lesions 
• Arrhythmia and ↑ AV valve 
regurgitation and HF if 
residual left AV valve 
regurgitation459,460 
• ↑ Paradoxical emboli risk in 
unoperated (partial) AVSD 
• Offspring mortality in 
6% primarily due to 
recurrence of the 
congenital heart 
disease459 
Unrepaired and 
uncomplicated AVSD: 
consider TTE at 
28–32 weeks 
↑ FU frequency in 
significant valve 
regurgitation, PAH, ↓ 
ventricular function, or ↑ 
NYHA class461 
• Residual shunt: see ASD and/or 
VSD 
• ↑ AV valve regurgitation and/or HFf 
• PAHe 
• Delivery: see ASD and VSD 
Pulmonary valve and RVOT disease 
RVOTO/PV stenosis 
• Mild to moderate: low risk 
• Severe: RV failure and 
arrhythmia21 
• Very low complication 
risk462,463 
• Mild to moderate: 
• TTE at 28–32 weeks 
• Severe stenosis: 
Pre-pregnancy severe RVOTO (Doppler 
peak gradient>64 mmHg) or/and any 
signs of right HF:                                                    
Continued


<!-- PAGE 45 -->

### Page 45

• (Bi)monthly TTE 
(focused on RV 
function) 
• Intervention (at any level of the 
RVOT)21 
Severe symptomatic PV stenosis (not 
responding to bed rest and conservative 
management): 
• Consider transcatheter balloon 
valvotomy21 
Consider caesarean section in severe 
RVOTO/PV stenosis463 
PV regurgitation 
• ↑ Risk when impaired RV 
function462 
• Premature birth463 
Bimonthly TTE if severe 
PV regurgitation and ↓ 
RV function  
Post pulmonary valve 
replacement (surgical 
or transcatheter 
without severe 
stenosis/regurgitation) 
• Low risk463–466 
• Very low complication 
risk462,463 
TTE at 28–32 weeks 
Vaginal delivery is preferred 
Repaired TOF  
• Low risk if no residual 
lesions467 
• ↑ Risk of arrhythmia and HF 
(7%–10%) if pulmonary 
regurgitation, ↓ RV function, 
severe RVOTO467,468 
• 15% risk of foetal and 
obstetric complications, 
mainly pre-term delivery 
and low birth weight467 
• Low foetal mortality 
(0.7%)467 
• Recurrence risk in the 
offspring in 22q11 
deletion syndrome: 50% 
• First trimester and at 
28–32 weeks FU with 
TTE (increase FU 
depending on 
functional status) 
• RV failure management: 
Bed rest and diuretics 
• Arrhythmia managementg 
• Severe PV stenosis/regurgitation: 
see above 
• Vaginal delivery is preferred 
Consider caesarean section in severe 
RVOTO/PV stenosis 
Ebstein anomaly  
• Overall MACE rate in 
ROPAC 9.9% 
• Low risk in mild/ moderate 
Ebstein 
• (Very) high risk when 
pre-pregnancy HF, cyanosis 
due to atrial shunt 
• ↑ Arrhythmia risk due to 
accessory pathways469 
• Foetal risk is related to ↓ 
maternal CO and 
cyanosis3,469: 
• Miscarriage 
• Pre-term birth 
(20%–24%) 
• Neonatal death (3%) 
• PPH 
• Recurrence risk (5%) 
• Mild to moderate: 
baseline and 28–32 
weeks assessment with 
TTE and ECG 
• Severe: monthly/ 
bimonthly TTE & ECG 
• Monitor for 
arrhythmias if 
palpitations 
• Severe tricuspid regurgitation with 
HF can usually be managed 
medically 
• Treat arrhythmias promptlyg 
• Appropriate pre-pregnancy 
counselling about very high risk of 
MACE when HF and/or cyanosis    
Transposition of the great arteries 
TGA after atrial 
switch (Mustard or 
Senning) and CCTGA 
• High pregnancy risk—MACE 
rate up to 28% in 
retrospective series470— 
lower risk in ROPAC6: Atrial 
and ventricular arrhythmias in 
6.7%, HF in 10% 
• Atrial arrhythmias often 
poorly tolerated 
• Baffle leaks may lead to 
desaturation and paradoxical 
embolism471 
• Predictors of MACE: 
symptoms of HF before 
pregnancy and systemic RV EF 
<40%6 
• Foetal risks associated 
with maternal CO and 
saturation 
• Pre-term birth (21%) 
• Low birth weight 
(18%–21%)6,472,473 
• Rare foetal and neonatal 
death (1%)474 
• PPH (7%)6 
• According to 
anatomical and 
functional status: TTE 
every 1–3 months and 
serial NP 
• Holter monitoring if 
palpitations 
• Pre-pregnancy counselling about 
very high risk if NYHA class III/IV, 
systemic RV EF <40%, more than 
moderate tricuspid regurgitation, 
or treated HF472,473,475 
• Treat HF primarily with medical 
therapyh 
• Promptly treat arrhythmiag 
• Consider prolonged post-partum 
monitoring (48–72 h) and early 
post-partum FU given the ↑ risk of 
post-partum HF 
No clear evidence for long-term 
deterioration or ↑ cardiovascular 
events associated with pregnancy6,476 
TGA with arterial 
switch 
• Low risk 
• Ventricular arrhythmias 
(2.5%–7%), HF (2%–4%)8 
• Low rate of prematurity 
or foetal loss474,477 
• Consider TTE at 20 
weeks 
• Intensify if ↓ ventricular 
function, ↑ aortic 
• Vaginal delivery is preferred 
• Surgery before pregnancy when 
the neo-aortic root is 
>55 mm21,478or if severe ARf                                    
Continued  
ESC Guidelines                                                                                                                                                                                               45


<!-- PAGE 46 -->

### Page 46

regurgitation and ↑ 
aortic dilatation 
Single ventricle physiology palliated with Fontan circulation  
High pregnancy risk 
CV events479: 
• Supraventricular arrhythmias 
(8%–11%) 
• HF (4%–14%) 
Risk factors:479 
• Oxygen saturations <85% 
• ↓ Ventricular function 
• Arrhythmias 
• Significant valvular disease 
• NYHA class III/IV 
• FALD 
↑ Very high foetal 
complication risk:479–483 
• Low live birth rate (56%) 
• Miscarriages (45%–54%) 
• SGA (20%–55%) 
• Premature birth (59%– 
72%) 
• Neonatal death (5%– 
18%) 
Obstetric risk: 
• Hypertension (14%) 
• PPH (13%) 
• According to 
anatomical and 
functional status: TTE 
every 1–3 months and 
serial NP484 
• FU in specialized 
ACHD centre 
• Pre-pregnancy counselling about 
very high risk especially if any risk 
factor (see maternal risk) 
• Pregnancy may be well tolerated 
and successful in a subset of 
women with single ventricle and 
Fontan circulation without 
complications479,480,485–487 
• ASA and/or LMWH (depending on 
the presence of complications) 
should be considered in shared 
decision484 
• Atrial tachyarrhythmias should be 
promptly treated with 
cardioversioni 
Labour/delivery with preload dependent 
circulation:461 
• Epidural with slow titration 
• Labour in left lateral decubitus 
position 
• Low thresholds for assisted second 
stage (↓ Valsalva duration) 
• i.v. air filter (if fenestration or 
significant venovenous collaterals) 
Unrepaired cyanotic ACHD (without pulmonary hypertension)  
HF, thrombosis, arrhythmia and 
endocarditis in ≥15%488 
Degree of maternal 
hypoxaemia is the most 
important predictor of 
foetal outcome: 
10% foetal loss if resting 
maternal blood saturation 
>90%, 
chance of a live birth 12% if 
maternal oxygen 
saturation<85%489 
FU in expert centre 
• Pre-pregnancy counselling about 
very high risk especially if maternal 
resting saturation <85%489 
• i.v. air filter 
© ESC 2025
ACHD, adult congenital heart disease; ASA, acetylsalicylic acid; ASD, atrial septal defect; AV, atrioventricular; AVSD, atrioventricular septal defect; BAV, bicuspid aortic valve; BP, blood 
pressure; CCTGA, congenitally corrected transposition of the great arteries; CMR, cardiovascular magnetic resonance; CO, cardiac output; CV, cardiovascular; ECG, electrocardiogram; 
EF, ejection fraction; FALD, Fontan-associated liver disease; FU, follow-up; HF, heart failure; i.v., intravenous; LMWH, low-molecular-weight heparin; LV, left ventricle; LVEF, left 
ventricular ejection fraction; LVOTO, left ventricular outflow tract obstruction; MACE: major adverse cardiovascular events; NP, natriuretic peptide; NYHA, New York Heart 
Association; PAH, pulmonary arterial hypertension; PPH, post-partum haemorrhage; PV, pulmonary valve; ROPAC, Registry of Pregnancy and Cardiac Disease; RV, right ventricle, 
RVOTO, right ventricle outflow tract obstruction; SGA, small for gestational age; TGA, transposition of the great arteries; TOF, tetralogy of Fallot; TTE, transthoracic echocardiogram; 
VSD, ventricle septal defect. 
↑ increase ↓ decrease. 
aRefer to Section 12.3 Hypertensive disorders. 
bRefer to Section 12.5.1 Stenotic native valve lesions. 
cRefer to Section 8.3 Bicuspid aortic valve disease. 
dRefer to Section 5 Drugs during pregnancy and lactation. 
eRefer to Section 10 Pregnancy in women with pulmonary arterial hypertension. 
fRefer to Section 12.5.2 Regurgitant native valve lesions. 
gRefer to Section 12.4 Arrhythmias. 
hRefer to Section 12.6 Heart failure. 
iRefer to Section 12.4.3 Cardioversion, ablation, and device implantation and implantable cardioverter defibrillator management.


<!-- PAGE 47 -->

### Page 47

### 10 Pregnancy in women with

pulmonary arterial hypertension 
Pulmonary hypertension (PH) is defined as a mean pulmonary 
arterial pressure >20 mmHg, derived from invasive right-heart catheterization, and is classified by aetiology and pathophysiology.490 
Pulmonary arterial hypertension (PAH) is pre-capillary PH characterized by a pulmonary vascular resistance >2 Wood units and pulmonary arterial wedge pressure ≤15 mmHg. Untreated, idiopathic PAH 
results in death within a median of 2.8 years, but with PAH therapies, 
median survival extends to over 7 years.491,492 There is a preponderance of females in the incidence of PAH, and this includes women of 
childbearing age. The first clinical manifestations may be seen in 
pregnancy.493 
Women with PAH should be managed by a Pregnancy Heart Team, 
and a PH expert experienced in diagnostic pathways, medical treatment, and anticoagulation management from the ante- to the peri- 
and post-partum period. 
10.1. Pre-existing pulmonary arterial 
hypertension 
In women with PAH, maternal and foetal outcomes vary according to the 
PAH subset. With improved treatment of PAH and a multidisciplinary 
approach during pregnancy and the peri-partum period, maternal mortality has declined but remains high, ranging from 11% to 25%.2,490,494,495 
10.1.1. Maternal and foetal risk 
Although there is no safe cut-off for elevated pulmonary artery pressure and risk, pregnancies with mild PAH and vasoreactive PAH 
seem to have better maternal and foetal outcomes than those with 
moderate to severe PAH.141,496–498 Women with severe PAH, non- 
vasoreactive idiopathic PAH, and Eisenmenger syndrome have the highest risk of maternal and foetal mortality.496,497,499–502 As the clinical 
course of PAH during pregnancy remains associated with unforeseeable risks and pregnancy may accelerate PAH progression, all women 
with PAH496 wishing to become pregnant should be counselled by a 
multidisciplinary team regarding the very high risk of pregnancy-related 
adverse events. 
Women with Eisenmenger syndrome are unlikely to tolerate pregnancy due to additional risks of RV failure and paradoxical emboli. 
Chronic cyanosis may worsen due to systemic vasodilatation during 
pregnancy, an increased right-to-left shunt, and decreased pulmonary 
blood flow. 
Foetal and neonatal mortality risk is high in women with PAH, mainly related to pre-term delivery, reduced maternal CO, and/or hypoxaemia.503 Miscarriage is common. If oxygen saturation is >90%, there 
is usually a better foetal outcome (10% foetal loss). If oxygen saturation is <85%, miscarriage, IUGR, prematurity, and foetal death are 
common (live birth rate of only 12%).504,505 
10.1.2. Counselling and contraception 
Women of childbearing potential with PAH should be counselled 
at the time of diagnosis about the very high risk and uncertainties associated with becoming pregnant. Clear advice against becoming 
pregnant, including referral for psychological support if needed, 
and clear contraceptive advice are required, taking into account the 
woman’s individual needs. Reduced efficacy of hormonal contraceptives should be carefully considered and discussed with women treated with ERAs, as well as the addition of barrier methods for 
contraception.490,493 
10.1.3. Management during pregnancy 
When pregnancy occurs, termination should be discussed. Rigorous 
planning with the optimization of targeted PAH therapies and close 
monitoring are key in managing women with PAH who wish to continue with the pregnancy after appropriate counselling on the high maternal and foetal risks. 
Bed rest may be required in symptomatic women, and it may be appropriate to avoid additional risk factors (such as air travel). Right-heart 
catheterization can be performed to assist management in women 
showing deterioration. 
Diuretics may be needed in women with HF, and iron deficiency 
should be treated.43 It is recommended to stop ERAs, riociguat, and 
selexipag because of potential or unknown teratogenicity.43,490 
PAH therapies that can be used during pregnancy include 
phosphodiesterase-5 inhibitors and prostacyclin analogues. Sildenafil 
is used in the vast majority of women and is combined with a prostacyclin analogue depending on the disease severity. The subset of women with true vasodilator responsiveness who are well controlled on 
CCB therapy should continue taking this during pregnancy.43,490,506 
Recommendation Table 9 — Recommendations for 
congenital heart disease and pregnancy (see Evidence 
Table 8) 
Recommendations 
Classa 
Levelb  
Vaginal delivery is recommended in most women 
with ACHD.161,163 
I 
B 
It is recommended that all women with Fontan 
circulation who wish to become pregnant receive 
counselling from the Pregnancy Heart Team 
regarding the high risk of pregnancy-related adverse 
events.479,480,484,486,487 
I 
C 
It is recommended that women with a systemic RV 
(Mustard/Senning or congenitally corrected TGA), in 
NYHA class III/IV, systemic ventricular dysfunction 
(EF <40%), or severe TR wishing to become 
pregnant are counselled by the Pregnancy Heart 
Team regarding the high risk of pregnancy-related 
adverse events.473–475 
I 
C 
In women with significant haemodynamic lesions, 
discussion about guideline-directed interventions is 
recommended prior to pregnancy. 
I 
C 
© ESC 2025
ACHD, adult congenital heart disease; EF, ejection fraction; NYHA, New York Heart 
Association; RV, right ventricle; TGA, transposition of the great arteries; TR, tricuspid 
regurgitation. 
aClass of recommendation. 
bLevel of evidence.   
ESC Guidelines                                                                                                                                                                                               47


<!-- PAGE 48 -->

### Page 48

In women with Eisenmenger syndrome, caution is warranted when 
administering drugs that may lead to sudden systemic vasodilation or 
a risk of paradoxical air embolism (i.v. line filters should be used for 
i.v. therapies). Thromboembolism is a major risk, and anticoagulation 
regimens (type and dosage) should be considered individually, balancing the risk of bleeding vs VTE at each stage of pregnancy. LMWH 
is most commonly used. Regular follow-up is advisable, initially every 
2–4 weeks and then weekly in the third trimester. Women need to be 
monitored for increasing hypoxaemia and symptoms of HF, including 
breathlessness, syncope, and congestion. Regular echocardiography 
and blood testing, including NP levels, can provide evidence of HF 
where appropriate. 
10.2. New diagnosis in pregnancy 
The usual diagnostic algorithm as per the 2022 ESC/ERS Guidelines 
for the diagnosis and treatment of pulmonary hypertension should 
be followed in a pregnant woman with suspected PAH. Right-heart 
catheterization should be considered if there is diagnostic uncertainty in identifying de novo PAH in pregnancy and to assist with important therapeutic decisions.490 If this is required, it should be 
performed in a specialized centre. An individualized approach is required for starting PAH therapies. Many centres start therapy with 
oral sildenafil. Close follow-up by an experienced Pregnancy Heart 
Team with a PH expert is needed and prompt escalation of PAH 
therapy, usually with i.v. epoprostenol, is indicated depending on 
the disease severity. 
10.3. Delivery in women with pulmonary 
arterial hypertension 
A detailed delivery plan, including the optimal mode and timing of delivery, should be provided on a timely basis by the Pregnancy Heart 
Team with a PH expert. Early delivery, with careful tracking of foetal 
growth, is often required in women with progressive, decompensated 
HF not responding to PAH therapies and to reduce the risk of an unplanned birth outside an expert centre.245 Therapeutic LMWH 
should be stopped 24 h prior to any mode of delivery to reduce 
the risk of maternal haemorrhage. Caesarean section providing for 
a more controlled delivery may be preferred over vaginal delivery.494,507 Regional anaesthesia is usually favoured over general 
anaesthesia. 
10.3.1. Peri- and post-partum monitoring 
Due to the rapid changes in haemodynamics, the post-partum period is 
particularly high risk, with the majority of maternal mortality occurring 
after delivery.245 During delivery and post-delivery, women should be 
monitored in the intensive care setting with ECG, pulse oximetry, 
CO monitoring, meticulous fluid balance with central venous pressure 
monitoring, and optimization of RV function all important determinants 
of a good outcome. Women remain at high risk for many months after 
delivery, and individualized counselling is required to discuss the need 
for ongoing therapies and the avoidance of future pregnancies. In women with severe PAH and those who had complications during pregnancy and/or delivery, optimization of PAH therapies should be 
prioritized over lactation. 
11. Venous thromboembolism in 
pregnancy and post-partum 
11.1. Epidemiology and maternal risk 
Venous thromboembolism includes PE and DVT. The pooled incidence of 
pregnancy-related VTE (including post-partum) is 1.2 per 1000 deliveries510, and it is a major cause of pregnancy-related morbidity and mortality.510 Pregnancy-related VTE has a fatality rate of 0.68% and a recurrence 
rate (during pregnancy and post-partum) of 4.27%, which is higher post- 
partum.510 A documented assessment of VTE risk factors is recommended before or in early pregnancy. The VTE risk is highest in the third 
trimester and in the first 6 weeks post-partum.510 Mortality in 
pregnancy-related VTE is associated with CVD, hypertension, twin gestation, pre-term birth, caesarean section, transfusion, and black ethnicity.511 
11.2. Risk factors for pregnancy-related 
venous thromboembolism 
Pregnancy is accompanied by physiological changes leading to an 
increased VTE risk. First, increased procoagulant activity as well as decreased physiological anticoagulant and fibrinolytic activity result in a hypercoagulable state.512,513 Second, the expanding uterus causes 
mechanical compression of the inferior vena cava and the pelvic veins, 
leading to impeded venous flow.512,513 In addition, non-pregnancy- 
related and pregnancy- or delivery-related conditions may modify the individual VTE risk (see Supplementary data online, Table S5). 
In pregnancy, as well as in the early post-partum period, an emerging 
suspicion of VTE requires immediate diagnostic clarification. 
Recommendation Table 10 — Recommendations for 
pulmonary arterial hypertension and pregnancy 
Recommendations 
Classa 
Levelb  
It is recommended that women of childbearing 
potential with PAH wishing to become pregnant are 
counselled by a multidisciplinary team regarding the 
very high risk of pregnancy-related adverse events, 
encouraging a shared decision-making process about 
whether to become pregnant.490 
I 
C 
It is recommended to provide clear contraceptive 
advice to women of childbearing potential with 
PAH.490 
I 
C 
For women with PAH requiring pregnancy 
termination, it is recommended to perform this in 
PH centres.490 
I 
C 
Right-heart catheterization should be considered 
during pregnancy if there is diagnostic uncertainty or 
to assist with important therapeutic decisions.490 
IIa 
C 
Endothelin receptor antagonists, riociguat, and 
selexipag are not recommended during 
pregnancy.490,508,509 
III 
C 
© ESC 2025
PAH, pulmonary arterial hypertension; PH, pulmonary hypertension. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 49 -->

### Page 49

11.3. Prevention of venous 
thromboembolism 
Thromboprophylaxis follows an individualized risk assessment weighing 
the VTE risk against the bleeding risk ante- and post-partum. 
11.3.1. Pregnant women with no prior indications for 
long-term anticoagulation 
If prevention and treatment of VTE are initiated in the antepartum period, continuation for up to 6 weeks post-partum should be considered. 
In women with low-risk thrombophilia without a history of VTE, routine antepartum thromboprophylaxis is not required.514 In women 
with a history of VTE or a high-risk thrombophilia, medical thromboprophylaxis is recommended (Table 13). In women with ovarian hyperstimulation syndrome after in vitro fertilization, thromboprophylaxis is 
recommended during the first trimester.515,516 
The drug class of choice for the prevention and treatment of 
pregnancy-related VTE is LMWH.517,518 Fondaparinux may be considered as an alternative. A randomized controlled trial comparing a 
weight-adjusted intermediate-dose LMWH with a fixed low-dose 
LMWH regimen found that weight adjustment did not reduce the 
risk of recurrent VTE in the combined ante- and post-partum periods.519 Post-hoc analyses suggested a higher efficacy of weight-adjusted 
intermediate-dose LMWH in the post-partum period only, but this 
needs to be confirmed by future studies. In morbidly obese women, 
weight-based prophylactic dosing (considering anti-factor Xa measurement) instead of fixed dosing might be more appropriate.198 
11.3.2. Pregnant women with prior indication for 
long-term anticoagulation 
In case of pre-existing oral anticoagulation therapy due to previous 
VTE, oral anticoagulation (DOAC or VKA) should be replaced by 
LMWH at recognition of pregnancy.517 
11.4. Management of acute venous 
thromboembolism 
11.4.1. Clinical presentation and diagnosis 
11.4.1.1. Deep vein thrombosis 
The expanding uterus potentially reduces the blood flow in the iliocaval 
veins. In addition, a constitutional narrowing of the left-sided common 
iliac vein between the spine and the crossing artery could contribute to 
an increased risk of left-sided iliofemoral thrombosis.520 The clinical 
LEFt criteria (L = Left, symptoms in the left leg; E = Edema, calf circumference difference ≥2 cm; Ft = First trimester of presentation) may be 
used to identify low risk of pregnancy-related DVT.521,522 In pregnant 
women with suspicion of acute DVT, immediate diagnostic clarification 
is indicated (Figure 9). 
Table 13 Reasons for antepartum/post-partum thromboprophylaxis 
Medical conditions 
Antepartum thromboprophylaxis 
Post-partum thromboprophylaxis  
History of unprovoked VTE 
History of hormone-associated VTE 
Homozygous factor V Leiden mutation 
Heterozygous factor V Leiden mutation 
Homozygous prothrombin gene mutation 
a 
Heterozygous prothrombin gene mutation 
Antithrombin deficiency 
a 
a 
Antiphospholipid syndrome 
b 
Protein C or S deficiency 
a 
Combined thrombophilia 
© ESC 2025
Adapted from Nichols et al.213 under the terms of the Creative Commons Attribution-NonCommercial-No Derivatives License (CC BY NC ND). 
VTE, venous thromboembolism. 
= yes; 
= no; 
= no clear evidence to administer or not—to be individualized.  
aWith family history of VTE (to be considered without family history of VTE). 
bWith history of VTE or pregnancy loss.   
ESC Guidelines                                                                                                                                                                                               49


<!-- PAGE 50 -->

### Page 50

11.4.1.2. Pulmonary embolism 
Clinical signs and symptoms of PE in pregnancy do not differ from those of 
PE in non-pregnant women. The diagnostic approach in haemodynamically 
stable pregnant women with suspicion of PE aims to reduce the need for 
computed tomography pulmonary angiography (CTPA) by implementing 
additional diagnostic strategies, such as clinical features, D-dimer, and venous ultrasound. Levels of D-dimer increase physiologically up to 39% per 
trimester.524 A multinational study demonstrated the efficiency of a diagnostic strategy involving clinical probability, D-dimer measurements 
(threshold <500 µg/L), and peripheral venous compression ultrasound 
to reduce the need for CTPA.525 Using both the YEARS criteria (1, clinical 
signs of acute DVT; 2, haemoptysis; 3, PE is the most likely diagnosis) and 
adapted D-dimer thresholds allows a further reduction in the need for 
CTPA (D-dimer threshold if YEARS criteria present <500 µg/L, if 
YEARS criteria absent <1000 µg/L).526 Another meta-analysis confirmed 
the value of including D-dimer in a diagnostic algorithm to rule out PE in 
pregnant women with suspicion of PE (Figure 10).527 
11.4.2. Treatment of venous thromboembolism 
in pregnancy 
In pregnant women with a suspicion of VTE, anticoagulation with therapeutic LMWH should be commenced immediately, even before imaging, 
until the diagnosis of VTE is either excluded or confirmed. In pregnant women with confirmed acute VTE, therapeutic anticoagulation with weight- 
adjusted LMWH based on early pregnancy weight is recommended by 
using either a twice-daily or a once-daily regimen, each one resulting in 
a therapeutic daily dose518 (see also Section 5.2.1). Currently, there is insufficient evidence to favour once- or twice-daily regimens.217,218,518 
Suspicion of pregnancy-related 
Deep vein thrombosis 
Administration of ﬁrst therapeutic dose of LMWH
if anticipated diagnostic delay
(Class IIa) 
Venous ultrasound compression ultrasound of infrainguinal veins and ultrasound of iliac veins
Serial venous ultrasound scans
(2 exams within 7 days)
or MR-venography
Positive
Positive
Negative
Negative
Inconclusive
Diagnosis of DVT
Therapeutic dose LMWH
(Class I)
AND
Consultation with
Pregnancy Heart Team including a vascular specialist and a haematologist
(Class I)
No DVT
Figure 9 Algorithm for the diagnosis and treatment of deep vein thrombosis during pregnancy. DVT, deep vein thrombosis; LMWH, low-molecular-weight 
heparin, MR, magnetic resonance. Adapted from Chan et al.523


<!-- PAGE 51 -->

### Page 51

Stable patient with clinical suspicion of pulmonary embolism
No PE
Venous ultrasound compression ultrasound of infrainguinal veins and ultrasound of iliac veins   
Diagnosis of PE
Search for alternative causes of instability 
Therapeutic dose anticoagulation
Evaluation of reperfusion strategy
A
B
Administration of ﬁrst therapeutic dose of LMWH
if anticipated diagnostic delay
(Class IIa) 
AND
D-Dimer
Diagnosis of DVT
Positive
Negative
Chest X-ray
CTPA
Inconclusive
Positive
Therapeutic dose
LMWH
(Class I) 
Consultation with Pregnancy Heart
Team including a vascular specialist and a haematologist
(Class I)
Consultation with
Pregnancy Heart Team including a vascular specialist and a haematologist
(Class I)
AND
Unstable patient with suspicion of pregnancy-related pulmonary embolism
Administration of ﬁrst therapeutic dose of
UFH or LMWH
(Class IIa)   
AND
AND
TTE
CTPA
Negative
RV dysfunction
No RV dysfunction
Diagnosis of PE
Positive
AND
Positive
Positive
Negative
No PE
if CTPA not available
Negative
Perfusion lung scan 
Negative or inconclusive
Figure 10 Algorithm for the diagnosis and treatment of pulmonary embolism in pregnancy in stable (A) and unstable women (B). CTPA, computed tomography pulmonary angiography; DVT, deep vein thrombosis; LMWH, low-molecular-weight heparin; PE, pulmonary embolism; RV, right ventricle; TTE, 
transthoracic echocardiogram; UFH, unfractionated heparin. Adapted from Barrios et al.528 with permission from Elsevier.   
ESC Guidelines                                                                                                                                                                                               51


<!-- PAGE 52 -->

### Page 52

Despite fluctuations of anti-factor Xa levels during pregnancy, routine 
anti-factor Xa monitoring does not affect clinical outcomes and should 
only be considered in women with renal insufficiency or obesity.211–213 
Fondaparinux may be considered as an alternative. In unstable pregnant 
women with PE, UFH may be used in the initial phase of therapeutic 
anticoagulation. 
After delivery, therapeutic-dose anticoagulation should be administered 
for a minimum of 6 weeks, up to an overall duration of 3 months, except 
for cases in which an indefinite duration of anticoagulation is indicated.510,529 LMWH or VKAs may be given during lactation. A more detailed discussion of anticoagulants in the lactation period can be found in 
Section 5. Thrombolytic or interventional treatment of PE is not recommended in the peripartum period and should only be considered in women 
with high-risk PE after consultation with a specialized multidisciplinary 
team. In pregnant women with acute iliofemoral DVT, interventional 
thrombus removal should not routinely be performed. Data on the effectiveness and risks of the placement of temporary inferior vena cava filters 
for the prevention of PE in pregnant women are limited but appear to 
be comparable to non-pregnant women. Due to limited data and potential 
complications associated with the inferior vena cava filters, their placement 
should be limited to recurrent VTE despite appropriate anticoagulation or 
contraindication to therapeutic-dose anticoagulation therapy.530,531 
11.5. Management of delivery and the 
post-partum period 
For pregnant women receiving a prophylactic dose of anticoagulation, 
there is no specific need for a planned delivery. However, pregnant women receiving a therapeutic dose of anticoagulation need a planned delivery with prior discontinuation of LMWH to prevent spontaneous 
delivery in a period of full anticoagulation. Details for the management 
of anticoagulation during pregnancy and delivery, including for VTE, are 
provided in Sections 4.5.6. and 5.2.1. 
12. Pregnancy in women with 
acquired heart disease 
12.1. Acute chest pain in pregnancy 
Diagnostic evaluation for chest pain in pregnant women 
follows the same protocol as in non-pregnant women, including 
clinical examination, ECG, biomarkers and echocardiography 
(Figure 11).207,537,538 Importantly, spontaneous coronary artery 
dissection (SCAD) is a more prevalent cause of chest pain during 
pregnancy and in the early post-partum period than in non- 
pregnant women.539 
Treatment and management of the specific differential diagnoses 
should follow established respective guidelines. The specificity of 
D-dimer is reduced during pregnancy540,541 and women should not 
undergo chest CT based solely on D-dimer levels (Section 11). In suspected acute aortic syndromes, there should be a low threshold for 
aortic CT and consultation with the aortic team in emergencies 
(Section 8).542 
12.2. Coronary artery disease 
12.2.1. Acute coronary syndrome 
12.2.1.1. Coronary artery disease epidemiology and aetiology 
Acute coronary syndromes (ACS) are a major cause of maternal 
death in developed countries, accounting for 20% of cardiovascular 
deaths.543 The risk of ACS is three to four times higher in pregnant 
women than in non-pregnant women of reproductive age,544 and 
mortality is estimated at 5%.545 Because the age at giving birth is 
increasing overall, ACS in pregnancy may become more common.546 Although ACS can occur at any stage of pregnancy, it is 
more common in the third trimester or post-partum.544 Classic 
ASCVD risk factors are associated with ACS during pregnancy. 
Recommendation Table 11 — Recommendations for venous thromboembolic diseases and pregnancy (see Evidence 
Tables 9 and 10) 
Recommendations 
Classa 
Levelb  
For pregnant or post-partum women at high riskc of VTE, a prophylactic fixed dose of LMWH is recommended over a higher 
weight-adjusted dose to reduce the risk of VTE.519 
I 
B 
In pregnant women or women in the post-partum period with suspicion of VTE (DVT and/or PE), an immediate formal diagnostic 
assessment with validated methods is recommended and should not be postponed.525,526 
I 
B 
In pregnant women or women in the post-partum period with newly diagnosed VTE (DVT and/or PE), the involvement of the Pregnancy 
Heart Team, including a vascular specialist and a haematologist, is recommended. 
I 
C 
In pregnant or post-partum women with a diagnosis of VTE without haemodynamic instability, anticoagulation is recommended by using 
therapeutic-dose LMWH based on early pregnancy body weight.212,532 
I 
C 
In pregnant women or women in the post-partum period with a strong clinical suspicion of VTE, initiation of treatment with a therapeutic 
dose of LMWH should be considered until the presence of VTE has been ruled out or confirmed. 
IIa 
C 
In pregnant or post-partum women with a diagnosis of acute high-risk PE,d a catheter-based reperfusion strategy or systemic thrombolysis 
should be considered.533–535 
IIa 
C 
In pregnant or post-partum women with a diagnosis of acute high-risk PE,d surgical thrombectomy may be considered as an alternative to a 
catheter-based approach or systemic thrombolysis.533–535 
IIb 
C 
© ESC 2025
DVT, deep vein thrombosis; LMWH, low-molecular-weight heparin; PE, pulmonary embolism; VTE, venous thromboembolism. 
aClass of recommendation. 
bLevel of evidence. 
cSee Supplementary data online, Table S5 for VTE risk factors. 
dAccording to the Pulmonary Embolism Severity Index from the 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism.536


<!-- PAGE 53 -->

### Page 53

Management of chest pain during pregnancy and up to 6 months post-partum
• Check for vital signs
• Perform: ECG, hs-cTn, TTE
• Assess: week of gestation, cardiovascular risk factors, previous CAD, DVT, family history of DVT/PE, 
 family history of aortic disease  
a
Suspicion of 
Other cause of chest pain 
Acute coronary syndrome 
Pulmonary embolism 
Acute aortic syndrome 
CT
Consult aortic team 
Go to algorithm 
on PE 
Check diﬀerential diagnoses e.g.:  
• Myocarditis and pericarditis
• Gastroesophageal reﬂux
• Amniotic ﬂuid embolism
• Musculoskeletal pain
Non-high risk
High-risk
Very high-risk
Inpatient invasive strategy
Immediate invasive strategy 
Selective invasive strategy
Diagnosis of
ASCVD
SCAD
MINOCA
Takotsubo
Additional examinations
Haemodynamically stable
Haemodynamically unstable or ongoing ischaemia
Conservative management 
PCIb or CABG or conservative management
PCIb or urgent
CABG
Figure 11 Management of chest pain during pregnancy and within 6 months post-partum. ASCVD, atherosclerotic cardiovascular disease; B-blocker, beta- 
blocker; CABG, coronary artery bypass graft; CAD, coronary artery disease; CT, computed tomography; DVT, deep venous thrombosis; ECG, electrocardiogram; EF, ejection fraction; hs-cTn, high sensitivity cardiac troponin; i.v., intravenous; MINOCA, myocardial infarction with non-obstructive coronary arteries; o.d., once a day; PCI, percutaneous coronary intervention; PE; pulmonary embolism; SCAD, spontaneous coronary artery dissection; TTE, 
transthoracic echocardiogram. aIn patients without very high or high-risk features and a low index of suspicion for unstable angina. bDual anti-platelet therapy: 
clopidogrel: loading dose of 300–600 mg orally, followed by an oral maintenance dose of 75 mg o.d. Aspirin: loading dose of 150–300 mg orally or 75–250 mg 
i.v. if oral ingestion is not possible, followed by an oral maintenance dose of 75–100 mg o.d.   
ESC Guidelines                                                                                                                                                                                               53


<!-- PAGE 54 -->

### Page 54

Additional risk factors are pre-eclampsia, thrombophilia, transfusion, post-partum infection, multiparity, and PPH. Pregnancies 
that required fertility treatment have not been shown to have an 
increased risk of ACS.547 
Pregnancy-associated SCAD is the single most frequent cause of ACS 
during pregnancy and post-partum (43%),548 followed by atherosclerotic 
lesion (27%), coronary embolism (17%), and vasospasm (2%).239 
Coronary thromboembolism may be due to pregnancy-related hypercoagulability and paradoxical embolization.549 Vasospasm has been associated with the use of ergot derivatives prescribed for lactation 
suppression or to treat PPH.549 
12.2.1.2. Presentation and diagnosis 
Clinical presentation of ACS in pregnancy is the same as in the non- 
pregnant population. However, pregnant women with SCAD tend 
to have a more severe clinical presentation than women with 
non-SCAD ACS.550–553 
An ACS in pregnancy should be suspected in women presenting with 
cardiac arrest, acute onset chest pain, dyspnoea, ischaemic changes on 
ECG, or elevated cardiac biomarkers.551,554 Diagnostic evaluation 
should follow ACS strategies (Figure 11).555–557 Major ischaemic ECG 
changes due to pregnancy itself are not expected (Figure 1). 
Invasive coronary angiography during pregnancy should be reserved 
for those with ACS, or when other diagnostic methods are inappropriate. ECG changes, such as transient ST-segment depression and T-wave 
inversion can be normal during pregnancy, but a serum troponin rise 
suggests myocardial injury as in non-pregnant women. ST elevation is 
not normal in pregnancy and warrants urgent attention.558 
ST-elevation myocardial infarction (STEMI) in pregnant women involves the anterior wall in 70%–80% of cases.239,558 In more than half 
the cases, a reduction of LVEF <40% is observed, leading to a high incidence of complications.20 Myocardial infarction with non-obstructive 
coronary arteries (MINOCA) should be considered a working diagnosis 
warranting further investigation.559 
12.2.1.3. Pregnancy-associated spontaneous coronary artery 
dissection 
Pregnancy-associated SCAD affects 1.81 per 100 000 pregnancies560 
and may occur at any time during or after pregnancy, although >70% 
occur early post-partum, most commonly within the first week.550 
Multiple predisposing factors have been described, including oestrogen 
and progesterone surges causing structural changes to the coronary tunica media. SCAD predominantly occurs in the left-sided coronaries, 
with multivessel involvement.561 
Percutaneous coronary intervention (PCI) in SCAD is associated 
with an increased risk of complications, particularly iatrogenic dissection and haematoma extension.562 For this reason, a conservative approach to revascularization is advised in clinically stable women with 
SCAD without active or ongoing ischaemia.539,563 If SCAD involves 
the left main coronary artery or proximal vessels, a coronary artery bypass graft (CABG) may be considered depending on technical considerations and local expertise.539 A multidisciplinary team should 
decide whether the patient is a candidate for PCI or CABG. 
Optimal medical management following SCAD is unknown but is 
currently being investigated in an ongoing clinical trial.562 Limited observational data suggest that beta-blockers (e.g. labetalol) and avoiding 
hypertension may be associated with a lower risk of recurrent 
SCAD.564,565 The role of antiplatelet therapies in conservatively managed SCAD has been controversial, with evidence favouring single 
antiplatelet therapy with aspirin.563,566 Women with a history of 
SCAD should be carefully counselled regarding the risk of recurrent 
events in subsequent pregnancy.567,568 
12.2.2. Coronary artery interventions 
The indications for acute revascularization are comparable to those 
for non-pregnant women. In patients with high or very high-risk ACS, 
immediate coronary angiography and PCI, if indicated, are recommended.557 Moreover, an early invasive strategy with coronary angiography is recommended for pregnant women with a confirmed or a 
working diagnosis of non-ST-elevation ACS (NSTE ACS) and with a 
high index of suspicion for unstable angina. In atherosclerotic lesions557 
PCI is indicated when there is ongoing or recurrent chest pain, haemodynamic instability, or ongoing ischaemia due to functionally significant 
coronary stenoses or acute occlusions.122 
The choice of coronary stents should not be different from that for 
non-pregnant women. Duration of DAPT should follow recommendations for non-pregnant patients with an individual approach considering ischaemic and delivery-related risks, including bleeding risk during delivery 
and neuraxial anaesthesia. Stents approved for short DAPT may be preferred during pregnancy in specific cases according to gestational age and 
timing of delivery. In the case of coronary embolism, thrombo-aspiration 
and/or a simple angioplasty can be performed.43,569 Invasive procedures 
should follow the ALARA principle (see Section 4.3.5). 
Systemic thrombolysis may be an alternative reperfusion strategy if 
timely PCI is not available. Recombinant tissue plasminogen activator 
does not cross the placenta but can induce bleeding complications, including subplacental. 
12.2.3. Chronic coronary syndromes in pregnancy 
Pregnant women with chronic coronary syndromes (CCS) are at high 
risk of adverse maternal and foetal outcomes: 32% have cardiovascular 
complications (including 9% with ischaemic cardiovascular complications) and there is 2% maternal mortality.570 The CARPREG II score, 
now also included in the mWHO 2.0 classification (Table 6, Section  
4), highlights the high risk of CCS as a predictor of maternal complications. When counselling women with CCS, pregnancy can preferably be 
considered when there is no residual ischaemia or LV dysfunction 12 
months after an index event. 
12.2.4. Management and delivery 
Women with ACS or CCS should be managed by a Pregnancy Heart 
Team. Treatment should be tailored to the underlying pathophysiology, 
although foetal considerations may affect the choice of therapy.50,571 
All pregnant women with ACS and their foetus should be monitored 
at an intensive cardiac care unit. 
The mode of delivery in a patient with gestational ACS or CCS 
should be determined by obstetric considerations and the clinical status 
of the mother. A vaginal delivery is indicated in most women with obstructive coronary artery disease (CAD). Vaginal delivery eliminates the 
potential risks associated with general anaesthesia and a major surgical 
procedure. Clopidogrel must be withheld a minimum of 5 days before 
neuraxial anaesthesia to reduce the risk of epidural hematoma.572 An 
elective caesarean section avoids a long or stressful labour and allows 
better control of the time of delivery. A plan for emergency delivery 
of a potentially viable foetus in case of sudden maternal deterioration 
should also be established. An arbitrary minimum time to delivery in 
stable women is at 2 weeks after ACS.18 
Lipid-lowering and antiplatelet therapy are described in Section 5.


<!-- PAGE 55 -->

### Page 55

12.3. Hypertensive disorders 
Hypertensive disorders of pregnancy are the second most common medical complications (after PPH), affecting 5%–15% of pregnancies worldwide, and are a major cause of maternal, foetal, and neonatal morbidity 
and mortality.583 Hypertensive disorders in pregnancy include pre-existing 
hypertension (chronic hypertension), gestational hypertension, and pre- 
eclampsia (Table 14). Over recent years an upward incidence trend has 
been observed due to older age at first childbirth and rising prevalence 
of obesity.586,587 Maternal risks include placental abruption, stroke, 
multiple organ failure, and disseminated intravascular coagulation.588 
Table 14 Hypertensive disorders of pregnancy 
A. Pre-existing (chronic) hypertension  
Hypertension which either precedes pregnancy or develops before 20 weeks gestation, usually persisting >6 weeks post-partum, and which may be associated with 
proteinuria.  
(1) 
Primary hypertension  
(2) 
Secondary hypertension  
(3) 
White-coat hypertension  
(4) 
Masked hypertension  
B. Gestational hypertension 
Hypertension which develops after 20 weeks gestation and usually resolves within 6 weeks post-partum. 
Transient gestational hypertension 
Usually detected in the clinic but then settles with repeated BP measurements taken over several hours; associated with a 40% risk of developing true gestational 
hypertension or pre-eclampsia in the remainder of the pregnancy, thus requiring careful follow-up. 
C. Pre-eclampsia 
Gestational hypertension accompanied by one or more of the following new-onset conditions at or after 20 weeks gestation: 
• Proteinuria [urinary albumin excretion in a 24 h urine sample >0.3 g/day or UACR in a random spot urine sample >30 mg/mmol (0.3 mg/mg)] 
• Other maternal organ dysfunction including: 
• Acute kidney injury (serum creatinine ≥90 μmol/L; 1 mg/dL) 
• Liver dysfunction (elevated ALT or AST >40 IU/L; >0.67 μkat/L with or without right upper quadrant or epigastric abdominal pain) 
• Neurological complications (e.g. eclampsia/convulsions, altered mental status, blindness, stroke, clonus, severe headaches, persistent visual scotomata) 
• Haematological complications (platelet count <150 000/μL, disseminated intravascular coagulation, haemolysis) 
• Uteroplacental dysfunction (IUGR, abnormal umbilical artery Doppler waveform analysis, or stillbirth).  
D. Pre-existing hypertension + superimposed pre-eclampsia 
Pre-existing hypertension associated with any of the above maternal organ dysfunctions consistent with pre-eclampsia or a further increase in BP with new-onset 
proteinuria. 
E. Antenatally unclassifiable hypertension 
When BP is first recorded after 20 weeks gestation and hypertension is diagnosed, reassessment is necessary at or after 6 weeks post-partum. If hypertension 
resolves, it should be reclassified as gestational hypertension, whereas if hypertension persists, it should be reclassified as pre-existing/chronic hypertension. 
© ESC 2025
Based on Mancia et al.584 and McEvoy et al.585 
ALT, alanine transaminase; AST, aspartate aminotransferase; BP, blood pressure; IUGR, intrauterine growth restriction; UACR, urine albumin–creatinine ratio.  
Recommendation Table 12 — Recommendations for coronary artery disease and pregnancy (see Evidence Table 11) 
Recommendations 
Classa 
Levelb  
In pregnant women with chest pain, it is recommended to exclude life-threatening cardiovascular conditions, including PE, ACS (including 
SCAD), and acute aortic syndrome.538,539 
I 
C 
It is recommended to manage pregnant women with ACS in the same way as non-pregnant women, including diagnostic investigations and 
interventions.557 
I 
C 
Low-dose ASA is recommended as the antiplatelet treatment of choice during pregnancy and lactation when single antiplatelet treatment is 
indicated.573–579 
I 
B 
If DAPT is required, clopidogrel is recommended as the P2Y12 inhibitor of choice during pregnancy.239 
I 
C 
The duration of DAPT (aspirin and clopidogrel) in pregnant women undergoing coronary stent implantation is recommended to be the 
same as in non-pregnant women, with an individual approach considering ischaemic risk and delivery-related bleeding risks.239 
I 
C 
A vaginal delivery should be considered in most pregnant women with ACS, depending on LV function and clinical symptoms. 
IIa 
C 
Continuation of statins may be considered during pregnancy in women with established ASCVD.580–582 
IIb 
C 
© ESC 2025
ACS, acute coronary syndrome; ASA, acetylsalicylic acid; ASCVD, atherosclerotic cardiovascular disease; DAPT, dual antiplatelet therapy; LV, left ventricular; PE, pulmonary embolism; SCAD, 
spontaneous coronary artery dissection. 
aClass of recommendation. 
bLevel of evidence.   
ESC Guidelines                                                                                                                                                                                               55


<!-- PAGE 56 -->

### Page 56

The foetus is at high risk of IUGR prematurity, and intrauterine death 
(25%, 27%, and 4%, respectively, in cases of pre-eclampsia).589 
12.3.1. Definition and classification of hypertension in 
pregnancy 
Hypertension in pregnancy is typically defined as systolic blood pressure (BP) of ≥140 mmHg and/or diastolic BP of ≥90 mmHg,585 
measured using repeated BP readings in the office or hospital on 
two separate occasions or ≥15 min apart in severe hypertension 
(≥160/110 mmHg).584,590 
12.3.1.1. Pre-eclampsia/eclampsia 
Pre-eclampsia is defined as gestational hypertension complicated by 
new onset of the laboratory or clinical changes reported in Table 14 
at or after 20 weeks. Eclampsia is defined as the new onset of seizures 
or coma in a pregnant woman with pre-eclampsia.584,585 
The combination of haemolysis, thrombocytopenia, and elevated 
transaminases defines HELLP syndrome, which is usually considered 
to be a variant of pre-eclampsia.43 Risk factors for pre-eclampsia are described in Table 15. 
12.3.2. Diagnosis and risk assessment 
12.3.2.1. Blood pressure measurement 
Maternal BP should be assessed at each encounter and should be measured 
in the sitting position (or the left lateral recumbent position during labour) 
with an appropriately sized arm cuff at heart level and using Korotkoff V for 
diastolic BP. Mercury sphygmomanometers remain the gold standard for BP 
measurement in pregnancy as automatic devices tend to under-record BP 
and are unreliable in severe pre-eclampsia. Only automatic devices specifically validated for pregnancy should be used.584,591 
The diagnosis of hypertension in pregnancy by ambulatory BP monitoring is superior to office BP measurements or home BP monitoring 
for the prediction of pregnancy outcomes.584,592 Ambulatory BP monitoring avoids unnecessary treatment of white-coat hypertension, and is 
useful in the management of high-risk pregnant women with hypertension and those with diabetic or hypertensive nephropathy.593,594 Either 
home BP monitoring or office BP measurements may be used alternatively or complementarily to diagnose hypertensive disorders during 
pregnancy in women at risk of pre-eclampsia. 
However, among pregnant women with pre-existing or gestational 
hypertension, home BP monitoring is not associated with better BP 
control compared with scheduled office BP measurements.584,595,596 
Either can be used for BP monitoring.595,596 
12.3.2.2. Laboratory tests 
Basic laboratory investigations recommended for monitoring hypertensive disorders of pregnancy include urinalysis, blood count, haematocrit, liver enzymes, serum creatinine, and serum uric acid. All 
pregnant women should be assessed for proteinuria in early pregnancy 
to detect pre-existing renal disease and, in the second half of pregnancy, 
to screen for pre-eclampsia.43 
In addition to basic laboratory tests, the following investigations may 
be considered: 
• Ultrasound of the adrenals, and plasma and urinary fractionated metanephrine assays. 
• Doppler ultrasound of uterine arteries (after 20 weeks of gestation).597 
• A ratio of soluble fms-like tyrosine kinase-1 (sFlt-1) to placental 
growth factor (PlGF) of <38 can be used to reliably exclude the development of pre-eclampsia over the next 7 days when clinically 
suspected.43,598  
If women with chronic hypertension are suspected of developing 
pre-eclampsia, testing for PlGF may help rule out pre-eclampsia between 20 and 36 weeks.599,600 
12.3.3. Management of hypertension in pregnancy 
Management of hypertension in pregnancy depends on the woman’s 
BP and gestational age, and the presence of associated maternal and foetal risk factors.601,602 In pregnant women with BP >160/110 mmHg, hospital admission is recommended603 (Figure 12A). If BP is ≥140–159/90– 
99 mmHg, BP control is mandatory with a BP target of <140/90 mmHg. 
In two large trials,583,604 tight diastolic BP control (<85–90 mmHg) in 
women with pre-existing hypertension was superior to less tight diastolic BP control (<100–105 mmHg) and caused no harm. 
In pregnant women with diagnosed hypertension, blood tests, clinical 
examination, and assessment of proteinuria are mandatory and should 
be repeated regularly.599 If a urine dipstick is positive or borderline for 
proteinuria, and symptoms and laboratory tests (including biomarker 
assessment) are indicative of pre-eclampsia, the diagnosis of pre- 
eclampsia can be made and hospital admission is recommended where 
there are clinical concerns.599 
12.3.3.1. Non-pharmacological management 
Pregnant women with hypertension should be advised to follow a 
healthy lifestyle including physical activity, smoking cessation, a healthy 
diet, and control of body weight. Lifestyle changes before and during 
pregnancy may ameliorate both maternal and foetal risks.605 Salt restriction is not advised to reduce hypertensive disorders during pregnancy, but it is reasonable for women with pre-existing hypertension 
to continue with a low sodium diet.584 Unless contraindicated, aerobic 
exercise should be recommended in pregnant women with hypertension to maintain ideal body weight and reduce adverse pregnancy 
Table 15 Risk factors for pre-eclampsia 
High risk factors for pre-eclampsia  
Hypertensive disorders during a previous pregnancy 
Chronic hypertension 
Chronic kidney disease 
Type 1 or type 2 diabetes mellitus 
Autoimmune diseases such as systemic lupus erythematosus or 
antiphospholipid syndrome 
Assisted reproductive therapy in the current pregnancy 
Moderate risk factors for pre-eclampsia 
Nulliparity 
Age ≥40 years 
Pregnancy interval of more than 10 years 
BMI ≥35 kg/m2 at the first visit 
Family history of pre-eclampsia 
Multi-foetal pregnancy 
© ESC 2025
Based on Mancia et al.584 and McEvoy et al.585 
BMI, body mass index.


<!-- PAGE 57 -->

### Page 57

outcomes.606 Obese women are advised to avoid an increase in weight 
of more than ∼7 kg from pre-conception.601 
Calcium supplements are recommended for the prevention of pre- 
eclampsia in women with a low dietary intake of calcium (<600 mg/ 
day),607 where low-dose calcium supplementation (<1 g/day) has 
been shown to be as effective as high-dose (≥1 g/day).608 
12.3.3.2. Pharmacological treatment 
12.3.3.2.1. Mild hypertension (BP 140/90 – 159/109 mmHg). In 
mild gestational hypertension it seems reasonable to initiate treatment 
at BP values of 140/90 mmHg,583,609 whereas a diastolic BP reduction 
to <80 mmHg is not recommended. 
Methyldopa, beta-blockers (most data are available for labetalol), 
and dihydropyridine CCBs (most data are available for nifedipine) 
are the drugs of choice for mild gestational and pre-existing 
hypertension.584 
ACE-Is, ARBs, and direct renin inhibitors are strictly contraindicated. 
Diuretics are not advised in gestational hypertension and pre-eclampsia, 
due to the reduction of intravascular volume and reduction of uteroplacental perfusion and thereby possible foetal adverse effects. 
12.3.3.2.2. Pre-eclampsia. Pre-eclampsia may require hospital admission, but not all women will require ongoing hospitalization and care 
should be individualized (Figure 12B and Figure 12C). Women with 
at least one high-risk factor or two moderate-risk factors for pre- 
eclampsia (Table 15) should be advised to take 75–150 mg aspirin daily 
at bedtime from week 12 to week 36/37.599,610 We advise discontinuation of low-dose aspirin at week 36/37 when the aspirin indication is 
pre-eclampsia. 
Pre-eclampsia with severe features (severe hypertension with or 
without proteinuria, any hypertension grade with neurological, haematological, or cardiovascular complications, liver dysfunction, or renal 
dysfunction) should be managed with a magnesium sulfate infusion 
to prevent eclampsia, in addition to early delivery.43,611 Magnesium 
toxicity can present with cardiac effects, including ECG interval 
changes (prolonged PR, QRS, and QT intervals) at magnesium levels 
of 2.5–5 mmol/L, and can progress to atrioventricular (AV) nodal conduction block, bradycardia, hypotension, and cardiac arrest at levels of 
6–10 mmol/L. If magnesium toxicity is suspected, it is recommended 
to stop the magnesium infusion and give 30 mL i.v. calcium gluconate.612–614 
Management of pregnant women with hypertension
BP 140/90 to 159/109 mmHg
BP ≥160/≥110 mmHg
Admission to hospital
(Class I)
Do not admit routinely
Proteinuria or maternal organ dysfunction or 
uteroplacental dysfunctiona
Pre-eclampsia
Aim for BP <140/90 mmHg 
(Class I)
Evaluate level of care
Regular monitoringb
Figure 12A Management of hypertension and pre-eclampsia in the emergency ward. BP, blood pressure; N, no; Y, yes.  
a See Figure 12B.  
b See Figure 12C.   
ESC Guidelines                                                                                                                                                                                               57


<!-- PAGE 58 -->

### Page 58

Hypertension (BP ≥140/90 mmHg) 
Pre-eclampsia diagnosed
Proteinuria
Evaluate
Albumin/creatinine ratio ≥8 mg/mmol 
Protein/creatinine ratio ≥30 mg/mmol 
OR
One or more clinical features of pre-eclampsia
OR
Symptoms
• Headache
• Vision problems
• Breathing problems
• Severe pain below 
 the ribs
• Vomiting
• Oedema
• Trouble urinating
 
Laboratory
Biomarker sFlt-1/PIGF ≥85
or PIGF <12 pg/mL
Positive
Positive
Inconclusive
Uteroplacental dysfunction (foetal growth restriction,
abnormal umbilical artery Doppler waveform analysis, 
or stillbirth)
OR
• Haemolysis
• Deterioration of renal
 function
• Abnormal liver tests
• Falling platelet count
 
Figure 12B Proteinuria assessment and diagnosis of pre-eclampsia. BP, blood pressure; PlGF, placental growth factor; sFLt-1, soluble fms-like tyrosine 
kinase-1.


<!-- PAGE 59 -->

### Page 59

Monitoring and treatment of hypertension and pre-eclampsia
BP 140/90−159/109
mmHg
BP ≥160/110
mmHg
Pre-eclampsia
Hypertension
BP 140/90−159/109
mmHg
BP ≥160/110
mmHg
Every
15−30 min
At least every 48 h
(more frequently if admitted)
Every
15−30 min
Once or twice
 a week
Once or twice a week
Daily
Only repeat if clinically indicated
BP monitoring schedule
Screening for proteinuria
Once a week
Oﬀer PIGF-based testing once,
if pre-eclampsia is suspected
Twice a week
3 times a week
Blood tests: full blood count,  liver function, renal function
Treatment 
p.o. labetalola or metoprololb
(Class I)
Monitoring p.o. methyldopac
(Class I)
i.v. labetalol,  i.v. nicardipine,
 i.v. urapidil, i.v. Mg++
(Class I)
p.o. nifedipined
(Class I)
Figure 12C Monitoring and treatment of hypertension and pre-eclampsia. Mg, magnesium; PlGF, placental growth factor; p.o., per oral.  
aLabetalol 100 mg p.o. b.i.d. bMetoprolol 100 mg p.o. b.i.d. cMethyldopa 250 mg p.o. b.i.d./t.i.d. dNifedipine 5–10 mg p.o. 10 mg p.o. if >160/110 mmHg.   
ESC Guidelines                                                                                                                                                                                               59


<!-- PAGE 60 -->

### Page 60

12.3.3.2.3. Severe hypertension (BP ≥160/110 mmHg). In severe 
hypertension, assessment and gradual BP reduction to <160/ 
110 mmHg is mandatory in a hospital setting. Continuous cardiotocographic monitoring is also compulsory. The selection of antihypertensive drugs and the route of administration depend on initial diagnosis, 
expected delivery time, presence or absence of pre-eclampsia, and 
the preferences and experience of the attending physicians.43,611 
Recent comprehensive meta-analyses comparing commonly used antihypertensive drugs (e.g. oral nifedipine, labetalol, methyldopa) 
(Figure 12C) showed they had similar efficacy in lowering BP in severe 
hypertension in pregnancy, with nifedipine showing superiority in some 
studies (see Section 5.2.6).43,253,254,611,615 Nifedipine also has the advantage of wider distribution, availability, and lower pricing. Available data 
showed that hydralazine is less effective than other drugs and is associated with more side effects.616 Hydralazine is therefore a second-line 
option to be used only if other drugs are not available. 
In cases of pre-eclampsia with severe features, persistent severe 
hypertension, or recurrent severe hypertension despite orally administered agents, i.v. administration of labetalol (or nicardipine) is advised. Intravenous urapidil can also be used but may not be available 
in all countries.611,617,618 Sodium nitroprusside is the drug of last resort because prolonged treatment is associated with an increased 
risk of foetal cyanide poisoning.619 The drug of choice when 
pre-eclampsia is associated with pulmonary oedema is nitroglycerine 
(glyceryl trinitrate), given as an i.v. infusion of 5 μg/min, gradually 
increasing every 3–5 min to a maximum dose of 100 μg/min, in combination with diuretics.43,611 
12.3.4. Hypertension and delivery 
A recent randomized controlled trial from the United Kingdom found 
that once a diagnosis of pre-eclampsia was made in women with late 
pre-term pre-eclampsia (34–37 weeks), there was a lower rate of maternal morbidity and less severe maternal hypertension when delivery 
was planned to occur within the next 48 h.620 However, a greater proportion of neonates were admitted to the neonatal intensive care unit 
compared to mothers who were managed from an earlier stage. 
Decisions around timing of delivery should be individualized considering 
both maternal and foetal well-being. If well managed hypertension 
alone, delivery should be planned around 39 weeks of gestation. 
When choosing the mode of delivery, the clinical scenario should 
take into consideration the current gestational age and a full foetal assessment, as well as the preference of the mother. If induction of labour is to be considered, continuous foetal monitoring is required. 
Women with severe pre-eclampsia benefit from neuraxial anaesthesia 
to reduce the hypertensive response to pain. Additionally, an epidural 
will provide adequate anaesthesia should a caesarean delivery be 
required. 
After delivery, methyldopa should be avoided due to the risk of 
post-partum depression. Methyldopa should be stopped within 2 
days after delivery and changed to an alternative treatment. 
Recommendation Table 13 — Recommendations for hypertensive disorders and pregnancy (see Evidence Tables 
12–17) 
Recommendations 
Classa 
Levelb  
It is recommended to aim for systolic BP <140 mmHg and diastolic BP <90 mmHg in pregnant women.583,585,609 
I 
B 
Systolic BP ≥160 mmHg or diastolic BP ≥110 mmHg in a pregnant woman is an emergency, and treatment in a hospital setting is 
recommended.43,584 
I 
C 
Low-dose aspirin (75–150 mg daily) is recommended in women at moderate or high risk of pre-eclampsia (i.e. at least one high-risk factor or 
two moderate-risk factors for pre-eclampsia) from weeks 12 to 36/37.610,621,622 
I 
A 
In women with gestational hypertension, initiation of drug treatment is recommended at systolic BP ≥140 mmHg or diastolic BP 
≥90 mmHg.c583–585,609 
I 
B 
Methyldopa is recommended for the treatment of hypertension in pregnancy.623,624 
I 
B 
Labetalol, metoprolol, and dihydropyridine CCBs are recommended for the treatment of hypertension in pregnancy.623 
I 
C 
In severe hypertension, drug treatment with i.v. labetalol, urapidil, nicardipine, or oral short acting nifedipine or methyldopa is 
recommended for acute reduction in blood pressure.625,626 Intravenous hydralazine is a second-line option. 
I 
C 
In pre-eclampsia associated with pulmonary oedema, nitroglycerine given as an i.v. infusion is recommended.627 
I 
C 
In women with pre-eclampsia without severe features, delivery is recommended at 37 weeks.620,628 
I 
B 
It is recommended to expedite delivery in women with pre-eclampsia associated with adverse markers such as haemostatic disorders.629 
I 
C 
In women with gestational hypertension, delivery is recommended at 39 weeks.620,628 
I 
B 
Ambulatory BP or home BP monitoring should be considered to exclude white-coat and masked hypertension, which are common in 
pregnancy. 
IIa 
C 
Home BP monitoring may be considered as an adjunct to office BP measurements in pregnant women to detect new-onset hypertension or 
for monitoring BP control.595,596 
IIb 
B 
© ESC 2025
BP, blood pressure; CCB, calcium channel blocker; i.v, intravenous. 
aClass of recommendation. 
bLevel of evidence. 
cOffice BP measurements.


<!-- PAGE 61 -->

### Page 61

12.4. Arrhythmias 
The number of pregnant women presenting with arrhythmia is rising 
due to increasing age at pregnancy and cardiovascular risk factors 
such as obesity, hypertension, diabetes, and CAD in pregnant women.630 Haemodynamic, metabolic, and hormonal changes, and 
changes in autonomic function may contribute to increased arrhythmogenesis during pregnancy and women with prior history of arrhythmia 
may experience worsening of symptoms during pregnancy 
(Figure 13).630 Arrhythmia may have serious effects on the health of 
both the mother and the foetus and should be treated similarly to arrhythmias in non-pregnant women. 
12.4.1. Supraventricular arrhythmias 
12.4.1.1. New-onset narrow QRS tachycardia  
New-onset narrow QRS (<120 ms) tachycardias in pregnancy are 
treated according to haemodynamic stability. In all cases with 
haemodynamic instability caused by any supraventricular tachycardia 
(SVT) including AF and AFL, synchronized, direct current cardioversion is indicated (Figure 14).631 The foetal heart rate should be closely 
monitored after cardioversion.632 In haemodynamically stable narrow QRS tachycardias, the use of vagal manoeuvres (modified 
Valsalva manoeuvre, carotid sinus massage) may terminate an atrioventricular (nodal) re-entry tachycardia (AV(N)RT) arrhythmia.633 








	












		


	




		




	






	
	
	

	


	
Figure 13 Arrhythmogenesis in pregnant women. CV; cardiovascular.   
ESC Guidelines                                                                                                                                                                                               61


<!-- PAGE 62 -->

### Page 62

If these manoeuvres fail, i.v. adenosine (6–18 mg bolus) is recommended for termination of AV(N)RT. Intravenous beta-1-selective 
blockers (preferably metoprolol) can be administered for all SVTs, 
which either terminate the SVT or slow AV conduction and thereby 
the ventricular rate.634 Intravenous beta-1-selective blockers (metoprolol), non-dihydropyridine CCBs (verapamil), and digoxin can be 
used safely.635 In stable patients without structural heart disease, flecainide and ibutilide may be considered for termination of AF and 
AFL (Figure 15). In patients with congenital disease, synchronized, 
direct current cardioversion may be preferred. 
12.4.1.2. Atrial fibrillation including anticoagulation 
The incidence of arrhythmias among pregnant women is increasing, 
with AF being the most clinically relevant.252,271,636 Atrial enlargement 
during pregnancy is accompanied by increased atrial function and both 
size and function of the left atrium reverse after normal pregnancy.637 
Atrial fibrillation is more frequent in pregnant women at older age, with 
high BMI638, with ACHD, or with predisposing acquired conditions (e.g. 
hypertension, HF).637 Compared to women <25 years of age, the 
odds ratio (OR) of AF episodes was 5.2 in women aged ≥40, and the 
OR was higher in the third compared to the first trimester.638 Rapid 
atrioventricular conduction of AF may have serious haemodynamic 
consequences for both mother and foetus. Atrial fibrillation during 
pregnancy is associated with increased maternal death.639 Atrial flutter 
in pregnant women most often occurs in the presence of ACHD or 
valvular heart disease (VHD) and in metabolic disturbances such as 
thyrotoxicosis or electrolyte disturbances. 
Direct current cardioversion in pregnancy is required in haemodynamically unstable patients with monitoring of foetal heart rate 
(Figure 15).250,268,271 Rhythm control is the preferred AF treatment 
strategy during pregnancy. For women with structurally normal hearts, 
anti-arrhythmic drugs (e.g. flecainide and sotalol, see Section 5.2.5) are 
not associated with foetal harm, although sotalol’s beta-blocker effect 
necessitates monitoring of foetal growth.250,268,271 There are minimal 
data on the use of propafenone during pregnancy, but this sodium channel blocker may be considered if flecainide is not available. Intravenous 
ibutilide or flecainide may be considered for termination of AFL and AF 
in haemodynamically stable patients.640 
The indication for anticoagulation with LMWH before cardioversion 
or the need for transoesophageal echocardiography should be evaluated as in non-pregnant women and be maintained for at least 4 weeks 
after cardioversion.636,641 
Management of narrow QRS tachycardia in pregnant women
Haemodynamically unstable SVT
Electrical cardioversion
(Class I)
Vagal manoeuvres:
Valsalva manoeuvre,
carotid sinus massage
(Class I)
i.v. beta-blockersb e.g. metoprololc
(Class I)
i.v. verapamild
(Class IIa)
Pad position:
sterno-apical/
antero-posterior 
Avoid breast tissue
Foetal heart rate monitoring i.v. adenosinea
(Class I) 
If sinus rhythm not achieved
OR
Haemodynamically stable SVT
Figure 14 Management of narrow QRS tachycardia in pregnant women. i.v., intravenous; SVT, supraventricular tachycardia. aAdenosine 6–18 mg bolus. 
bAtenolol contraindicated. cMetoprolol 2.5–15 mg. dVerapamil 2.5–10 mg bolus over 5 min.


<!-- PAGE 63 -->

### Page 63

When a rate control strategy is needed in the case of (long-standing) 
persistent or permanent AF, beta-blockers, verapamil, or digoxin 
should be used, also in combination, taking into consideration the concomitant conditions affecting the mother.271,642 
Atrial fibrillation is a strong risk factor for cardioembolic events, 
and the hypercoagulable state of pregnancy may increase this risk. In 
pregnant women with persistent or permanent AF, the decision to anticoagulate is the same as in non-pregnant women and depends on the 
risk of thromboembolic events according to the CHA2DS2-VA score 
[congestive heart failure, hypertension, age ≥75 (doubled), diabetes, 
stroke (doubled), vascular disease, age 65–74].643 The CHA2DS2-VA 
score threshold of ≥2 to anticoagulate has not been validated in 
pregnancy.643,644 DOACs are contraindicated in pregnancy. The presence of mechanical valves or moderate to severe mitral stenosis require 
VKA (see Section 5.2.1 and Section 12.5). 
12.4.1.3. Pre-existing supraventricular tachycardia 
In women with AVNRT, atrioventricular re-entry tachycardia (AVRT), 
and focal atrial tachycardia (FAT), chronic oral prophylaxis can be 
achieved with beta-blockers (metoprolol) or verapamil. For women 
with drug-refractory SVT or who have a contraindication to these 
drugs, flecainide or sotalol are reasonable alternatives, as is propafenone if flecainide is not available. 
Management of atrial ﬁbrillation and atrial ﬂutter in pregnant women
Haemodynamically unstable AF/AFL
Electrical cardioversion
(Class I)
i.v. ﬂecainidee
(Class IIb)
i.v. ibutilidef
(Class IIb)
Avoid amiodarone or dronedarone 
AF/AFL with pre-excitation and high ventricular rates
Haemodynamically stable AF/AFL
Severe structural heart disease
Pharmacological cardioversion
Acute rate control i.v.
beta-blockersa e.g. metoprololb
(Class I)
i.v.
verapamilc
(Class IIa)
i.v. digoxind
(Class IIa)
OR
OR
Figure 15 Management of atrial fibrillation and atrial flutter in pregnancy. AF, atrial fibrillation; AFL, atrial flutter; i.v., intravenous; N, no; SVT, supraventricular tachycardia; Y, yes. aAtenolol: contraindicated. bMetoprolol: 2.5–15 mg. cVerapamil: 2.5–1 mg bolus over 5 min. dDigoxin: 0.5 mg bolus, 0.75–1.5 mg 
over 24 h in divided doses. eFlecainide: 2 mg/kg over 10 min. fIbutilide: <60 kg: 0.01 mg/kg over 10 min, repeated after 10 min if necessary; ≥60 kg: 1 mg over 
10 min, repeated after 10 min if necessary.   
ESC Guidelines                                                                                                                                                                                               63


<!-- PAGE 64 -->

### Page 64

In pregnant women with AVRT and Wolff–Parkinson–White (WPW) 
syndrome, arrhythmia episodes can be prevented by using oral flecainide, 
or propafenone when flecainide is not available. When AV-nodal blocking 
agents are used in WPW syndrome and AF occurs, the risk of rapid ventricular rates is increased. However, in pregnant women without documented AF, with known orthodromic AVRT, and with intermittent 
pre-excitation, long-term AV blockade is acceptable for prevention. 
If catheter ablation treatment is necessary, it should be performed by 
experienced operators in a centre equipped with non-fluoroscopic 
mapping techniques (Section 12.4.3.2). 
12.4.2. Ventricular arrhythmias 
New-onset VT and ventricular fibrillation (VF) arising during pregnancy 
are rare (18 per 100 000 pregnancy-related hospitalizations).652 The 
most common type of VT in pregnant women is idiopathic VT originating 
from the right ventricular outflow tract (RVOT) (Figure 16). When new- 
onset VT develops during the last 6 weeks of pregnancy or during the first 
month post-partum, underlying PPCM should be excluded.370 
The use of amiodarone is not recommended in pregnancy and 
should be limited to women with refractory or life-threatening arrhythmias that cannot be controlled with any other anti-arrhythmic therapy. 
If administered, it requires close monitoring for potential side effects in 
the foetus, such as bradycardia or IUGR. 
In women with known underlying substrates for VT, beta-blockers 
are recommended for prevention of VT.148,252 In case of refractoriness 
or contraindications to beta-blockers, anti-arrhythmic therapy with flecainide, sotalol, or quinidine is recommended, with the choice of drug 
based on the underlying cardiac substrate (Figure 16).148,252 Idiopathic 
RVOT-VT can be prevented with beta-blockers or verapamil.653 
When this is ineffective, flecainide654 or sotalol650,655–659 are safe options to consider for prophylaxis of idiopathic RVOT-VT. 
Recommendations on the acute management of ventricular arrhythmias during pregnancy are described in the 2022 ESC Guidelines for the 
management of patients with ventricular arrhythmias and the prevention of sudden cardiac death, and are depicted in Figure 16.252 
12.4.3. Cardioversion, ablation, and device 
implantation, and implantable cardioverter 
defibrillator management 
12.4.3.1. Electrical cardioversion 
Electrical cardioversion is safe and effective in all pregnancy phases as it 
does not affect foetal circulation or induce foetal arrhythmia. In pregnancy there are no changes in transthoracic impedance compared to 
non-pregnant women,660 and shock energies delivered should therefore be the same as in non-pregnant patients. The foetal heart rate 
should be monitored after cardioversion.631,632,661,662 
12.4.3.2. Catheter ablation 
Catheter ablation in pregnant women should preferably be performed 
after the first trimester in a centre with experience in non-fluoroscopic 
Recommendation Table 14 — Recommendations for supraventricular tachycardia and pregnancy 
Acute management of SVT and AF 
Classa 
Levelb  
Immediate electrical cardioversion is recommended for acute treatment of SVT with haemodynamic instability. 
I 
C 
Vagal manoeuvres and i.v. adenosine are recommended for conversion of haemodynamically stable supraventricular tachycardias.645 
I 
C 
Intravenous beta-blockersc (e.g. metoprolol) are recommended as the first-line option for acute rate control in pregnant women with AF or 
AF with preserved LVEF and rapid ventricular rate.646 
I 
C 
Intravenous digoxin or verapamil (if preserved LVEF) should be considered as a second-line option for initial rate control in pregnant 
women with AF or AFL and rapid ventricular rate.635 
IIa 
C 
Ibutilide or flecainide may be considered for termination of AF and AFL in pregnant women without structural heart disease.640,647 
IIb 
C 
Long-term management of SVT and AF 
Therapeutic anticoagulation with LMWH is recommended for pregnant women with persistent or permanent AF at elevated 
thromboembolic risk.636,641 
I 
C 
Beta-1-selective blockersc are recommended for rate control in pregnant women with AF, AFL, or FAT.146,271,648 
I 
C 
Beta-1-selective blockersc or verapamil are recommended for the prevention of SVT in women without pre-excitation on resting 
ECG.146,268,649 
I 
C 
Flecainide or propafenone are recommended for the prevention of arrhythmias in pregnant women with WPW syndrome.650 
I 
C 
Digoxin or verapamil should be considered for rate control in pregnant women with AF, AFL, or FAT when beta-blockers fail or are not 
tolerated.146,271,645 
IIa 
C 
Flecainide, in addition to beta-blockers, should be considered for long-term AF rhythm control in pregnancy.250,268,271,640 
IIa 
C 
Sotalol may be considered for rhythm management of AF and AFL with controlling for pro-arrhythmic risk factors as in non-pregnant 
women.651 
IIb 
C 
Catheter ablation may be considered in pregnant women with recurrent, long symptomatic SVT, or with contraindications to 
pharmacological therapies. 
IIb 
C 
© ESC 2025
AF, atrial fibrillation; AFL, atrial flutter; ECG, electrocardiogram; FAT, focal atrial tachycardia; i.v., intravenous; LMWH, low-molecular-weight heparin; LVEF, left ventricular ejection fraction; 
SVT, supraventricular tachycardia; WPW, Wolff–Parkinson–White. 
aClass of recommendation. 
bLevel of evidence. 
cExcept for atenolol.


<!-- PAGE 65 -->

### Page 65

electro-anatomical mapping and catheter navigation systems.663–665 
Catheter ablation for drug-refractory and poorly tolerated VT or for 
recurrent drug-refractory AVNRT, AVRT, FAT, cavotricuspid isthmus- 
dependent AFL, and certain benign right-sided VTs may be considered 
to avoid potentially harmful anti-arrhythmic drug effects during pregnancy, although it has no role in AF.664,666 
12.4.3.3. Device implantation 
An ICD is indicated in pregnant women who are at high risk of sudden 
cardiac death.252 Implantation of a device is not associated with a higher risk of major complications and can be performed safely,667,668 particularly after 8 weeks of gestation. During implantation, radiation 
exposure should be minimized following the ALARA principle (see 
Management of ventricular tachycardia in pregnancy
Pharmacological acute conversion and/or management of recurrent VT/VF
Electrical cardioversion
(Class I)
Idiopathic
RVOT-VT
i.v. beta-blockers
(Class IIa)
i.v adenosine
(Class IIa)
i.v. procainamide
(Class IIa)
i.v. beta-blockers
(routine usage)
Long QT or
Torsade de
Pointes VT
Remove 
precipitating 
factors
Overdrive pacing i.v. Mg++/K+
i.v. beta-blockers
(e.g. propranolol)
(Class I)
Brugada 
syndrome i.v. isoproterenol p.o. quinidine
(Class IIa)
Idiopathic VF
i.v. verapamil p.o. quinidine
Failure of pharmacologic conversion/control i.v. isoproterenol
Structural heart disease i.v. beta-blockers
(routine usage)
Unknown/ 
other aetiology
Fascicular VT
i.v verapamil
(Class IIa)
CPVT
i.v. beta-blockers
(Class I)
Figure 16 Management of ventricular tachycardias in pregnancy. CPVT, catecholaminergic polymorphic ventricular tachycardia; i.v., intravenous; N, no; 
RVOT, right ventricular outflow tract; VF, ventricular fibrillation; VT, ventricular tachycardia; Y, yes. See Supplementary data online (Table S6) for medication 
dosages. Adapted from Zeppenfeld et al.252.   
ESC Guidelines                                                                                                                                                                                               65


<!-- PAGE 66 -->

### Page 66

Section 4.3.5) or with non-fluoroscopic imaging techniques.669 
Women with an ICD should maintain their regular ICD care throughout pregnancy.669 
12.4.3.4. Implantable cardioverter defibrillator management 
Routine ICD interrogation and guidance are recommended prior to delivery. Management of pregnant women with an ICD or pacemaker is 
summarized in Figures 17 and 18. 
Women with structural heart disease are at higher risk of atrial and 
ventricular tachyarrhythmias during pregnancy.670 Consequently, pregnant women with ICDs may present with either an inappropriate shock 
(due to e.g. lead defects, new-onset supraventricular tachyarrhythmias, 
or technical issues such as T-wave oversensing or noise sensing) or an 
appropriate ICD shock caused by ventricular tachyarrhythmias. In case 
of tachyarrhythmia, triggering events such as HF, electrolyte abnormalities, ischaemia, or infectious disease should be ruled out, as with non- 
pregnant women. Depending on the underlying cause, therapy consists 
of device reprogramming or initiating or adapting anti-arrhythmic drug 
therapy. In the case of drug-refractory arrhythmias or serious anti- 
arrhythmic drug side effects, catheter ablation may be considered in experienced centres.664 
Most data indicate that maternal ICD shocks do not have major foetal adverse effects.668,671 The approach to pregnant women presenting 
with ICD shocks is no different from non-pregnant women 
(Figure 18).252 
A WCD may be considered when pregnant women have an ICD indication from reversible conditions.365,672–674 







	

	


















	

	


	
































	

	


	













Figure 17 Management of pacemaker and implantable cardioverter defibrillator and pregnancy. b.p.m., beats per minute; ICD, implantable cardioverter 
defibrillator; VF, ventricular fibrillation; VT, ventricular tachycardia. aPatients with an increase in arrhythmias during pregnancy, history of ventricular tachyarrhythmias. bSingle zone configuration: VT detection at 250 b.p.m., prolonged detection duration, e.g. 30 out of 40 beats.


<!-- PAGE 67 -->

### Page 67

Management of implantable cardioverter deﬁbrillator shocks during pregnancy
ICD interrogation
Appropriate shocks
VT/VF
Programmer available
Inappropriate shocks
Haemodynamically stable
Reprogramme to avoid T-wave oversensing
Reprogramme to discriminate 
SVT
Position magnet over the ICD
Start advanced life support
(see related section)
Identify and treat triggers 
Anti-arrhythmic drug therapy 
(see related section)
If serious side eﬀects or drug refractoriness,
consider catheter ablation
(Class IIb)
Device reprogramming
Figure 18 Management of implantable cardioverter defibrillator shocks in pregnancy. ICD, implantable cardioverter defibrillator; N, no; SVT, supraventricular tachycardia; VF, ventricular fibrillation; VT, ventricular tachycardia; Y, yes.  
Recommendation Table 15 — Recommendations for 
ventricular tachycardia, device implantation, catheter 
ablation, and pregnancy 
Recommendations 
Classa 
Levelb  
Immediate electrical cardioversion is recommended 
for both unstable and stable ventricular 
tachycardias.252 
I 
C 
Beta-blockers or verapamil are recommended for 
the prevention of idiopathic sustained VT. 
I 
C 
If an ICD, pacemaker, or resynchronization therapy 
device is indicated during pregnancy, implantation is 
recommended with optimal radiation 
protection.667,675 
I 
C 
In idiopathic RVOT-VT, flecainide should be 
considered if beta-blockers fail, to prevent 
recurrence. 
IIa 
C                                                                                                   
Continued 
For acute conversion of haemodynamically stable 
sustained VTs during pregnancy, i.v. beta-blocker, 
adenosine (idiopathic RVOT-VT), verapamil 
(fascicular VT), procainamide, or overdrive 
ventricular pacing (ICD lead) should be 
considered.252,653,676–678 
IIa 
C 
When performing catheter ablation during 
pregnancy, the use of non-fluoroscopic mapping and 
navigation systems should be considered.663–665 
IIa 
C 
Catheter ablation with electro-anatomical mapping 
systems may be considered in experienced centres in 
the case of sustained drug-refractory, recurrent, and/ 
or poorly tolerated VT if there are no other 
alternatives. 
IIb 
C 
© ESC 2025
ICD, implantable cardioverter defibrillator; i.v., intravenous; RVOT, right ventricular 
outflow tract; VT ventricular tachycardia. 
aClass of recommendation. 
bLevel of evidence.   
ESC Guidelines                                                                                                                                                                                               67


<!-- PAGE 68 -->

### Page 68

12.4.4. Cardiac arrest 
Maternal cardiac arrest occurs in 8/100 000 hospitalizations in the United 
States of America679 and 7.6/100 000 pregnancies in the Netherlands.680 
Haemorrhage and anaesthetic complications are the most common 
overall causes of cardiac arrest,681 and HF, ACS, arrhythmias, aortic dissection, and PE are the most common cardiovascular causes of cardiac 
arrest.682,683 
Because most of the underlying causes of cardiac arrest in pregnancy 
tend to be reversible, pregnant women have better outcomes than non- 
pregnant women.684 Basic cardiac arrest resuscitation principles apply 
to pregnant women, although some differences should be considered.684 If cardiac arrest occurs beyond 20 weeks of pregnancy, left lateral manual displacement of the uterus or left lateral position of the 
woman is indicated to avoid aortocaval compression (Figure 19).684,685 
Chest compressions should be according to basic life support guidelines. 
Management of cardiac arrest in pregnancy
Potential aetiology
• Anaesthetic complications 
• Bleeding
• Cardiovascular causes 
• Drugs
• Amniotic ﬂuid embolism
• Pulmonary embolism 
• Eclampsia
Obstetric interventions
If no ROSC after
4 min of resuscitation eﬀorts and foetus is viable, immediate caesarean section
(Class IIa)
Maternal interventions
Neonatal Team
Pregnancy-speciﬁc
In women with Mg++
infusion (pre-eclampsia): 
Stop Mg++ infusion and administer calcium gluconatea
In resuscitated pregnant women,
temperature control on an individual basis
Not pregnancy-speciﬁc
Airway management
Continuous manual left uterus displacement
(Class I)
i.v. access above diaphragm
(Class I)
Chest compressions as in non-pregnant
(Class I)
Anterolateral deﬁbrillator pad placement with the lateral pad placed under the breast
(Class I)
Deﬁbrillation protocol as in non-pregnant
(Class I)
Drug choices and doses as in non-pregnant
(Class I)
Figure 19 Management of cardiac arrest in pregnancy. i.v., intravenous; ROSC, return of spontaneous circulation. a30 mL calcium gluconate 10% solution.


<!-- PAGE 69 -->

### Page 69

In post-arrest care, the full left lateral decubitus position is recommended. The use of device-assisted chest compressions in pregnancy 
is currently not recommended due to lack of data.684 Importantly, no 
drugs should be withheld because of concerns about teratogenicity.614,686 Foetal monitoring after cardiac arrest is mandatory. 
Emergency caesarean section should be immediately prepared for 
and considered when initial resuscitation fails.682 If this is not feasible, 
rapid maternal transfer is advised to an appropriate clinical setting 
with uninterrupted resuscitation. 
12.4.5. Bradycardia 
12.4.5.1. Sinus node dysfunction 
Sinus bradycardia due to sinus node dysfunction is uncommon in 
pregnant women who do not have structural heart disease. In 
the second trimester, symptomatic bradycardia may occur as a result of a reduction in systemic resistance, but this rarely requires 
treatment. Symptomatic bradycardia during pregnancy may be 
caused by the supine hypotensive syndrome, defined as a systolic 
BP decrease of >15 mmHg due to compression of the inferior 
vena cava by the uterus.690 Management depends on the underlying 
cause, severity of symptoms, and potential risks to both the mother 
and the foetus. 
12.4.5.2. Atrioventricular block 
Mobitz type I AV block is common in pregnant women and rarely 
progresses during pregnancy.691 There are no data on progression 
of congenital AV conduction block during pregnancy and vaginal 
delivery does not cause extra risk for mothers who are asymptomatic, haemodynamically stable, and have a normal cardiac anatomy and function.691 Prophylactic placement of temporary 
pacemaker wires is not usually indicated but is an individualized 
decision. 
12.4.5.3. Management of sinus node dysfunction and 
atrioventricular block 
In acute, life-threatening settings, bradycardia should be treated as in 
non-pregnancy. Isoproterenol can be used when benefits outweigh 
risks. It is not known if it is excreted in human milk. Pacing indications 
(temporary and permanent) do not differ between pregnant and 
non-pregnant women and can be found in the 2021 ESC 
Guidelines on cardiac pacing and cardiac resynchronization therapy.692 Pacemakers can be implanted safely during pregnancy using 
standard methods with minimal fluoroscopy or non-fluoroscopic 
methods.675,693–695 
12.5. Valvular heart disease 
During childbearing years VHD is usually either congenital or rheumatic 
in cause. Complications during pregnancy include new-onset AF, which 
can lead to deterioration in cardiac function, an increased risk of 
thromboembolic events, and heart failure.696,697 Women with valve 
disease should have access to pre-conception counselling and their cardiac condition should be optimized. This may include pre-pregnancy 
intervention or surgery for those with symptoms or severe disease 
(Figure 20), in keeping with the 2021 ESC/EACTS Guidelines for the 
management of valvular heart disease.698 Dedicated tools for risk stratification may be needed in the setting of rheumatic heart disease.697 
12.5.1. Stenotic native valve lesions 
Stenotic valve lesions limit the ability to increase CO during pregnancy. 
The result of this may be presentation with symptoms for the first time 
during pregnancy. Serial TTE in pregnancy will usually demonstrate an 
increase in valve gradient of up to 50% due to the normal 
pregnancy-related increase in CO.699 
Recommendation Table 16 — Recommendations for 
cardiac arrest and pregnancy 
Recommendation 
Classa 
Levelb  
Continuous manual left uterine displacement during 
CPR in pregnant women (≥20 weeks) with cardiac 
arrest is recommended to relieve aortocaval 
compression.614 
I 
C 
It is recommended to establish i.v. access above the 
diaphragm to ensure that the i.v. therapy is not 
obstructed by the gravid uterus.614 
I 
C 
It is recommended to perform the same chest 
compressions and defibrillation protocols in 
pregnant as in non-pregnant women.554,614,687 
I 
C 
Anterolateral defibrillator pad placement is 
recommended with the lateral pad placed under the 
breast.614,660 
I 
C 
It is recommended that no drugs are withheld in 
pregnant women with cardiac arrest due to concerns 
of teratogenicity.686 
I 
C 
Immediate caesarean section at the site of the arrest 
should be considered and immediately prepared if 
ROSC has not been achieved in the mother after 
4 min of resuscitative efforts and if the foetus is 
viable, taking gestational age, comorbidities, and 
the available level of medical care into 
account.614,688,689 
IIa 
C 
© ESC 2025
CPR, cardiopulmonary resuscitation; i.v, intravenous; ROSC, return of spontaneous 
circulation. 
aClass of recommendation. 
bLevel of evidence.  
Recommendation Table 17 — Recommendation for 
congenital atrioventricular block and pregnancy 
Recommendation 
Classa 
Levelb  
In pregnant women with asymptomatic congenital 
AV block, normal cardiac anatomy and function, a 
narrow QRS complex, and ventricular rate 
(≥50 b.p.m.), a prophylactic temporary pacemaker 
during delivery is not recommended.691 
III 
C 
© ESC 2025
AV, atrioventricular; b.p.m., beats per minute; QRS, Q, R, and S waves. 
aClass of recommendation. 
bLevel of evidence.   
ESC Guidelines                                                                                                                                                                                               69


<!-- PAGE 70 -->

### Page 70

12.5.1.1. Mitral valve stenosis 
Mitral valve stenosis is a common cause of HF during pregnancy.11 Mild 
stenosis is usually well tolerated.11 However, symptoms may occur if 
the valve area is <1.5 cm2. Maternal mortality in mitral stenosis is higher 
in those with NYHA >II, systolic pulmonary arterial pressure (PAP) 
>30 mmHg, severe stenosis, older age, and in low-income countries11,696,700 (Figure 20). Foetal risks include increased rates of premature delivery, IUGR, and foetal death, especially in highly symptomatic 
mothers (NYHA III/IV).701 
12.5.1.1.1. Management. Diagnosis is as per usual criteria.698 
During pregnancy, valve area by 2D-planimetry is thought to be 
more reliable than flow-dependent measures, because higher stroke 
volume and tachycardia will increase the measured gradient across 
the valve.702 Mitral valve anatomy, especially the presence of subvalvar involvement or the presence of MR, is important if considering 
intervention. 
If signs or symptoms of PH are present, activity restriction should be 
suggested, and beta-blockers and/or diuretics should be started. 
Anticoagulation regimens should be individualized. Therapeutic anticoagulation with full therapeutic-dose LMWH or VKA (see Section 5) 
is indicated in those with AF, left atrial clot, or a previous embolism. 
Anticoagulation should be considered in those with significant mitral 
stenosis, spontaneous echo contrast in the left atrium, dilated left atrium with left atrial volume index >60 mL/mL2, or those in HF. 
12.5.1.1.2. Interventions. Pre-pregnancy intervention should be considered in those with significant stenosis (valve area <1.5 cm2). Before 
and during pregnancy, percutaneous mitral balloon commissurotomy is 
the primary intervention in those who remain in NYHA III/IV or with 
severe PAP elevation despite medical therapy.703 Balloon techniques 
are highly successful during pregnancy unless there is complex subvalvar 
involvement. Closed commissurotomy is rarely used but is an alternative. Open valve surgery should only be used when there is a risk to maternal life and other options are not possible or have failed.704 
12.5.1.1.3. Delivery. Vaginal delivery is the preferred option. 
Caesarean section is preferred in cases of severe mitral stenosis and 
for those with refractory HF. Delivery is a time of increased risk of 
HF and thrombotic events.182 
12.5.1.1.4. Post-partum. Close monitoring is needed in the days following delivery and diuretics may be required to treat fluid overload. The long- 
term outcome depends on the risk of valve progression and the success of 
commissurotomy if performed. Lifelong follow-up is required. 
12.5.1.2. Valvular aortic stenosis 
Bicuspid aortic valve disease is a common cause of valvular aortic stenosis in 
women of childbearing age. The outcome is related to the baseline severity 
of the stenotic lesion. Women with severe stenosis and those with symptoms prior to pregnancy have a 1 in 4 risk of developing HF during pregnancy.703 Exercise testing and measurement of NP can be used to 
stratify risk prior to pregnancy. Those with symptomatic severe aortic stenosis should be offered intervention prior to pregnancy. Risk-stratifying 
those with asymptomatic aortic stenosis is more challenging. Left ventricular systolic dysfunction, or effort limitation on exercise testing, indicate that 
intervention before pregnancy should be considered.698 
Women with severe aortic stenosis contemplating pregnancy should 
be counselled regarding the risks and offered surgery if they prefer. 
Despite this, maternal mortality is rare for those under expert 
care.703 The risk of sudden death in those with severe stenosis is increased but difficult to quantify. BAV-associated aortopathy is discussed in Section 8.3. 
12.5.1.2.1. Management. Medical therapy has a limited role in 
symptomatic aortic stenosis. Diuretics may help those with HF or 
high filling pressures, but caution should be exercised. In women 
with severe symptomatic aortic stenosis, rest and possibly hospital admission should be considered. Intervention should be considered in 
women with persisting symptoms including angina or with new ST 
changes on ECG. In symptomatic pregnant women with severe aortic 
stenosis not responding to medical therapy, non-surgical options such 
as balloon valvuloplasty or transcatheter aortic valve implantation 
(TAVI) may be considered during pregnancy.705,706 Procedures 
should be performed in an experienced valve centre. If no catheter- 
based options are available, surgical valve replacement or repair is recommended. If the foetus is at a viable gestation, taking account of 
other comorbidities and the available level of neonatal care, delivery 
should occur prior to valve intervention. These complex decisions 
should be discussed with the full Pregnancy Heart Team.707 Cardiac 
surgery with cardiopulmonary bypass is associated with at least a 
20% risk of foetal loss.708 
Vaginal delivery is the preferred mode of delivery for the majority of 
women. In those with severe symptomatic aortic stenosis, caesarean 
delivery should be considered. Early post-partum HF may develop. 
For pulmonary stenosis, see Section 9 on congenital heart disease. 
12.5.2. Regurgitant native valve lesions 
Valve regurgitation is generally better tolerated than valve stenosis in 
pregnancy. Increased maternal and foetal event rates can be seen in 
those with severe regurgitation.709 
12.5.2.1. Mitral and aortic valve regurgitation 
Women with valve regurgitation and either symptoms or LV 
dysfunction incur an increased risk of HF, occurring in 20%–25% 
of those with at least moderate regurgitation.182,710 Acute regurgitant 
lesions are often less well tolerated than chronic regurgitation.710 
12.5.2.1.1. Management. Diuretics can be used in those with severe 
symptomatic mitral or aortic regurgitation. Cardiac surgery is rarely required during pregnancy. Vaginal delivery is preferred unless the 
mother is in refractory HF. 
12.5.2.2. Arrhythmogenic mitral valve prolapse 
Arrhythmic mitral valve prolapse (AMVP) is defined as the presence of 
mitral valve prolapse and arrhythmia symptoms or signs, such as frequent ventricular premature contractions or complex ventricular arrhythmias.711 The arrhythmias may arise from myocardial fibrosis 
resulting from prolonged and increased stretch of papillary muscles 
and of the inferolateral LV wall by the prolapsing valves. 
Several reports have included female sex as a risk factor for severe 
arrhythmic events.711 Other risk factors include syncope, the presence of mitral annular disjunction, late gadolinium enhancement 
on CMR, complex ventricular arrhythmias, including non-sustained 
ventricular tachycardia, syncope, T-wave inversions in the inferolateral ECG leads, bi-leaflet mitral valve prolapse, and reduced LVEF. 
Little is known about the effect of pregnancy in women with AMVP, 
but altered loading conditions may lead to increased tension in mitral


<!-- PAGE 71 -->

### Page 71

valve apparatus and thereby increased risk of ventricular arrhythmias. 
A recent publication indicated increased arrhythmic risk during pregnancy in women with AMVP and life-threatening ventricular 
arrhythmias.712 
It is recommended that women with AMVP undergo pre-conception 
counselling and optimization of medication. Medical treatment includes 
anti-arrhythmic therapy with, for example, beta-blockers and/or flecainide.713 If started pre-pregnancy, treatment should continue during pregnancy with close follow-up and arrhythmic monitoring. A pregnant 
woman with AMVP should be monitored during pregnancy at a tertiary 
centre with experience in AMVP and with periodic Holter monitoring 
to identify a potential increase in arrhythmic burden.711 Risk stratification 
for ICD implantation should follow the consensus for AMVP in general.711 
12.5.2.3. Tricuspid regurgitation 
Medical treatment for tricuspid regurgitation is usually not required 
but during pregnancy diuretics and medication for rhythm management may be needed. Surgery for isolated TR in pregnancy is rarely 
indicated except for the setting of endocarditis. 
Stenosis



Regurgitation




Regurgitation





	





	



	
 









Regurgitation

Stenosis
	
­
	





	





	




		



	


		
	
Poor RV function
Ebstein anomaly


Figure 20 Valvular heart disease and pregnancy. ECG, electrocardiogram; LV, left ventricle; LVH, left ventricular hypertrophy; PASP, pulmonary arterial 
systolic pressure; RV, right ventricle; RVH, right ventricular hypertrophy. Red flags indicate high-risk features.   
ESC Guidelines                                                                                                                                                                                               71


<!-- PAGE 72 -->

### Page 72

12.5.3. Prosthetic valves 
When a woman of childbearing age or a girl requires valve surgery, 
careful consideration should be given to the possibility of future pregnancies. When appropriate, the discussion regarding valve choice 
should involve the Pregnancy Heart Team. In general, valve repair, 
valve-in-valve, or non-mechanical valves are preferable, avoiding the 
need for anticoagulation. Data from the ROPAC III study, focusing 
on prosthetic valves, show that the chance of an uncomplicated pregnancy with a live birth in women with a MHV was 54%, compared to 
79% in women with a tissue valve.177 Regional differences, especially between high-income and low- and middle-income countries, need to be 
acknowledged, as also indicated in a recent study from Madras in India 
(M-PAC registry) describing pregnancy outcomes in 70 women with a 
prosthetic heart valve.717 A very high foetal death rate and major adverse cardiovascular events (MACE) rate (40% and 34%, respectively),717 including a high number of valve thromboses, is believed to 
relate not only to differences in organization of care, but also to underlying valvular disease, with more rheumatic heart disease in low- and 
middle-income countries. The Ross procedure in aortic valve disease 
is an alternative option to be considered. In the absence of aortic dilatation, pregnancy risk is low after the Ross procedure.718 
12.5.3.1. Bioprosthetic valves 
Prior to pregnancy, a full assessment of valve function should be 
performed. Many women are on lifetime low-dose aspirin treatment, 
and this should be continued during pregnancy unless there is a contraindication. If there is severe valve dysfunction prior to pregnancy, 
reintervention should be considered. However, in this setting 
the risk of pregnancy with the current valve dysfunction should be balanced against the risk of the new valve being proposed. Mechanical 
valve implantation should be avoided when possible. Transcatheter 
valve-in-valve intervention may have a role in extending the lifespan 
of a failing bioprosthetic valve in a young woman contemplating pregnancy. In a recent retrospective study of CARPREG data, 215 pregnancies in 101 women who had implanted bioprosthetic valves prior to 
pregnancy were described. More than a quarter had some degree of 
valvar dysfunction, although the time since the last valve replacement 
surgery was only 6 ± 3 years on average. Bioprosthetic valve dysfunction was more than twice as common in women with left-sided as opposed to right-sided valves.719 
The chance of a pregnancy without serious adverse events and a live 
birth in women with a bioprosthetic valve is 79%.177 When significant 
bioprosthetic dysfunction is present, the risk of complications can be 
significant, especially if associated with severe stenosis or ventricular 
dysfunction. There is no compelling evidence that pregnancy is associated with accelerated valve deterioration. 
12.5.3.2. Mechanical valves 
Pregnant women with MHVs are exposed to a high risk of complications (mWHO 2.0 risk classification ≥III). The chances of an event-free 
pregnancy with a live birth were only 58% in the initial ROPAC II study 
and showed no improvement after 8 years in the ROPAC III study 
(54%).177,204 Thrombotic complications occur in 9%–24% and bleeding 
complications in 20%–30% of the cases in the ROPAC III and a United 
Kingdom study, respectively.176,177 Women with a mechanical valve in 
the mitral position are especially at risk of adverse outcomes, including 
mortality.177 
All women with MHVs should be fully counselled pre-pregnancy regarding the risks and benefits of the various anticoagulation regimens. 
When planning the optimal anticoagulation strategy, logistical issues, 
Recommendation Table 18 — Recommendations for native valve disease and pregnancy 
Recommendations 
Classa 
Levelb  
Intervention is recommended before pregnancy in symptomatic patients with severe aortic stenosis.698 
I 
C 
Intervention is recommended before pregnancy in women with mitral stenosis and a valve area <1.5 cm2. 698,701,714 
I 
C 
In pregnant women with symptomatic mitral stenosis or pulmonary hypertension, restricted activities and beta-blockers are 
recommended.20 
I 
C 
In pregnant women with mitral stenosis, diuretics are recommended when congestive symptoms persist despite beta-blockers.20 
I 
C 
Full therapeutic-dose anticoagulation is recommended in women with mitral stenosis complicated by AF, left atrial thrombus, or prior 
embolism. 
I 
C 
Surgical treatment is recommended before pregnancy in women with severe aortic or mitral regurgitation with symptoms, impaired 
ventricular function, or marked ventricular dilatation.698,715 
I 
C 
Diuretics are recommended in pregnant women with regurgitant lesions when symptoms or signs of congestion occur. 
I 
C 
Intervention should be considered before pregnancy in those with asymptomatic severe aortic stenosis after counselling on the risks and 
benefits.698 
IIa 
C 
Percutaneous mitral commissurotomy for mitral stenosis should be considered in pregnant women with severe symptoms or systolic 
pulmonary artery pressure >50 mmHg despite medical therapy.698 
IIa 
C 
Valve surgery during pregnancy should only be considered when there is a maternal mortality risk and other treatment options have 
failed.421 
IIa 
C 
In very selected symptomatic pregnant women with severe aortic stenosis not responding to medical therapy, non-surgical options such as 
balloon valvuloplasty or TAVI may be considered.716 
IIb 
C 
© ESC 2025
AF, atrial fibrillation; TAVI, transcatheter aortic valve implantation. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 73 -->

### Page 73

such as access to timely anti-factor Xa level testing and maternal ability to 
adhere to treatment regimens, need to be considered. 
12.5.3.2.1. Anticoagulation during pregnancy. The most effective 
regimen in preventing maternal thrombotic complications is the continuous use of VKAs. Thrombotic events not only compromise the 
mother but also jeopardize the baby.170,200,204,206,720,721 However, 
there remain concerns about the foetal impact of VKAs. Data from 
the ROPAC III study indicated a higher risk of miscarriage in VKA 
users.177 As discussed in Section 5, the foetal risk of VKAs is in part 
dose-related. Although there is no safe dose for the foetus, event rates 
are reduced when lower doses of VKA are used.200 For these reasons, 
continuation of VKAs should be considered when the risk of thrombosis is high and the dose required to achieve the target INR is low 
(see Section 5). Target INRs are unchanged from non-pregnant values.698 INR monitoring should be weekly or every 2 weeks (see 
Section 5). 
The alternative strategy is switching to therapeutic-dose LMWH 
(twice daily) until the 12th week of pregnancy with a monitoring 
plan. The target peak levels of anti-factor Xa should be discussed individually and vary between 1 and 1.2 IU/mL. The value of trough anti- 
factor Xa levels is less clear. Adjusting dosing to obtain levels of 
>0.6 IU/mL has been suggested, however, with little evidence.170,216 
Dosing regimens for therapeutic LMWH are provided in Section 5. 
In women with a very high thrombotic risk, the addition of low-dose 
acetylsalicylic acid (ASA) should be considered.170 In rare circumstances, such as the unavailability of anti-factor Xa level testing, i.v. 
UFH can be used. Target aPTT levels with a prolongation of ≥2 times 
the control can be challenging to achieve and may require multiple adjustments of dosing and prolonged inpatient care. In the majority of 
cases, VKAs will be the favoured therapy in the second and third trimesters to minimize the maternal risks after the period of embryogenesis.176,204 Despite this, some women will choose to remain on 
therapeutic-dose LMWH throughout pregnancy. The management 
of anticoagulants during pregnancy in women with MHVs is summarized in Figure 21. 
12.5.3.2.2. Mechanical valve thrombosis. Regular maternal cardiac 
ultrasound should be performed during pregnancy to assess valve function and rule out valve thrombosis. Imaging once per trimester will usually suffice unless there is pre-existing valve dysfunction or HF. Changes 
in valve gradient that exceed the usual increase due to changing cardiac 
output should be investigated. Symptoms such as new HF, embolic 
event, or syncope need urgent assessment. Changes in valve clicks 
and new murmurs should also trigger investigation. Transthoracic and 
transoesophageal echocardiography, fluoroscopy, and CT can all be 
used to assess MHV leaflet movement. 
Valve thrombosis has a high maternal mortality. Its management is 
comparable with management in non-pregnant women. In a subacute 
setting, optimizing anticoagulation with UFH and re-establishing a 
therapeutic INR with VKA may be sufficient. Thrombolysis may be considered, especially in non-critically ill women, when surgery is not immediately available for critically ill women, and in right-sided prosthetic 
valve thrombosis.698 Urgent intervention is often required in acute 
thrombosis with obstruction or severe regurgitation.722 This is associated with high maternal and foetal risks. There is a clear survival benefit for the foetus without increasing maternal mortality if cardiac 
surgery is performed after caesarean section. Therefore, the optimal 
treatment strategy, as determined by the Pregnancy Heart Team, will 
depend on type of valve involved, haemodynamic stability of the 
mother, and gestational age.421 
12.5.3.2.3. Anticoagulation during delivery in women with mechanical heart valves. The management of delivery for women with 
MHV is discussed in Section 4.5.6. These are high-risk deliveries with significant bleeding complications. 
Recommendation Table 19 — Recommendations for prosthetic valves and pregnancy (see Evidence Table 18) 
Recommendations 
Classa 
Levelb  
A bioprosthetic valve is recommended (over a mechanical valve) in young women contemplating pregnancy requiring a valve prosthesis.177 
I 
B 
It is recommended that the type of valve surgery or intervention for a woman contemplating pregnancy is chosen in consultation with the 
Pregnancy Heart Team. 
I 
C 
Women with mechanical heart valves 
It is recommended that a care plan documenting the agreed anticoagulant strategy (including the decision to continue VKAs or converting to 
therapeutic-dose LMWH in the first trimester) is in place for women of childbearing age with an MHV prior to pregnancy or as soon as 
pregnancy is recognized.170 
I 
C 
It is recommended that pregnant women with an MHV are managed by the Pregnancy Heart Team.170 
I 
C 
In pregnant women on VKAs, it is recommended to perform INR monitoring weekly or at a minimum every 2 weeks. 
I 
C 
In pregnant women with MHVs on therapeutic-dose LMWH, it is recommended to check peak anti-factor Xa levels and to target levels 
according to individualized risk. 
I 
C 
During the second and third trimesters until the 36th week, continuing VKAs should be considered in women with prosthetic heart valves at 
higher risk of thrombosis. 
IIa 
C 
During the second and third trimesters, continuing LMWH with anti-factor Xa level monitoring and dose adjustment may be considered in 
women at lower risk of thrombosis. 
IIb 
C 
LMWH is not recommended when anti-factor Xa level monitoring is not available. 
III 
C 
© ESC 2025
INR, international normalized ratio; LMWH, low-molecular-weight heparin; MHV, mechanical heart valve; VKA, vitamin K antagonist. 
aClass of recommendation. 
bLevel of evidence.   
ESC Guidelines                                                                                                                                                                                               73


<!-- PAGE 74 -->

### Page 74

Management of pregnant women with mechanical heart valves by the Pregnancy Heart Team (Class I) 
Good control of anticoagulation with therapeutic INRs
Pregnancy Heart Team decision taking into account: 
Counsel that pregnancy risks are very high 
Discuss pregnancy alternatives
Dose-adjusted LMWH
Continue VKA
Continuous i.v. UFH
(rarely used) 
• No high-risk of valve 
 thrombosis (See box below)
• High dose VKA
• Availability of 
 anti-factor Xa testing
• High risk of valve thrombosis 
 (See box below)
• VKA dosea
• Maternal choice
• High-risk of valve 
 thrombosis (See box below)
• Only if high VKA dose and/or 
 no anti-factor Xa testing 
 available
Pregnancy Heart Team decision taking into account: 
VKA
(usual care)
Second/third trimester
First trimester (risk of embryopathy)
High risk of valve thrombosis
VKA, if higher risk of valve thrombosis
(Class IIa)
Right sided valves
Mitral valve replacement
Atrial ﬁbrillation
Poor LV function
Previous thrombotic events
Valve dysfunction especially 
stenosis
Other clotting risks (smoker)
Older generation valves 
• High risk of valve thrombosis (See box below)
• Maternal choice
Dose-adjusted LMWH, if
(Class IIb)
• Lower risk of valve thrombosis
• Availability of anti-factor Xa testing
• High-risk of valve thrombosis (See box below)
Last 2 weeks of pregnancy and deliveryb
Figure 21 Management of anticoagulants during the different stages of pregnancy in women with mechanical heart valves. INR, international normalized 
ratio; i.v., intravenous; LMWH, low-molecular-weight heparin; LV, left ventricle; N, no; UFH, unfractionated heparin; VKA, vitamin K antagonist; Y, yes. aSee  
Table 10. bSee Figure 5 and Section 4.5.7.


<!-- PAGE 75 -->

### Page 75

12.5.4. Endocarditis prophylaxis 
Infective endocarditis during pregnancy is a rare yet severe event associated with maternal and foetal morbidity and mortality. An increasing risk factor is represented by i.v. drug abuse associated with the 
opioid epidemic in the United States of America.723 The most common pathogens are Staphylococcus (74%) and Serratia (13%).724 A recent comparison across antepartum, delivery, and post-partum 
maternity-associated infective endocarditis showed the 60-day mortality rate was highest in the delivery subgroup and the rate of valve 
replacements was highest in post-partum cases.725 Antibiotics should 
be given according to guidelines,178,726 laboratory data on culture and 
antibiotic sensitivity, and the differential foetal toxicity of antibiotics 
(see Section 5). 
12.6. Heart failure 
12.6.1. Chronic heart failure 
Heart failure complicates 11% of pregnancies in women with pre-existing 
heart disease and has an in-hospital maternal mortality rate of 9%.2 
Specific pre-pregnancy counselling is needed for women with ventricular 
dysfunction irrespective of the cause. As many HF medications are contraindicated in pregnancy (see Section 5), modifying the drug regimen pre- 
pregnancy should be part of pregnancy risk stratification, with reassessment 
after at least 3 months.727 Contractile reserve off HF therapy, measured by 
stress echocardiography, can be used for reassessing ventricular function.371 
Two peaks of HF deterioration occur in pregnancy: at 23–30 weeks and 
peri-delivery.182 Pre-conception counselling should include a discussion of 
management if there is a clinical deterioration during the first peak. Early delivery due to maternal cardiac deterioration will impact foetal outcomes. 
Patients with mild ventricular dysfunction may tolerate pregnancy with 
no increase in symptoms. However, those with worse than mild ventricular dysfunction (mWHO 2.0 class >II) (Table 6) require expert care from 
the Pregnancy Heart Team, with additional input from the advanced HF 
team including transplant and mechanical circulatory support experts. 
Women with pre-existing severe HF (LVEF <30%, mWHO 2.0 class 
IV) are at high risk of maternal morbidity and mortality and account for 
up to 15% of maternal deaths globally.2,728 
Assessment of patients with pre-existing HF includes regular assessment of symptoms, echocardiography, and NP at intervals determined 
by the severity of HF and other non-cardiac issues. 
12.6.2. Acute heart failure (including cardiogenic shock) 
Acute heart failure can develop in women without pre-existing heart 
disease as can be the case in PPCM (Section 7), or secondary in women 
with known cardiac disease such as cardiomyopathy, ischaemic heart 
disease, ACHD, and severe VHD. The diagnosis can be challenging because the symptoms and signs of AHF can be misinterpreted as changes 
due to pregnancy (Figure 22).349,729 Pregnant women presenting with 
AHF require urgent hospital admission. These patients should be referred to an expert centre with established advanced HF care, including 
on-site surgery and mechanical circulatory support or even a transplant 
programme as backup. 
In case of cardiogenic shock, recommended inotropic agents include levosimendan,730 dobutamine, and milrinone (Figure 22). Levosimendan is 
administered as a continuous infusion without an initial loading dose. 
Dobutamine is an option, whereas adrenaline should be avoided. 
Milrinone may be an alternative if benefits outweigh the risk, due to 
placental transfer (see Supplementary data online, Table S2). Mechanical 
circulatory support [preferably veno-arterial extracorporeal membrane 
oxygenation (VA-ECMO)731] should be considered in case of severe 
refractory cardiogenic shock.339 In cardiogenic shock, urgent delivery by 
caesarean section with combined spinal/epidural analgesia or general anaesthesia is recommended.732–734 
Milder cases of acute HF can be treated with oral diuretics, 
b1-selective beta-blockers (bisoprolol, metoprolol succinate), hydralazine, and oral nitrates. Diuretics (loop diuretics and thiazides if required) should be used with caution due to a potential reduction in 
uterine blood flow, but may be necessary in pulmonary congestion 
or echocardiographic signs of high LV end-diastolic pressure.732 
Recommendation Table 20 — Recommendations for 
chronic and acute heart failure and pregnancy (see  
Evidence Table 19) 
Chronic heart failure 
Classa 
Levelb  
It is recommended that women with HFrEF are 
advised about the risk of deterioration of cardiac 
function during pregnancy and peripartum.34 
I 
C 
In pregnant women with HFrEF, it is recommended 
that non-selective beta-blockers are switched to 
beta-1-selective blockers (metoprolol, bisoprolol) 
with close maternal and foetal 
monitoring.733,734,738,739 
I 
C 
Anticoagulation with therapeutic doses of LMWH is 
recommended in pregnant women with intracardiac 
thrombus or decreased LV function with EF <35%.216 
I 
C 
It is recommended to optimize HF guideline-directed 
medical therapy after delivery, taking contraindicated 
drugs during lactation into accountc.339,734 
I 
C 
Due to the high metabolic demands of lactation, 
avoiding lactation may be considered in women with 
severe HF.360,733 
IIb 
C 
ACE-Is, ARBs, ARNIs, MRAs, ivabradine, and SGLT2 
inhibitors are not recommended during pregnancy 
due to adverse foetal effects. 
III 
C 
Acute heart failure 
Inotropes and/or vasopressors are recommended in 
pregnant women with cardiogenic shock with 
levosimendan, dobutamine, and milrinone as 
recommended agents.730 
I 
C 
Urgent delivery with caesarean section is 
recommended in pregnant women with cardiogenic 
shock as soon as the foetus is viable, taking 
gestational age, comorbidities, and the available level 
of medical care into account.689 
I 
C 
Early transfer of pregnant women in cardiogenic 
shock to a facility providing mechanical circulatory 
support should be considered.345,740 
IIa 
C 
Preventing lactation may be considered in women 
with severe HF due to the high metabolic demands of 
lactation.360 
IIb 
B 
© ESC 2025
ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, 
angiotensin receptor/neprilysin inhibitor; EF, ejection fraction; HF, heart failure; HFrEF, heart 
failure with reduced ejection fraction; LMWH, low-molecular-weight heparin; LV, left ventricle; 
MRA, mineralocorticoid receptor antagonist; SGLT2, sodium–glucose co-transporter-2. 
aClass of recommendation. 
bLevel of evidence. 
cSee Figure 6 and Supplementary data online, Table S2.   
ESC Guidelines                                                                                                                                                                                               75


<!-- PAGE 76 -->

### Page 76

Management of acute heart failure and cardiogenic shock in pregnancy and up to 6 months post-partum
Assess HF severitya
Delivered
Preload optimization: 
volume versus diuretics
-initiate nitrates if
SBP >110 mmHg
Severe HF or cardiogenic shock
No severe HF or cardiogenic shock
Oxygen optimization:
non-invasive mechanical 
ventilation 
or invasive ventilation,
if SpO2 <95%
Add inotropes and/or vasopressors; 
levosimendan without loading dose,
dobutamine or 
milrinone
(Class I)
Urgent delivery by caesarean section in case of cardiogenic shock
(Class I)
If delivered:
Bromocriptineb
(Class IIb)
In PPCM
Anticoagulant therapy
(heparin/LMWH) to reduce thromboembolic events if bromocriptine is used
(Class IIa) 
MCS (preferably VA-ECMO or LVAD), in accordance with local availability and team experience;
‘bridge-to-recovery’ or as ‘bridge-to-bridge’ in case of refractory cardiogenic shock.
ACE-I, ARB,
ARNI,
beta-blocker,
MRA,
SGLT2-I,
diuretic
(Class I)
Ivabradine
Hydralazine,
nitrate,
beta-blocker,
(bisoprolol,
metoprolol succinate),
diuretic 
ACE-I, ARB,
ARNI, MRA
 ivabradine,
and SGLT2-I
(Class III)
Consider 
vaginal delivery with epidural analgesia
(Class I)
No recovery
Heart transplantation
Consider corticosteroids for foetal lung maturation if  <35 weeks of gestation 
Figure 22 Management of acute heart failure and cardiogenic shock in pregnancy and up to 6 months post-partum. ACE-I, angiotensin-converting enzyme 
inhibitors; ARB, angiotensin receptor blockers; ARNI, angiotensin receptor/neprilysin inhibitor; b.p.m., beats per minute; HF, heart failure; HR, heart rate; 
LMWH, low-molecular-weight heparin; LVAD, left ventricular assist device; MCS, mechanical circulatory support; MRA, mineralocorticoid receptor antagonist; PPCM, peripartum cardiomyopathy; SGLT2-I, sodium–glucose co-transporter-2 inhibitor; SBP, systolic blood pressure; SpO2, oxygen saturation; 
VA-ECMO, veno-arterial extracorporeal membrane oxygenation. aAssessment of heart failure severity: SBP <90 mmHg; HR >130 b.p.m. or <45 b.p.m.; 
respiratory rate >25/min; SpO2 <90%; Blood lactate >2.0 mmol/L; low central–venous oxygen saturation <60% (if available); altered mental state; cold, 
clammy, mottled skin; oliguria <0.5 mL/kg/h. bBromocriptine: starting dose 2.5 mg twice daily with up-titration if needed.


<!-- PAGE 77 -->

### Page 77

Beta-blockers should be initiated and gradually up-titrated to the maximum tolerated dose.345,357,732–734 ACE-Is, ARBs, ARNIs, MRAs, ivabradine, SGLT2 inhibitors, and atenolol are contraindicated during 
pregnancy due to adverse effects on the foetus. Hydralazine and nitrates appear safe.43,345,357,733,734 
In the post-partum period, the use of ivabradine to control the heart 
rate may be considered in addition to beta-blockers, or if there is a 
contraindication for beta-blockers.43,339,735,736 In HF with a reversible 
cause, HF treatment in accordance with guidelines should be recommended for at least 12 months after full LV recovery, followed by gradual tapering350 (see also Section 7). Women with pregnancy-associated 
HF should be counselled about the risks of recurrence in subsequent 
pregnancies.737 
12.7. Special populations 
12.7.1. Heart transplantation 
Successful pregnancies have been reported in women with heart 
transplantation, but these pregnancies carry a higher risk. Before 
transplantation and before a post-transplantation pregnancy, women should be counselled about maternal and foetal risks, including the risks of rejection, infection, graft dysfunction, and potential 
teratogenicity of drugs. Based on the individual risk factors, it is 
recommended to postpone pregnancy until at least 1 year after 
transplantation.275 Women with heart transplantation are at 
higher risk of experiencing cardiometabolic complications during 
pregnancy such as pre-eclampsia, gestational diabetes, hypertension, decreased kidney function, and infections.741–745 The risk 
of complications is lower in women with normal graft function 
and no signs of rejection. Pre-pregnancy evaluation should include 
standard assessments and, if clinically indicated, coronary angiography, right-heart catheterization, and endomyocardial biopsy.741–745 
All drugs should be reviewed before pregnancy275 and mycophenolic acid therapy275,741 should be avoided due to the teratogenic risk. In 
cases where the father has the same human leucocyte antigen (HLA) 
as the donated heart, there is a risk of developing donor-specific antibodies.746,747 Therefore, consideration should be given to performing 
paternal HLA testing before conception. 
During pregnancy, changes in maternal metabolism can affect the 
serum drug levels of immunosuppression therapy.748 Close monitoring 
of serum drug levels is recommended.275 Echocardiographic evaluations are recommended to assess graft function during pregnancy. 
Foetal growth should be regularly evaluated due to the risk of lower 
birth weight.745 Vaginal delivery should be considered in stable 
patients.745 
Close monitoring of cardiac function, immunosuppression, 
and donor-specific antibodies is necessary until 6–12 months after 
delivery due to the risk of post-pregnancy rejection.275,741,749–751 
Lactation may be possible in patients on immunosuppressive drugs, 
depending on the type of medication (see Section 5.2.10). 
12.7.2. Cardio-oncology 
12.7.2.1 Gestational cancer 
Gestational cancer is defined as cancer that occurs during pregnancy or 
within 12 months after delivery. The occurrence is ∼1 in 1000 pregnancies, with a possible rise in incidence as maternal childbearing age increases. The most frequent cancers affecting pregnant women are 
breast cancer, cervical and ovarian cancer, lymphoma, leukaemia, colorectal cancer, and melanoma.752–754 Women diagnosed with cancer 
during pregnancy should be evaluated and considered by a multidisciplinary team. Both the effect of pregnancy on the cancer and the effect of 
the cancer on the pregnancy should be evaluated. Patients should be 
followed in centres with neonatal units in case of premature delivery. 
The baseline assessment prior to chemotherapy, and the monthly or 
bimonthly follow-up during chemotherapy, should include clinical history, 
physical examination, ECG, cardiac biomarkers, and TTE in the context of 
physiological haemodynamic changes during pregnancy.107,755,756 LVEF, 
NP serial measurements,756 and high-sensitivity cTn can be used for monitoring of cancer-therapy-related cardiac dysfunction (CTRCD).734,756 
Chemotherapy given during the first trimester is associated with a high 
risk of malformation (up to 20%) and miscarriage. Chemotherapy is often 
avoided after 34 weeks of gestation to provide a ≥3 week window between the last chemotherapy and delivery. Cytotoxic chemotherapies 
provide different risk profiles during the second and third trimesters.752,754 
The suggested chemotherapy treatments for pregnant women with cancer are summarized in the 2022 ESC Guidelines on cardio-oncology.757 
Recommendation Table 21 — Recommendations for 
heart transplantation and pregnancy 
Recommendations 
Classa 
Levelb  
It is recommended to postpone pregnancy until at 
least 1 year after heart transplantation, taking 
individual risk factors into account.275,741 
I 
C 
In women with a heart transplant, it is recommended 
that immunosuppression serum drug levels are 
monitored during pregnancy every 4 weeks until the 
32nd week, then every 2 weeks until the 36th week, 
then weekly until delivery, and for 6–12 months after 
delivery to guide dosing.275 
I 
C 
It is recommended to perform weekly monitoring of 
donor-specific antibodies for at least 6–12 months 
after delivery.275,741,749–751 
I 
C 
Paternal HLA testing prior to conception should be 
considered due to the risk of developing 
donor-specific antibodies.746,747 
IIa 
C 
Mycophenolic acid therapy is not recommended in 
pregnancy and should be discontinued 6 weeks 
before conception.275,741 
III 
C 
© ESC 2025
HLA, human leucocyte antigen. 
aClass of recommendation. 
bLevel of evidence.   
ESC Guidelines                                                                                                                                                                                               77


<!-- PAGE 78 -->

### Page 78

###### 12.7.2.2 Pregnancy in cancer survivors

Improved cancer treatments have led to an increased number of women with pregnancies after oncological therapy. Previous treatment 
with anthracycline chemotherapy or chest radiotherapy implies a 
15-fold increased lifetime risk of developing HF. Furthermore, both 
the cancer and the cancer treatment have an impact on fertility, pregnancy outcomes, and cardiovascular health. The major risk factors for 
cardiovascular events during pregnancy in cancer survivors include 
CTRCD (28%; 47.4 times higher odds), younger age at cancer diagnosis,758,759 higher cumulative doses of anthracycline, and greater duration between cancer treatment and first pregnancy.758,759 
13. Adverse pregnancy outcomes 
and long-term management 
Adverse pregnancy outcomes (APO), including gestational hypertensive disorders, pre-eclampsia, gestational diabetes mellitus (GDM), 
small or large for gestational age babies, or pre-term birth are a group 
of interrelated disorders that share common pathways.760 Placental 
dysfunction and oxidative stress in the context of cardiometabolic, genetic, or environmental risk factors may cause APOs.761 A multidisciplinary care approach is essential (Figure 23)761,762 for optimizing 
modifiable cardiovascular risk factors after all APOs.761,762 
13.1. Adverse pregnancy outcomes 
13.1.1. Post-partum hypertensive disorders 
Hypertension in the post-partum period is most common in women 
with antenatal hypertensive disorders, but it can also develop de novo 
in the post-partum period. New-onset or de novo post-partum pre- 
eclampsia is increasingly recognized as an important contributor to maternal morbidity and mortality in the post-partum period (Figure 24).763 
Women with pregnancy-related hypertensive disorders, most notably pre-eclampsia, have a higher incidence of several CVDs, including 
CAD, stroke, and HF.762,764 Treatment for uncomplicated post-partum 
hypertension (first 6 weeks after delivery) includes nifedipine and labetalol (metoprolol if labetalol is unavailable).764 A small randomized controlled trial showed that administration of furosemide in the first 5 days 
post-partum in women with gestational hypertension and pre- 
eclampsia significantly reduced the prevalence of persistently elevated 
BP at 7 days.765 Methyldopa should be avoided because of the risk of 
post-partum depression.602,766 Agents used for the management of 
acute, severe hypertension in the post-partum period are similar to 
those used during pregnancy and include labetalol, hydralazine, and nifedipine (see Sections 5 and 12).767 For women with persistent hypertension, antihypertensive therapy should be initiated with reference to 
lactating status following current guidelines (see Section 5).584,585,767 
13.1.2. Gestational diabetes mellitus 
Gestational diabetes mellitus is characterized by glucose intolerance 
that is first recognized during pregnancy.768 Haemoglobin A1c testing 
may help to identify women at high risk.768,769 Women with GDM 
have a sharply increased risk of developing type 2 diabetes later in life 
and a significantly higher likelihood of experiencing adverse cardiovascular events.770–772 Women with GDM are recommended to undergo 
a formal oral glucose tolerance test (oGTT) 6–12 weeks post-partum 
with a repeat assessment at 6–12 months (Figure 25). Thereafter, regular annual follow-up with glucose tolerance monitoring is recommended.773–775 
13.1.3. Pre-term birth 
Pre-term delivery occurs after 20 and before the completion of 37 
weeks of gestation, regardless of birth weight. There are strong associations between pre-term delivery (alone or with pregnancy-related 
hypertensive disorders), CVD, and mortality.771,772 Women with pre- 
term deliveries are more likely to have an increasing BP trajectory after 
pregnancy and to be affected by accelerated atherosclerosis independent of traditional CVD risk factors.776,777 The earlier pre-term delivery 
occurs, the more strongly it is associated with hypertension and CVD in 
later life. The relationship of pre-term birth to type 2 diabetes mellitus 
and dyslipidaemia is inconsistent. 
13.1.4. Small for gestational age 
Delivering a SGA baby (weight <10th percentile) has not been consistently related to an increased CVD risk, but has been associated with 
hypertension and diabetes.761,771,772 Conversely, large for gestational 
age babies (weight >90th percentile) have been reported to increase 
maternal CVD risk, but the evidence is limited.761 
13.1.5. Pregnancy loss and placental abruption 
Placental abruption, spontaneous pregnancy loss or stillbirth, and foetal 
loss after 28 weeks of gestation have been associated with an increased 
risk of future CVD, with a particularly high risk of hypertension and type 
2 diabetes mellitus.771,778 One or more terminations are associated 
with a higher CVD risk, however, with limited evidence.779 
13.2. Breastfeeding 
Breastfeeding fosters the recovery of maternal physiological systems to their 
pre-conception state. Breastfeeding women have a better cardiometabolic 
profile, and breastfeeding up to 12 months after childbirth has been shown 
to lower future risk of CVD and mortality,780–783 potentially due to lowered 
BP.784–787 Longer breastfeeding periods are associated with better CVD outcomes.782,784,788–790 The role of breastfeeding for women who experienced 
an APO is less clear, but it also appears to have beneficial effects.789,791,792 
There is inconclusive evidence about the beneficial effects of breastfeeding 
on the cardiovascular health of older women (i.e. aged ≥55 years).720,788,793,794 
Recommendation Table 22 — Recommendations for 
cardio-oncology and pregnancy 
Recommendations 
Classa 
Levelb  
It is recommended that pregnant women with cancer 
who require cardiotoxic cancer therapy are jointly 
managed by the Pregnancy Heart Team and the 
cardio-oncology team.43 
I 
C 
Cardiac troponin and NP measurements may be 
considered at baseline and during anthracycline 
chemotherapy in pregnant women with 
cancer.734,756 
IIb 
C 
© ESC 2025
NP, natriuretic peptide. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 79 -->

### Page 79

13.3. Women’s Heart Clinics 
Post-partum care is often segmented and only carried out by obstetricians. A longer duration of post-partum care, including cardiovascular risk assessment and counselling on CVD risk prevention, 
is likely to lower the long-term risk of CVD in women with an 
APO (Figure 25).762,795 Pregnancy Heart Teams and the potential 
establishment of Women’s Heart Clinics focusing on women of all 
ages with CVD are necessary to span the care up to post-partum.795 
Seamless communication between the various healthcare providers 
(e.g. obstetrician, cardiologist, internist, family physician) and multidisciplinary management of APOs is critical for long-term care and 
the woman’s future health.761,796,797 







	












	

	




















	 


Figure 23 Multidisciplinary approach of adverse pregnancy outcomes. CAD, coronary artery disease; CVD, cardiovascular disease. aSee Section 13.3 on 
Women’s Heart Clinics.   
ESC Guidelines                                                                                                                                                                                               79


<!-- PAGE 80 -->

### Page 80









	






	







	










	




	
 ­
≥

	









	





Figure 24 Algorithm for the management of new-onset post-partum hypertension. BP, blood pressure.  




	










	

	
	


		
 


­



	
	


		

	
Figure 25 Algorithm for the management of adverse pregnancy outcomes. CVD, cardiovascular disease.


<!-- PAGE 81 -->

### Page 81

### 14 Key messages

• A Pregnancy Heart Team should be involved in the risk assessment, counselling and management of women in mWHO 2.0 
class ≥II–III from pre-conception to the late post-partum. 
Each woman should have a detailed delivery plan agreed in 
advance. 
• In women with known CVD, a complete clinical re-evaluation 
should take place pre-pregnancy to estimate risk, optimize treatment, consider and evaluate the removal of contraindicated drugs, 
and reduce the probability of complications. 
• Women and their partner (if any) should be offered structured 
psychosocial support during the entire trajectory, especially 
for those at high risk and those considering pregnancy 
termination. 
• Women with known heritable cardiovascular disorders should be 
counselled about the transmission risk, including the option for assisted reproductive technology. 
• Management of women with CVD who are pregnant or wishing 
to become pregnant should be individualized and performed according to a shared decision-making model, respecting the woman’s 
autonomy. 
• Women in mWHO 2.0 class IV should be comprehensively 
counselled about the very high pregnancy risk, being careful 
to promote a detailed and transparent dialogue about the 
heightened maternal and foetal risks associated with pregnancy. 
A shared decision-making process is essential, allowing for informed choices, including the consideration of pregnancy termination if necessary. 
• Vaginal delivery is the first choice for the majority of women with 
CVD. 
• In a life-threatening situation, treatments such as defibrillation, interventions, acute coronary revascularization, mechanical circulatory support, and medication should be the same as in 
non-pregnant women, irrespective of contraindications. 
• The use of non-invasive imaging tests with ionizing radiation during 
pregnancy should only be performed when the benefits clearly outweigh the maternal and foetal risk, and if the result will significantly 
modify the medical management. 
• In women with LQTS and CPVT, the continuation of beta-blockers 
throughout pregnancy with monitoring of foetal growth is recommended (atenolol is the only contraindicated beta-blocker). 
Beta-blockers of choice are propranolol and nadolol. 
• In women with LQT2, post-partum is a distinct high-risk period, 
and therefore full dosage of beta-blockers is strongly recommended. 
• Genetic testing should be considered in PPCM. 
• In women with PPCM and DCM, subsequent pregnancy is not recommended if LV function does not normalize. 
• Genetic testing in women with aortic disease wishing to conceive is 
recommended and management should be based on the presence 
and type of P/LP variant. 
• Women with the following ACHD lesions should be provided with 
expert counselling and education by a Pregnancy Heart Team, with 
clear and thorough discussion of the very high pregnancy risk and 
the need for a shared decision-making process: 
⚬Systemic RV, in NYHA class III–IV, ventricular dysfunction 
(EF <40%), more than moderate TR, or treated HF; 
⚬A Fontan circulation and oxygen saturation <85%, reduced ventricular function, severe arrhythmias, or in NYHA class III–IV. 
• There is no safe cut-off value for elevated pulmonary artery pressure in pregnancy. 
Recommendation Table 23 — Recommendations for long-term effects of adverse pregnancy outcomes (see Evidence 
Tables 20 and 21) 
Recommendations 
Classa 
Levelb  
It is recommended to undertake a cardiovascular risk assessment in women with APOs, to recognize and document APOs when CVD risk is 
evaluated in women, and to provide counselling on the importance of healthy lifestyle choices that optimize cardiovascular health.771,772 
I 
B 
In women with persistent post-partum hypertension beyond 6 weeks to 3 months post-partum, initiation of antihypertensive therapy with 
reference to lactating status is recommended following current guidelines.584,602,798 
I 
B 
In cases where adoption of healthy lifestyle choices alone is inadequate to control post-partum glucose levels, initiation of pharmacotherapy 
following current guidelines is recommended.773,774,799 
I 
C 
It is recommended that women with a history of GDM undergo a formal oGTT 6–12 weeks post-partum with a repeat assessment at 6–12 
months and regular annual follow-up visits to screen for diabetes.773,774,800 
I 
C 
Nifedipine and labetalol (metoprolol if labetalol is unavailable) are recommended as treatments for uncomplicated post-partum 
hypertension in the first 6 weeks after delivery.602,766,767 
I 
C 
In women with a history of any APO, cardiovascular risk assessment should be considered at 3 months post-partum with repeat assessment 
at 6–12 months after implementation of appropriate lifestyle interventions, and regular long-term follow-up thereafter.761,795 
IIa 
C 
Breastfeeding may be considered in order to lower the future cardiovascular risk in women with APOs.789,791,792 
IIb 
C 
© ESC 2025
APO, adverse pregnancy outcomes; CVD, cardiovascular disease; GDM, gestational diabetes mellitus; oGTT, oral glucose tolerance test. 
aClass of recommendation. 
bLevel of evidence.   
ESC Guidelines                                                                                                                                                                                               81


<!-- PAGE 82 -->

### Page 82

• Women of childbearing potential with PAH should be counselled at 
the time of diagnosis about the risks and uncertainties associated 
with becoming pregnant. 
• Any suspicion of VTE, including DVT and PE, requires an immediate 
formal assessment with validated diagnostic tests by a multidisciplinary specialized team. 
• LMWH is the agent of choice for prophylaxis and treatment of VTE 
in pregnancy. 
• When treating women with HF during pregnancy, it should be 
noted that several drugs [ACE-Is, ARBs, direct renin inhibitors, sacubitril–valsartan (ARNIs), MRAs, and SGLT2 inhibitors] are not recommended. When inotropes or more advanced treatment is 
necessary, referral to an expert centre is recommended. 
• When possible, mechanical valves should be avoided in girls and women of childbearing age. 
• Methyldopa, labetalol, and CCBs are recommended for the treatment of hypertension in pregnancy. 
• Women at high or moderate risk of pre-eclampsia should be advised to additionally take 75–100 mg of ASA daily from weeks 12 
to 36/37. 
• After cardiac transplantation, it is recommended to postpone pregnancy for at least 1 year, taking individual risk factors into account. 
• Women with APOs should be informed about long-term risks and 
preventive strategies and offered appropriate follow-up, including 
psychosocial support (if necessary).  
15. Gaps in evidence 
Pre-pregnancy counselling and evaluation 
• Data on the adverse effects of assisted reproductive treatment in 
women with CVD are lacking. 
Diagnostic methods 
• There is a lack of data on the safety of echocardiographic contrast 
agents during pregnancy or lactation. 
• There are controversial data on the use of gadolinium-based contrast agents in pregnancy. 
• There are no clear cut-offs for NT-proBNP levels during pregnancy. 
• There are no normative values of cTnI and cTnT in pregnancy and 
the post-partum period. 
• There is a lack of data on normal lung ultrasound pattern during 
pregnancy. 
Drugs during pregnancy and lactation 
• Safety data of DOACs and antidotes (idarucizumab, andexanet alfa, 
cirapantag) in pregnancy are lacking. 
• Safety data of newer anti-arrhythmic drugs and rate-controlling 
drugs (vernakalant, ivabradine, landiolol) in pregnancy are lacking.  
Cardiomyopathy and primary arrhythmia syndromes 
• The available data on gene-specific management during pregnancy in 
different cardiomyopathies and primary arrhythmia syndromes are 
limited. 
Peripartum cardiomyopathy 
• The potential for recovery of cardiac function in PPCM remains unclear and the risks in subsequent pregnancies are not well defined. 
Aortopathies 
• More data are needed to correctly estimate the pregnancy risk in 
women with previous aortic dissection and/or aortic root surgery. 
• Risk factors for aortic dissection in the post-partum period are 
poorly understood, making counselling about this difficult. 
• It is unclear whether a distinction between root and ascending 
phenotype in women with BAV should lead to a different threshold 
for prophylactic surgery (as in non-pregnant women). 
Congenital heart disease 
• More data are needed to estimate the risk and the long-term effects 
of pregnancy (including multiple pregnancies), especially in women 
with a Fontan circulation or univentricular hearts. 
• Risk factors for the development of heart failure and arrhythmias 
in pregnant women with (systemic) right-heart failure are poorly 
understood. 
Pulmonary hypertension 
• Defining the optimal timing to start or escalate PAH therapies in 
pregnancy complicated with PAH remains challenging. 
Venous thromboembolism 
• Data on risk stratification of VTE in pregnancy are limited, specifically in those with other pre-existing comorbidities. 
• Data on the use of anticoagulant agents (other than LMWH) are 
limited, just as data on the efficacy and safety of inferior vena cava 
filters and catheter-based thrombectomy (in PE). 
Acquired heart disease 
• The foetal risks associated with the newer HF medications remain 
unclear, particularly regarding exposure during different trimesters. 
• The optimal tools to stratify risk of recurrence for atherosclerotic 
and SCAD ACS are unknown. 
• Physiopathological mechanisms of SCAD in pregnancy are 
unknown. 
• Optimal treatment of SCAD during pregnancy is not well 
established. 
• There is scarce evidence about the necessity of using statins during 
pregnancy in women with cardiovascular risk or established ASCVD. 
• Optimal anticoagulation strategies for women with MHVs during 
pregnancy remain uncertain. 
• The role of anti-factor Xa level monitoring needs to be determined. 
Women’s Heart Clinics 
• Optimal strategies for surveillance and follow-up of women with 
APOs are unclear. 
• It is unclear how social determinants of health (the environmental 
factors that affect how people live, learn, and work) affect APOs. 
• There is a need for studies exploring models of post-natal care, 
starting from the initial antenatal visit through to the end of the 
post-partum period.


<!-- PAGE 83 -->

### Page 83

• Further research is needed to identify risk factors for 
pregnancy-related depression and poor health behaviour engagement in women with CVD, enabling the development of tailored interventions to improve their health and quality of life.  
16. ‘What to do’ and ‘what not to 
do’ messages from the Guidelines 
Table 16 lists all Class I and Class III recommendations from the text 
alongside their level of evidence. 
17. Evidence tables 
Evidence tables are available at European Heart Journal 
online. 
18. Data availability statement 
No new data were generated or analysed in support of this 
research. 
Table 16 ‘What to do’ and ‘what not to do’ 
Recommendations 
Classa 
Levelb  
4. The Pregnancy Heart Team 
Counselling, pregnancy risk assessment, contraception, assisted reproductive technology, and the involvement of a Pregnancy Heart 
Team 
It is recommended to perform a risk assessment in all women with CVD of childbearing age using the mWHO 2.0 classification. 
I 
C 
A discussion by the Pregnancy Heart Team about the high risk of maternal mortality or morbidity and the related high foetal risk is 
recommended for women with mWHO 2.0 class IV conditions, including a shared decision-making process for pregnancy termination, 
involving psychological support. 
I 
C 
It is recommended that women with CVD of mWHO 2.0 class II–III and above are evaluated and managed by a Pregnancy Heart Team from 
pre-pregnancy onwards through pregnancy and post-partum. 
I 
C 
It is recommended that women with CVD of mWHO 2.0 class II and above, or those at risk of developing CVD, receive individualized advice 
to determine the most suitable contraception method, including emergency contraception. 
I 
C 
Assessment by a clinical geneticist prior to pregnancy is recommended in women fulfilling diagnostic criteria for inherited cardiovascular 
disease to guide risk stratification and pre-natal genetic testing. 
I 
C 
Pre-conception genetic counselling is recommended in couples with heritable CVD, whether genetic testing is being considered or not. It is 
recommended that this counselling is provided by an appropriately trained healthcare professional within a multidisciplinary team that offers 
psychological support and education to encourage decision-making. 
I 
C 
It is recommended that single embryo transfer is performed in women with CVD. 
I 
C 
It is recommended to offer women with CVD access to termination of pregnancy that is tailored to their cardiac condition to minimize the 
risks of the procedure. 
I 
C 
Diagnostic methods in pregnancy 
Transthoracic echocardiography is recommended as first-line imaging tool in any pregnant woman with unexplained or new cardiovascular 
signs or symptoms. 
I 
C 
It is recommended to limit exposure to all medical ionizing radiation doses to ALARA levels. 
I 
C 
It is recommended to keep the radiation dose to the foetus as low as possible (preferably <50 mGy), particularly if the foetus is in the field of 
view. 
I 
C 
Timing and mode of delivery 
Vaginal delivery is recommended in most women with CVD. 
I 
B 
Routine induction of labour prior to 39 weeks is not recommended in women with stable CVD. 
III 
C 
It is recommended that the timing of delivery is planned to ensure safe and effective peripartum anticoagulation. 
I 
C 
It is recommended to discontinue VKAs and start therapeutic-dose LMWH or adjusted-dose i.v. UFH at the 36th week of gestation or 2 
weeks before the planned delivery. 
I 
C 
In women at low risk on therapeutic-dose LMWH, neuraxial anaesthesia and vaginal delivery (or caesarean section for obstetric indications) 
is recommended 24 h after the last dose of LMWH. 
I 
C 
In women at high risk, it is recommended to convert LMWH to i.v. UFH at least 36 h prior to delivery and stop the UFH infusion 4–6 h prior 
to anticipated delivery. The aPTT should be normal before regional anaesthesia. 
I 
C 
If delivery starts while the mother is on VKAs or <2 weeks after discontinuation of VKAs, caesarean section is recommended for foetal 
protection. 
I 
C 
Post-delivery, it is recommended that the decision to restart LMWH or UFH is made after discussion with the Pregnancy Heart Team and 
the woman who gave birth. 
I 
C                       
Continued  
ESC Guidelines                                                                                                                                                                                               83


<!-- PAGE 84 -->

### Page 84

It is recommended to postpone the switch from heparin back to oral anticoagulants until 7–14 days post-partum when the wound area has 
healed, in consultation with the Pregnancy Heart Team. 
I 
C 
5. Drugs during pregnancy and lactation 
Direct oral anticoagulants and pregnancy 
DOACs are not recommended during pregnancy. 
III 
C 
6. Pregnancy in women with cardiomyopathies and primary arrhythmia syndromes 
Cardiomyopathies and pregnancy 
Clinical cardiological surveillance (ECG, echocardiogram, and Holter ECG monitoring) is recommended during pregnancy in women with 
CMPs, depending on individual risk. 
I 
C 
Vaginal delivery is recommended in most women with CMPs, unless there are obstetric indications for caesarean section, severe HF 
(EF <30% and/or NYHA class III/IV), uncontrolled arrhythmias, or severe outflow obstruction (≥50 mmHg) in women with HCM, or in 
women presenting in labour on VKAs. 
I 
C 
In women with DCM and worsening of EF during pregnancy, counselling on the risk of recurrence during a subsequent pregnancy is 
recommended in all cases, even after recovery of LV function. 
I 
C 
It is recommended to use the same risk stratification protocol for ventricular arrhythmias in pregnant women with HCM as for 
non-pregnant women with HCM. 
I 
C 
It is recommended to start beta-blockers in women with HCM who develop symptoms due to outflow tract obstruction or arrhythmia 
during pregnancy. 
I 
C 
It is recommended that women with HCM with symptomatic LV dysfunction (EF <50%) and or severe LVOTO (≥50 mmHg) wishing to 
become pregnant are counselled by the Pregnancy Heart Team regarding the high risk of pregnancy-related adverse events. 
I 
C 
Myosin inhibitors are not recommended in women during pregnancy due to lack of safety data. 
III 
C 
Primary arrhythmia syndromes and pregnancy 
Monitoring and treatment of hypokalaemia and hypomagnesaemia is recommended in pregnant women with primary arrhythmia 
syndromes suffering from hyperemesis. 
I 
C 
Beta-blockers, with pre-pregnancy dose and with nadolol and propranolol as drugs of choice, are recommended during pregnancy in 
women with LQTS. 
I 
B 
It is recommended to continue beta-blocker therapy during lactation in women with LQTS to reduce arrhythmic risk. 
I 
B 
Pre-pregnancy dose beta-blocker of nadolol or propranolol are recommended in women with LQT2, particularly in the post-partum 
period, which represents a high-risk period for life-threatening arrhythmias. 
I 
B 
Beta-blockers, with pre-pregnancy dose and with nadolol and propranolol as drugs of choice, are recommended during pregnancy and 
lactation in women with CPVT. 
I 
C 
Flecainide, in addition to beta-blockers, is recommended in women with CPVT who experience cardiac events such as syncope, VT, or 
cardiac arrest, during pregnancy. 
I 
C 
It is recommended that women with CPVT who are stable on beta-blockers (nadolol or propranolol as drugs of choice) and flecainide 
before pregnancy, continue both drugs also during pregnancy and post-partum. 
I 
C 
7. Peripartum cardiomyopathy 
Counselling for women with PPCM about the risk of recurrence during a subsequent pregnancy and about contraception is recommended 
in all cases, even after recovery of LV function (LVEF >50%). 
I 
C 
8. Pregnancy in women with aortopathies 
It is recommended that women with aortic disease have counselling about the risk of aortic dissection in pregnancy and the post-partum 
period. 
I 
C 
It is recommended that women with a history of aortic dissection or -surgery have pre-pregnancy counselling about the high risk by an 
extended Pregnancy Heart Team considering the presence and type of genetic variant, aortic morphology, growth rate, and aetiology of 
aortic dissection. 
I 
C 
It is recommended that women with vascular Ehlers–Danlos syndrome wishing to become pregnant are counselled regarding the very high 
risk of pregnancy-related adverse events by a multidisciplinary team, considering family history, genetic variant, and previous vascular events. 
I 
C 
Imaging of the entire aorta (CT or CMR) is recommended before pregnancy in women with known or suspected aortic disease. 
I 
C 
In women with aortic dilatation related to BAV, imaging (with TTE, and CMR/CT if needed) of the aortic root, ascending aorta, and 
descending aorta (to rule out coarctation) is recommended before pregnancy. 
I 
C 
In women with low-risk aortic disease (mWHO 2.0 classes II and II–III), one-time echocardiographic imaging between 20 and 30 weeks of 
gestation and imaging at 6 months post-partum is recommended. 
I 
C                         
Continued


<!-- PAGE 85 -->

### Page 85

In women with moderate to high-risk aortic disease (mWHO 2.0 classes III and IV), repeated echocardiographic imaging every 4–12 weeks 
(depending on diagnosis and severity of dilatation) is recommended during pregnancy and until 6 months post-partum. 
I 
C 
CMR (without gadolinium) imaging of the entire aorta is recommended in pregnant women at risk of or with known aortic dilatation who 
have not had recent pre-pregnancy cross-sectional imaging. 
I 
C 
It is recommended that centres managing pregnancies in women with moderate to high-risk aortic disease (mWHO 2.0 class III/IV) can 
provide cardiovascular surgery in case of peripartum adverse events. 
I 
C 
When a woman with known aortic dilatation, history of dissection, or P/LP variant associated with aortic disease becomes pregnant, strict 
and individualized BP control is recommended. 
I 
C 
Beta-blocker therapy throughout pregnancy and in the post-partum period is recommended in women with MFS and other HTADs. 
I 
C 
Celiprolol is recommended in women with vascular Ehlers–Danlos syndrome during pregnancy and lactation. 
I 
C 
It is recommended that indications for pre-pregnancy aortic root and/or ascending aortic surgery are guided by aortic morphology, 
underlying pathology, family history, genetic variant, previous vascular events, and patient’s preference. 
I 
C 
In women with MFS and aortic root diameters >45 mm, surgery before pregnancy is recommended. 
I 
C 
In women with LDS with P/LP variants in TGFBR1, TGFBR2, and aortic root diameters ≥45 mm, surgery before pregnancy is recommended. 
I 
C 
In women with nsHTAD with P/LP variants in MYH11, ACTA2, PRKG1, or MYLK, and aortic root diameters ≥45 mm, surgery before 
pregnancy is recommended. 
I 
C 
In women with BAV and aortic root or ascending aortic diameter ≥50 mm, surgery before pregnancy is recommended. 
I 
C 
In women without an identifiable P/LP variant with aortic root or ascending aortic diameters ≥50 mm, surgery before pregnancy is 
recommended. 
I 
C 
In women with an aorta <40 mm, vaginal delivery is recommended. 
I 
C 
In women with vascular Ehlers–Danlos syndrome, caesarean section at 37 weeks is recommended for obstetrical reasons. 
I 
C 
The use of ergometrine post-delivery is not recommended in women with aortopathy. 
III 
C 
9. Pregnancy in women with known congenital heart disease 
Vaginal delivery is recommended in most women with ACHD. 
I 
B 
It is recommended that all women with Fontan circulation who wish to become pregnant receive counselling from the Pregnancy Heart 
Team regarding the high risk of pregnancy-related adverse events. 
I 
C 
It is recommended that women with a systemic RV (Mustard/Senning or congenitally corrected TGA), in NYHA class III/IV, systemic 
ventricular dysfunction (EF <40%), or severe TR wishing to become pregnant are counselled by the Pregnancy Heart Team regarding the 
high risk of pregnancy-related adverse events. 
I 
C 
In women with significant haemodynamic lesions, discussion about guideline-directed interventions is recommended prior to pregnancy. 
I 
C 
10. Pregnancy in women with pulmonary arterial hypertension 
It is recommended that women of childbearing potential with PAH wishing to become pregnant are counselled by a multidisciplinary team 
regarding the very high risk of pregnancy-related adverse events, encouraging a shared decision-making process about whether to become 
pregnant. 
I 
C 
It is recommended to provide clear contraceptive advice to women of childbearing potential with PAH. 
I 
C 
For women with PAH requiring pregnancy termination, it is recommended to perform this in PH centres. 
I 
C 
Endothelin receptor antagonists, riociguat, and selexipag are not recommended during pregnancy. 
III 
C 
11. Venous thromboembolism in pregnancy and post-partum 
For pregnant or post-partum women at high risk of VTE, a prophylactic fixed dose of LMWH is recommended over a higher 
weight-adjusted dose to reduce the risk of VTE. 
I 
B 
In pregnant women or women in the post-partum period with suspicion of VTE (DVT and/or PE), an immediate formal diagnostic 
assessment with validated methods is recommended and should not be postponed. 
I 
B 
In pregnant women or women in the post-partum period with newly diagnosed VTE (DVT and/or PE), the involvement of the Pregnancy 
Heart Team, including a vascular specialist and a haematologist, is recommended. 
I 
C 
In pregnant or post-partum women with a diagnosis of VTE without haemodynamic instability, anticoagulation is recommended by using 
therapeutic-dose LMWH based on early pregnancy body weight. 
I 
C 
12. Pregnancy in women with acquired heart disease 
Coronary artery disease and pregnancy 
In pregnant women with chest pain, it is recommended to exclude life-threatening cardiovascular conditions, including PE, ACS (including 
SCAD), and acute aortic syndrome. 
I 
C                       
Continued  
ESC Guidelines                                                                                                                                                                                               85


<!-- PAGE 86 -->

### Page 86

It is recommended to manage pregnant women with ACS in the same way as non-pregnant women, including diagnostic investigations and 
interventions. 
I 
C 
Low-dose ASA is recommended as the antiplatelet treatment of choice during pregnancy and lactation when single antiplatelet treatment is 
indicated. 
I 
B 
If DAPT is required, clopidogrel is recommended as the P2Y12 inhibitor of choice during pregnancy. 
I 
C 
The duration of DAPT (aspirin and clopidogrel) in pregnant women undergoing coronary stent implantation is recommended to be the 
same as in non-pregnant women, with an individual approach considering ischaemic risk and delivery-related bleeding risks. 
I 
C 
Hypertensive disorders and pregnancy 
It is recommended to aim for systolic BP <140 mmHg and diastolic BP <90 mmHg in pregnant women. 
I 
B 
Systolic BP ≥160 mmHg or diastolic BP ≥110 mmHg in a pregnant woman is an emergency, and treatment in a hospital setting is 
recommended. 
I 
C 
Low-dose aspirin (75–150 mg daily) is recommended in women at moderate or high risk of pre-eclampsia (i.e. at least one high risk factor or 
two moderate risk factors for pre-eclampsia) from weeks 12 to 36/37. 
I 
A 
In women with gestational hypertension, initiation of drug treatment is recommended at systolic BP ≥140 mmHg or diastolic 
BP ≥90 mmHg. 
I 
B 
Methyldopa is recommended for the treatment of hypertension in pregnancy. 
I 
B 
Labetalol, metoprolol, and dihydropyridine calcium channel blockers are recommended for the treatment of hypertension in pregnancy. 
I 
C 
In severe hypertension, drug treatment with i.v. labetalol, urapidil, nicardipine, or oral short-acting nifedipine or methyldopa is 
recommended for acute reduction in blood pressure. Intravenous hydralazine is a second-line option. 
I 
C 
In pre-eclampsia associated with pulmonary oedema, nitroglycerine given as an i.v. infusion is recommended. 
I 
C 
In women with pre-eclampsia without severe features, delivery is recommended at 37 weeks. 
I 
B 
It is recommended to expedite delivery in women with pre-eclampsia associated with adverse markers such as haemostatic disorders. 
I 
C 
In women with gestational hypertension, delivery is recommended at 39 weeks. 
I 
B 
Supraventricular tachycardia and pregnancy 
Immediate electrical cardioversion is recommended for acute treatment of SVT with haemodynamic instability. 
I 
C 
Vagal manoeuvres and i.v. adenosine are recommended for conversion of haemodynamically stable supraventricular tachycardias. 
I 
C 
Intravenous beta-blockers (metoprolol) are recommended as the first-line option for acute rate control in pregnant women with AF or AF 
with preserved LVEF and rapid ventricular rate. 
I 
C 
Therapeutic anticoagulation with LMWH is recommended for pregnant women with persistent or permanent AF at elevated 
thromboembolic risk. 
I 
C 
Beta-1-selective blockers are recommended for rate control in pregnant women with AF, AFL, or FAT. 
I 
C 
Beta-1-selective blockers or verapamil are recommended for the prevention of SVT in women without pre-excitation on resting ECG. 
I 
C 
Flecainide or propafenone are recommended for the prevention of arrhythmias in pregnant women with WPW syndrome. 
I 
C 
Ventricular tachycardia, device implantation, catheter ablation, and pregnancy 
Immediate electrical cardioversion is recommended for both unstable and stable ventricular tachycardias. 
I 
C 
Beta-blockers or verapamil are recommended for the prevention of idiopathic sustained VT. 
I 
C 
If an ICD, pacemaker, or resynchronization therapy device is indicated during pregnancy, implantation is recommended with optimal 
radiation protection. 
I 
C 
Cardiac arrest and pregnancy 
Continuous manual left uterine displacement during CPR in pregnant women (≥20 weeks) with cardiac arrest is recommended to relieve 
aortocaval compression. 
I 
C 
It is recommended to establish i.v. access above the diaphragm to ensure that the i.v. therapy is not obstructed by the gravid uterus. 
I 
C 
It is recommended to perform the same chest compressions and defibrillation protocols in pregnant as in non-pregnant women. 
I 
C 
Anterolateral defibrillator pad placement is recommended with the lateral pad placed under the breast. 
I 
C 
It is recommended that no drugs are withheld in pregnant women with cardiac arrest due to concerns of teratogenicity. 
I 
C 
Congenital atrioventricular block and pregnancy 
In pregnant women with asymptomatic congenital AV block, normal cardiac anatomy and function, a narrow QRS complex, and ventricular 
rate (>50 b.p.m.), a prophylactic temporary pacemaker during delivery is not recommended. 
III 
C 
Native valve disease and pregnancy 
Intervention is recommended before pregnancy in symptomatic patients with severe aortic stenosis. 
I 
C 
Intervention is recommended before pregnancy in women with mitral stenosis and a valve area <1.5 cm2. 
I 
C                         
Continued


<!-- PAGE 87 -->

### Page 87

In pregnant women with symptomatic mitral stenosis or pulmonary hypertension, restricted activities and beta-blockers are recommended. 
I 
C 
In pregnant women with mitral stenosis, diuretics are recommended when congestive symptoms persist despite beta-blockers. 
I 
C 
Full therapeutic-dose anticoagulation is recommended in women with mitral stenosis complicated by AF, left atrial thrombus, or prior 
embolism. 
I 
C 
Surgical treatment is recommended before pregnancy in women with severe aortic or mitral regurgitation with symptoms, impaired 
ventricular function, or marked ventricular dilatation. 
I 
C 
Diuretics are recommended in pregnant women with regurgitant lesions when symptoms or signs of congestion occur. 
I 
C 
Prosthetic valves and pregnancy 
A bioprosthetic valve is recommended (over a mechanical valve) in young women contemplating pregnancy requiring a valve prosthesis. 
I 
B 
It is recommended that the type of valve surgery or intervention for a woman contemplating pregnancy is chosen in consultation with the 
Pregnancy Heart Team. 
I 
C 
It is recommended that a care plan documenting the agreed anticoagulant strategy (including the decision to continue VKAs or converting to 
therapeutic-dose LMWH in the first trimester) is in place for women of childbearing age with an MHV prior to pregnancy or as soon as 
pregnancy is recognized. 
I 
C 
It is recommended that pregnant women with an MHV are managed by the Pregnancy Heart Team. 
I 
C 
In pregnant women on VKAs, it is recommended to perform INR monitoring weekly or at a minimum every 2 weeks. 
I 
C 
In pregnant women with MHVs on therapeutic-dose LMWH, it is recommended to check peak anti-factor Xa levels and to target levels 
according to individualized risk. 
I 
C 
LMWH is not recommended when anti-factor Xa level monitoring is not available. 
III 
C 
Chronic and acute heart failure and pregnancy 
It is recommended that women with HFrEF are advised about the risk of deterioration of cardiac function during pregnancy and peripartum. 
I 
C 
In pregnant women with HFrEF, it is recommended that non-selective beta-blockers are switched to beta-1-selective blockers (metoprolol, 
bisoprolol) with close maternal and foetal monitoring. 
I 
C 
Anticoagulation with therapeutic doses of LMWH is recommended in pregnant women with intracardiac thrombus or decreased LV 
function with EF <35%. 
I 
C 
It is recommended to optimize HF guideline-directed medical therapy after delivery, taking contraindicated drugs during lactation into 
account. 
I 
C 
Urgent delivery with caesarean section is recommended in pregnant women with cardiogenic shock as soon as the foetus is viable, taking 
gestational age, comorbidities, and the available level of medical care into account. 
I 
C 
Inotropes and/or vasopressors are recommended in pregnant women with cardiogenic shock with levosimendan, dobutamine, and 
milrinone as recommended agents. 
I 
C 
ACE-Is, ARBs, ARNIs, MRAs, ivabradine, and SGLT2 inhibitors are not recommended during pregnancy due to adverse foetal effects. 
III 
C 
Heart transplantation and pregnancy 
It is recommended to postpone pregnancy until at least 1 year after heart transplantation, taking individual risk factors into account. 
I 
C 
In women with a heart transplant, it is recommended that immunosuppression serum drug levels are monitored during pregnancy every 4 
weeks until the 32nd week, then every 2 weeks until the 36th week, then weekly until delivery, and for 6–12 months after delivery to guide 
dosing. 
I 
C 
It is recommended to perform weekly monitoring of donor-specific antibodies for at least 6–12 months after delivery. 
I 
C 
Mycophenolic acid therapy is not recommended in pregnancy and should be discontinued 6 weeks before conception. 
III 
C 
Cardio-oncology and pregnancy 
It is recommended that pregnant women with cancer who require cardiotoxic cancer therapy are jointly managed by the Pregnancy Heart 
Team and the cardio-oncology team. 
I 
C 
13. Long-term effects of adverse pregnancy outcomes 
It is recommended to undertake a cardiovascular risk assessment in women with APOs, to recognize and document APOs when CVD risk is 
evaluated in women, and to provide counselling on the importance of healthy lifestyle choices that optimize cardiovascular health. 
I 
B 
In women with persistent post-partum hypertension beyond 6 weeks to 3 months post-partum, initiation of antihypertensive therapy with 
reference to lactating status is recommended following current guidelines. 
I 
B 
In cases where adoption of healthy lifestyle choices alone is inadequate to control post-partum glucose levels, initiation of pharmacotherapy 
following current guidelines is recommended. 
I 
C 
It is recommended that women with a history of GDM undergo a formal oGTT 6–12 weeks post-partum with a repeat assessment at 6–12 
months and regular annual follow-up visits to screen for diabetes. 
I 
C                       
Continued  
ESC Guidelines                                                                                                                                                                                               87


<!-- PAGE 88 -->

### Page 88

### 19 Author information

Author/Task Force Member Affiliations: Nina Eide 
Hasselberg, Department of Cardiology, Oslo University Hospital, 
Rikshospitalet, Oslo, Norway; Michèle de Hosson, Cardiology, 
Ghent University Hospital, Ghent, Belgium; Margarita Brida, 
Department of Rehabilitation and Sports Medicine, Faculty of 
Medicine, University of Rijeka, Rijeka, Croatia, and Adult Congenital 
Heart Disease Centre, Royal Brompton and Harefield Trust and 
Imperial College, London, United Kingdom; Silvia Castelletti, 
Cardiology Department, IRCCS Istituto Auxologico Italiano, Milan, 
Italy; Matthew Cauldwell, Obstetrics, St George’s Hospital, 
London, United Kingdom; Elisabetta Cerbai, Department of 
Neurosciences, Psychology, Drug Research and Child Health, 
University of Florence, Florence, Italy, and European Laboratory for 
Non-Linear Spectroscopy, LENS, Sesto Fiorentino, Italy; Lia Crotti, 
Department of Cardiology, Cardiomyopathy Unit, Center for 
Cardiac Arrhythmias of Genetic Origin and Laboratory of 
Cardiovascular Genetics, IRCCS, Istituto Auxologico Italiano, Milan, 
Italy, and Department of Medicine and Surgery, University of 
Milano-Bicocca, Milan, Italy; Natasja M.S. de Groot, Unit 
Translational Electrophysiology, Department of Cardiology, Erasmus 
University Medical Center, Rotterdam, Netherlands; Mette-Elise 
Estensen, Department of Cardiology, Oslo University Hospital, 
Oslo, Norway; Eva S. Goossens, Centre for Research and 
Innovation in Care, Department of Nursing and Midwifery, Faculty of 
Medicine and Health Sciences, University of Antwerp, Antwerp, 
Belgium, and Department of Public Health and Primary Care, KU 
Leuven, Leuven, Belgium, and Department of Patient Care, Antwerp 
University Hospital, UZA, Antwerp; Bernhard Haring, Klinik für 
Innere Medizin III, Saarland University, Homburg, Germany; Donata 
Kurpas, Division of Research Methodology, Department of Nursing, 
Wroclaw 
Medical 
University, 
Wroclaw, 
Poland; 
Carmel 
M. McEniery, Department of Medicine, University of Cambridge, 
Cambridge, United Kingdom; Sanne A.E. Peters, Julius Center for 
Health Sciences and Primary Care, University Medical Center 
Utrecht, Utrecht, Netherlands, and The George Institute for Global 
Health, School of Public Health, Imperial College London, London, 
United Kingdom, and The George Institute for Global Health, 
University of New South Wales, Sydney, Australia; Amina 
Rakisheva, Cardiology Department, City Cardiology Center, 
Almaty, Kazakhstan; Antonia Sambola, Acute Cardiac Care Unit, 
Department of Cardiology, Vall d'Hebron University Hospital, 
Barcelona, Spain; Oliver Schlager, Division of Angiology, 
Department of Medicine II, Medical University of Vienna, Vienna, 
Austria; Florian S. Schoenhoff, Department of Cardiac Surgery, 
Inselspital, University Hospital Bern, University of Bern, Bern, 
Switzerland; Tommaso Simoncini, Department of Clinical and 
Experimental Medicine, University of Pisa, Pisa, Italy; Françoise 
Steinbach, ESC Patient Forum, Sophia Antipolis, France; Isabella 
Sudano, Cardiology, University Hospital Zurich University Heart 
Center, Zurich, Switzerland, and University of Zurich, Switzerland; 
Lorna Swan, Scottish Adult Congenital Cardiac Service, Golden 
Jubilee National Hospital, Glasgow, United Kingdom; Anne Marie 
Valente, Cardiology, Boston Children’s Hospital, Boston, MA, 
United States of America, and Medicine, Brigham and Women’s 
Hospital, Boston, United States of America, MA, and Medicine and 
Pediatrics, Harvard Medical School, Boston, MA, United States of 
America. 
20. Appendix 
ESC Scientific Document Group 
Includes Document Reviewers and ESC National Cardiac Societies. 
Document 
Reviewers: 
Werner 
Budts 
(CPG 
Review 
Co-ordinator) (Belgium), Karen Sliwa (CPG Review Co-ordinator) 
(South Africa), Marianna Adamo (Italy), Elena Arbelo (Spain), Eloisa 
Arbustini (Italy), Giuseppe Boriani (Italy), Antonio Brucato (Italy), 
Sergio Buccheri (Sweden), Alessandra Bura Riviere (France), Pavel 
Calda (Czech Republic), G.-Andrei Dan (Romania), Konstantinos 
Dimopoulos (United Kingdom), Alexandra Frogoudaki (Greece), 
Estelle Gandjbakhch (France), Eva Gerdts (Norway), Sofie A Gevaert 
(Belgium), Bruna Gigante (Sweden), Bettina Heidecker (Germany), 
Borja Ibanez (Spain), Stefan James (Sweden), Mark Johnson (United 
Kingdom), Peter Jüni (United Kingdom), Jolanda Kluin (Netherlands), 
Lars Køber (Denmark), Konstantinos C. Koskinas (Switzerland), Greg 
Lip (United Kingdom), Emma F. Magavern (United Kingdom), Bill 
McEvoy (Ireland), Borislava Mihaylova (United Kingdom), Richard 
Mindham (United Kingdom), Inge Moelgaard (Denmark), Philip 
Moons (Belgium), Jens Cosedis Nielsen (Denmark), Ntobeko 
A. B. Ntusi (South Africa), Agnes A. Pasquet (Belgium), Tatjana 
Potpara (Serbia), Eva Prescott (Denmark), Bianca Rocca (Italy), Jolien 
Roos-Hesselink (Netherlands), Xavier Rosselló (Spain), Anna Sannino 
Nifedipine and labetalol (metoprolol if labetalol is unavailable) are recommended as treatments for uncomplicated post-partum 
hypertension in the first 6 weeks after delivery. 
I 
C 
© ESC 2025
ACE-I, angiotensin-converting enzyme inhibitor; ACHD, congenital heart disease; ACS, acute coronary syndrome; AF, atrial fibrillation; AFL, atrial flutter; ALARA, as low as reasonably 
achievable; aPTT, activated partial thromboplastin time; APO, adverse pregnancy outcome; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor/neprilysin inhibitor; ASA, 
acetylsalicylic acid; AV, atrioventricular; BAV, bicuspid aortic valve; BP, blood pressure; CMP; cardiomyopathy; CMR, cardiovascular magnetic resonance; CPR, cardiopulmonary 
resuscitation; CPVT, catecholaminergic polymorphic ventricular tachycardia; CT, computed tomography; CVD, cardiovascular disease; DAPT, dual antiplatelet therapy; DCM, dilated 
cardiomyopathy; DOAC, direct oral anticoagulant; DVT, deep vein thrombosis; ECG, electrocardiogram; EF, ejection fraction; FAT, focal atrial tachycardia; GDM, gestational diabetes 
mellitus; HCM, hypertrophic cardiomyopathy; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; HTAD, heritable thoracic aortic disease; ICD, implantable 
cardioverter defibrillator; INR, international normalized ratio; i.v., intravenous; LDS, Loeys–Dietz syndrome; LMWH, low-molecular-weight heparin; LQT2, long QT syndrome type 2; 
LQTS, long QT syndrome; LV, left ventricle; LVEF, left ventricular ejection fraction; LVOTO, left ventricular outflow tract obstruction; MFS, Marfan syndrome; MHV, mechanical heart 
valve; MRA, mineralocorticoid receptor antagonist; mWHO, modified World Health Organization; nsHTAD, non-syndromic heritable thoracic aortic disease; NYHA, New York Heart 
Association; oGTT, oral glucose tolerance test; PAH, pulmonary arterial hypertension; PE, pulmonary embolism; PH, pulmonary hypertension; P/LP, pathogenic/likely pathogenic; PPCM, 
peripartum cardiomyopathy; RV, right ventricle; SCAD, spontaneous coronary artery dissection; SGLT2, sodium–glucose co-transporter-2; SVT, supraventricular tachycardia; TGA, 
transposition of the great arteries; TR, tricuspid regurgitation; TTE, transthoracic echocardiogram; UFH, unfractionated heparin; VKA, vitamin K antagonist; VT, ventricular tachycardia; 
VTE, venous thromboembolism; WPW, Wolff–Parkinson–White. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 89 -->

### Page 89

(Germany), Felix Tanner (Switzerland), Ulf Landmesser (Germany), 
Ilonca Vaartjes (Netherlands), Christiaan Vrints (Belgium), Katja 
Zeppenfeld (Netherlands), Dayenne Zwaagman (Netherlands) 
ESC National Cardiac Societies actively involved in the review 
process of the 2025 ESC Guidelines for the management of cardiovascular disease and pregnancy: 
Albania: Albanian Society of Cardiology, Aurel Demiraj; Algeria: 
Algerian Society of Cardiology, Nora Henine; Armenia: Armenian 
Cardiologists Association, Hamlet G. Hayrapetyan; Austria: 
Austrian Society of Cardiology, Noemi Pavo; Azerbaijan: 
Azerbaijan Society of Cardiology, Gulane Aghayeva; Belgium: 
Belgian Society of Cardiology, Agnes A. Pasquet; Bosnia and 
Herzegovina: Association of Cardiologists of Bosnia and 
Herzegovina, Milan Gluhović; Bulgaria: Bulgarian Society of 
Cardiology, Nina Gotcheva; Croatia: Croatian Cardiac Society, 
Bosko Skoric; Cyprus: Cyprus Society of Cardiology, Maria 
Karakyriou; Czechia: Czech Society of Cardiology, Zuzana 
Motovska; Denmark: Danish Society of Cardiology, Dorte 
Guldbrand Nielsen; Egypt: Egyptian Society of Cardiology, Ghada 
Youssef; Estonia: Estonian Society of Cardiology, Maarja Maser; 
Finland: Finnish Cardiac Society, Sanna Laurila; France: French 
Society of Cardiology, Bernard Iung; Georgia: Georgian Society of 
Cardiology, Khatuna Jalabadze; Germany: German Cardiac Society, 
Stephanie Fichtner; Greece: Hellenic Society of Cardiology, 
Alexandra Frogoudaki; Hungary: Hungarian Society of Cardiology, 
Olga Hajnalka Balint; Iceland: Icelandic Society of Cardiology, Þórdís 
Jóna Hrafnkelsdóttir; Ireland: Irish Cardiac Society, Paul F. Brennan; 
Israel: Israel Heart Society, Rafael Kuperstein; Italy: Italian 
Federation of Cardiology, Gabriele Egidy Assenza; Kazakhstan: 
Association of Cardiologists of Kazakhstan, Gulnara Junusbekova; 
Kosovo (Republic of): Kosovo Society of Cardiology, Pranvera 
Ibrahimi; Kyrgyzstan: Kyrgyz Society of Cardiology, Saamay 
Abilova; Latvia: Latvian Society of Cardiology, Oskars Kalejs; 
Lebanon: Lebanese Society of Cardiology, Georges Saadé; Libya: 
Libyan Cardiac Society, Hanan Taher Bugaigis; Lithuania: 
Lithuanian Society of Cardiology, Jūratė Barysienė; Luxembourg: 
Luxembourg Society of Cardiology, Rouguiatou Sow; Malta: Maltese 
Cardiac Society, Maryanne Caruana; Moldova (Republic of): 
Moldavian Society of Cardiology, Lilia David; Morocco: Moroccan 
Society of Cardiology, Aatif Benyass; Netherlands: Netherlands 
Society of Cardiology, Anastasia D. Egorova; North Macedonia: 
National Society of Cardiology of North Macedonia, Marijan 
Bosevski; Norway: Norwegian Society of Cardiology, Elisabeth 
Leirgul; Poland: Polish Cardiac Society, Olga Trojnarska; Portugal: 
Portuguese Society of Cardiology, Rita Ilhão Moreira; Romania: 
Romanian Society of Cardiology, Ruxandra Jurcut; San Marino: San 
Marino Society of Cardiology, Marco Zavatta; Serbia: Cardiology 
Society of Serbia, Aleksandra Ilic; Slovakia: Slovak Society of 
Cardiology, Juraj Dubrava; Slovenia: Slovenian Society of 
Cardiology, Katja Prokšelj; Spain: Spanish Society of Cardiology, 
Milagros Pedreira Pérez; Sweden: Swedish Society of Cardiology, 
Christina 
Christersson; 
Switzerland: 
Swiss 
Society 
of 
Cardiology, Matthias Greutmann; Syrian Arab Republic: Syrian 
Cardiovascular Association, Elias Barakat; Tunisia: Tunisian Society 
of Cardiology and Cardiovascular Surgery, Meriam Drissa; Türkiye: 
Turkish Society of Cardiology, Alev Arat Ozkan; Ukraine: Ukrainian 
Association of Cardiology, Olena I Mitchenko; United Kingdom of 
Great Britain and Northern Ireland: British Cardiovascular 
Society, 
Dawn 
L. 
Adamson; 
Uzbekistan: 
Association 
of 
Cardiologists of Uzbekistan, Feruza Zakirova 
ESC Clinical Practice Guidelines (CPG) Committee: Ulf 
Landmesser (Chairperson) (Germany), Stefan James (Co-Chairperson) 
(Sweden), Marianna Adamo (Italy), Suleman Aktaa (United Kingdom), 
Folkert W. Asselbergs (Netherlands), Colin Baigent (United Kingdom), 
Michael A. Borger (Germany), Giuseppe Boriani (Italy), Margarita Brida 
(Croatia), Robert A. Byrne (Ireland), Estelle Gandjbakhch (France), 
Bettina Heidecker (Germany), Anja Hennemuth (Germany), Borja 
Ibanez (Spain), Peter Jüni (United Kingdom), Gregory Y.H. Lip (United 
Kingdom), John William McEvoy (Ireland), Borislava Mihaylova (United 
Kingdom), Inge Moelgaard (Denmark), Lis Neubeck (United Kingdom), 
Eva Prescott (Denmark), Bianca Rocca (Italy), Xavier Rossello (Spain), 
Anna Sannino (Germany), Felix C. Tanner (Switzerland), Wojtek 
Wojakowski (Poland), Katja Zeppenfeld (Netherlands) 
